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« Peut-être ne saurez-vous jamais quel a été le résultat de ce que vous avez 
fait. Mais, si vous ne faites rien, il n’y aura jamais de résultat. » 
 
Le Mahatma Gandhi (1869-1948) 
 
 
 
« Pour s’améliorer, il faut changer. Donc, pour être parfait, il faut avoir 
changé souvent. » 
 
Winston Churchill (1874-1965) 
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Summary 
 
Direct oral anticoagulants (DOACs) (i.e dabigatran, rivaroxaban, apixaban 
and edoxaban) are used for the prevention and treatment of thrombotic 
events including the treatment and prevention of recurrent venous 
thromboembolism (VTE) and stroke prevention in patients with non-
valvular atrial fibrillation (NVAF). Annually, approximately 10-15 % of 
these patients will require DOAC interruption before an elective or invasive 
procedure. 
Laboratory testing is not recommended routinely, as these drugs have a rapid 
onset and offset of action, a short half-life, predictable pharmacokinetics and 
a large on-therapy range. 
However, many frail patients (i.e. low body weight, several drug 
interferences) who receive DOACs in real-life were initially excluded from 
the clinical phase III trials. In addition, a link between dabigatran or 
edoxaban concentration and clinical events (venous thromboembolism or 
major bleeding) was demonstrated.  Multicenter studies have shown a high 
interindividual variability with DOACs in real-life patients that cannot 
account only for the renal function.  
Furthermore, there is no agreement between the different proposals that 
aimed at guiding the best timing to surgery.  
Therefore, DOAC monitoring has become progressively a part of the 
perioperative management of DOACs, especially in emergencies.  
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Initial perioperative proposals suggested that routine coagulation assays like 
the activated partial thromboplastin time (aPTT) or the prothrombin time 
(PT) could assess residual plasma concentrations of DOACs. Nevertheless, 
these assays give only qualitative informations, as their responsiveness is 
coagulometer and reagent dependent and as they are not sensitive enough to 
exclude clinically relevant DOAC concentrations. 
Thrombin time (TT) is the most sensitive coagulation test for dabigatran. 
However, its methodology is not standardized between the laboratories and 
its performance is reagent dependent. Therefore, its use has been restricted 
to exclude clinically relevant concentration of dabigatran in a perioperative 
context.  
Specific coagulation assays were proposed to allow quantitative 
measurements of DOACs. These include the diluted TT (dTT), the ecarin 
clotting time (ECT), or the ecarin chromogenic assay (ECA) for dabigatran, 
and chromogenic anti-FXa assays for rivaroxaban, apixaban, and edoxaban. 
They have been largely validated in several publications outside the 
perioperative context. These tests showed a limit of quantitation with 
standard methodology and calibrators around 30 and 50 ng/ml, which was 
not accurate enough for the perioperative context. Indeed, the safety 
threshold proposed for DOAC plasma concentrations before an invasive 
procedure carrying a high bleeding risk was set at 30ng/ml. 
Therefore, the primary objectives of this work were: 
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1) To optimize and validate the use of thrombin time in the 
perioperative management of patients on dabigatran etexilate. 
2) To compare the performance of coagulation tests, specifically 
developed for the measurement of low plasma concentrations of 
dabigatran and rivaroxaban with the reference LC-MS/MS method. 
3) To study the interference of heparin bridging on the performance of 
these specific coagulation assays. 
 
Our in vitro results demonstrated the influence of thrombin concentration, 
thrombin origin and the type of coagulometer on the measurement of 
thrombin time. To use thrombin time in a perioperative context, we 
optimized the thrombin concentration on two coagulometers. In addition, we 
illustrated the lack of stability of plasma samples and suggested measuring 
TT within 2 hours of sampling in plasma containing dabigatran.  
We confirmed in an ex vivo pilot study performed on 24 plasma samples 
from patients treated with dabigatran etexilate, that an optimised TT may be 
useful in assessing low dabigatran concentrations (< 50 ng/ml), especially 
for laboratories that do not have access to specific assays. However, 
clinicians need to consider the different variables affecting TT (i.e. heparin 
bridging, inflammatory syndrome, fibrin/fibrinogen degradation products).  
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In the second ex vivo study performed on 33 plasma samples from patients 
treated with dabigatran etexilate, we showed that two coagulation tests 
specifically developed for the measurements of low dabigatran plasma 
concentrations (the Hemoclot Thrombin Inhibitors
®
 LOW (HTI LOW) from 
Hyphen BioMed
®
, Neuville-sur-Oise, France and the STA
®
-ECA II (ECA-
II) from Diagnostica Stago
®
, Asnière-sur-Seine, France), performed well 
with dabigatran plasma concentrations < 50 ng/ml, and thus should be 
preferred to the standard procedure of HTI in this range of concentrations.  
When TT is available before a dabigatran level is requested, then it can 
guide the laboratory in choosing the more accurate coagulation tests (i.e. 
HTI or HTI LOW/ECA-II) in order to avoid unnecessary costs. The added 
value of this strategy was illustrated in a case-series of patients monitored in 
a perioperative context.  
 
In the last ex vivo study performed on 79 patients, we demonstrated that 
specific procedures with adapted methodology and calibrators (i.e. 
Biophen®DiXaI LOW and STA®-Liquid Anti-Xa) should be preferred for 
the estimation of rivaroxaban concentrations below 50 ng/ml. These 
methods are sensitive to low molecular weight heparins (LMWHs) and may 
consequently be influenced with residual LMWH found even 24 h after the 
last administration.  
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The development of a chromogenic anti-Xa assay accurate for low 
rivaroxaban concentrations and insensitive to heparins is required to 
optimize the perioperative management of patients at high risk of thrombosis 
that receive a bridging therapy with heparin before an elective procedure.  
In conclusion, DOACs monitoring may be necessary to manage some 
patients in a perioperative or emergent context.  
Accurate specific assays with an adapted methodology and calibrators for 
low DOACs concentrations may guide the clinicians for the optimal 
management of these patients.  
Despite attractive pharmacokinetic properties, the high interindividual 
variability of DOACs plasma concentration support that their pre-procedural 
interruption should not be based only on their respective half-life, but also 
on residual drug concentrations. Further perioperative studies using DOAC 
monitoring with accurate laboratory tests are needed to validate a unique and 
safe peri-procedural management.  
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Résumé 
 
Les agents anticoagulants oraux directs (AODs) (dabigatran, rivaroxaban, 
apixaban et edoxaban) sont utilisés pour la prévention et le traitement des 
événements thromboemboliques, incluant le traitement et la prévention de la 
maladie thromboembolique veineuse (MTEV) et la prévention des accidents 
vasculaires cérébraux chez les patients avec fibrillation auriculaire non 
valvulaire (FANV). Chaque année, environ 10-15 % des patients vont 
nécessiter une interruption de leur AOD avant une procédure élective ou 
invasive.  
Les tests de laboratoire ne sont pas recommandés en routine, étant donné que 
ces médicaments ont un temps d’action et un temps d’arrêt rapides, une 
demi-vie courte, une pharmacocinétique prévisible et un large éventail de 
concentrations plasmatiques sous traitement.  
Cependant, beaucoup de patients fragiles (ex: faible poids corporel, plusieurs 
interactions médicamenteuses) qui reçoivent un AOD dans notre pratique 
clinique, ont été exclus des études cliniques de phase III. De plus, un lien a 
été démontré entre les concentrations en dabigatran ou edoxaban, et des 
événements cliniques (MTEV ou saignement majeur).  Des études 
multicentriques ont montré une importante variabilité interindividuelle des 
concentrations plasmatiques en AODs chez les patients traités et qui ne peut 
être expliquée uniquement par la fonction rénale. 
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De plus, il n’y a pas de consensus entre les recommandations visant à guider 
le meilleur timing d’arrêt des AODs avant une chirurgie. 
Pour ces raisons, le monitoring des AODs a pris progressivement sa place 
dans la gestion périopératoire des AODs, et en particulier celle des urgences.  
Les premières propositions périopératoires suggéraient l’utilisation des tests 
de coagulation de routine tels que le temps de céphaline activée (TCA) ou le 
temps de prothrombine (TP) pour évaluer les concentrations plasmatiques 
résiduelles des AODs. 
Cependant, ces tests ne donnent qu’une information qualitative étant donné 
que leur réponse dépend du coagulomètre et du réactif et qu’ils ne sont pas 
assez sensibles pour exclure des concentrations en AODs cliniquement 
relevantes. 
Le temps de thrombine (TT) est par contre le test de coagulation le plus 
sensible au dabigatran. Cependant, sa méthodologie n’est pas standardisée 
entre les laboratoires et sa performance dépend du réactif utilisé. De ce fait, 
son utilisation en péri-opératoire a été limitée à exclure les concentrations 
cliniquement relevantes de dabigatran. 
Des tests de coagulation spécifiques ont été proposés pour permettre de 
quantifier les AODs. Ces tests incluent le temps de thrombine dilué (dTT), le 
temps de coagulation à base d’écarine (ECT), ou le test chromogénique à 
base d’écarine pour le dabigatran, et les tests chromogéniques anti-Xa pour 
le rivaroxaban, l’apixaban et l’edoxaban.  
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Ces tests ont été largement validés dans plusieurs publications en dehors du 
contexte péri-opératoire. Cependant, ces tests ont montré une limite de 
quantification entre 30 et 50 ng/ml avec une méthodologie et des calibrateurs 
standard, ce qui est insuffisamment exact pour guider des décisions péri-
opératoires. En effet, le seuil de concentrations plasmatiques qui a été 
proposé avant une procédure invasive à haut risque de saignement est de 30 
ng/ml. 
Dès lors, les objectifs primaires de ce travail de thèse furent: 
1) Optimiser et valider l’utilisation du temps de thrombine dans la 
gestion péri-opératoire des patients sous dabigatran etexilate. 
2) Comparer la performance des tests de coagulation, spécifiquement 
développés pour la mesure des faibles concentrations plasmatiques 
en dabigatran et rivaroxaban, avec la méthode de référence (LC-
MS/MS). 
3) Etudier l’interférence d’un relais par héparine sur la performance de 
ces tests de coagulation spécifiques. 
 
Nos résultats in vitro ont démontré l’influence de la concentration en 
thrombine, de l’origine de la thrombine et du type de coagulomètre sur le 
temps de thrombine. 
Pour utiliser le TT dans un contexte péri-opératoire, nous avons optimisé la 
concentration en thrombine sur deux coagulomètres. De plus, nous avons 
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illustré le manque de stabilité des échantillons plasmatiques et suggéré de 
mesurer le temps de thrombine sur les échantillons contenant du dabigatran 
endéans les 2 heures après prélèvement. Nous avons confirmé dans une 
étude pilote ex vivo réalisée sur 24 échantillons plasmatiques de patients 
traités par dabigatran etexilate, qu’un temps de thrombine optimisé peut être 
utilisé pour évaluer les faibles concentrations en dabigatran (< 50 ng/ml), en 
particulier pour les laboratoires n’ayant pas accès aux tests spécifiques. 
Cependant, les cliniciens doivent prendre en compte les différentes variables 
affectant le TT (ex: relais par héparine, syndrome inflammatoire, produits de 
dégradation de la fibrine et du fibrinogène).  
 
Dans la seconde étude ex vivo réalisée sur 33 échantillons de patients traités 
par dabigatran étexilate, nous avons montré que les deux tests de coagulation 
spécifiquement développés pour estimer les concentrations plasmatiques 
basses en dabigatran (le Hemoclot Thrombin Inhibitors
®
 LOW (HTI LOW) 
de Hyphen BioMed
®
, Neuville-sur-Oise, France et le STA
®
-ECA II (ECA-
II) de Diagnostica Stago
®
, Asnière-sur-Seine, France), présentent de bonnes 
performances pour les concentrations plasmatiques < 50 ng/ml et devraient 
être préférés à la procédure standard de l’HTI pour cette gamme de 
concentration.  
Lorsque le TT est accessible avant qu’une estimation du niveau 
d’anticoagulation par dabigatran ne soit demandée, alors il peut guider le 
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laboratoire dans le choix des tests de coagulation les plus exacts (HTI ou 
HTI LOW/ECA-II) afin d’éviter des coûts inutiles. La valeur ajoutée de 
cette stratégie a été illustrée dans une série de cas de patients suivis dans un 
contexte péri-opératoire.  
 
Dans la dernière étude ex vivo réalisée sur 79 patients, nous avons démontré 
que les procédures spécifiques avec méthodologie et calibrateurs adaptés 
(ex: le Biophen®DiXaI LOW et le STA®-Liquid Anti-Xa) devraient être 
préférées pour l’estimation des concentrations en rivaroxaban < 50 ng/ml.  
Cependant, ces méthodes sont sensibles aux héparines de bas poids 
moléculaire (HBPMs) et peuvent être influencées par des concentrations 
résiduelles en HBPM retrouvées minimum 24h après leur dernière 
administration.  
Le développement d’un test chromogénique anti-Xa pour les concentrations 
faibles en rivaroxaban et insensible aux héparines est nécessaire pour 
optimiser la gestion péri-opératoire des patients à haut risque thrombotique 
nécessitant un relais par héparine avant une procédure élective.  
 
En conclusion, le monitoring des AODs peut s’avérer nécessaire pour une 
prise en charge optimale de certains patients dans un contexte péri-
opératoire ou d’urgence. Des tests spécifiques exacts avec une méthodologie 
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et des calibrateurs adaptés pour les concentrations faibles en AODs, 
devraient guider les cliniciens en charge de ces patients. 
Malgré des propriétés pharmacocinétiques attractives, la grande variabilité 
interindividuelle des concentrations plasmatiques en AODs supportent le fait 
que leur interruption pré-procédurale ne doit pas être basée uniquement sur 
leur demi-vie respective, mais aussi sur leurs concentrations plasmatiques 
résiduelles. De futures études péri-opératoires utilisant des tests de 
laboratoires exacts pour quantifier les AODs sont nécessaires pour valider 
une procédure péri-opératoire unique et sure. 
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I. Introduction 
 
A. Overview of the main characteristics of the direct oral anticoagulants 
Direct oral anticoagulants (DOACs) (i.e dabigatran, rivaroxaban, apixaban 
and edoxaban) are used in several indications for the prevention and 
treatment of thrombotic events including the treatment and prevention of 
recurrent venous thromboembolism (VTE) and stroke prevention in atrial 
fibrillation (SPAF). Pharmacokinetic properties, indications and dose 
regimens of DOACs in the European Union are summarized in Table 1 and 
Table 2. These agents are administered as either once-daily (qd) or twice-
daily (bid) fixed-dose regimens, with dosage determined mainly by 
indication, age and/or creatinine clearance, body weight, and some co-
medication use (depending on the agent).
1-4
 As highlighted by data from 
clinical trials and case studies, all DOACs carry the risk of bleeding despite 
careful selection and patient management. 
Bleeding events have been reported in all the major clinical trials comparing 
DOACs with other anticoagulants, despite regular monitoring of adverse 
events, strong medication adherence and careful patient selection.
5-9
 
Large randomised trials comparing bleeding risks of different DOACs are 
not available as DOACs are always compared with warfarin, low molecular 
weight heparin (LMWH) and anti-platelet agents. When DOACs were 
prescribed at prophylactic doses in orthopaedic surgery, rates of bleeding 
were similar to LMWHs.
10
 In patients with non-valvular atrial fibrillation 
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(NVAF) or VTE, a recent meta-analysis showed a lower rate of fatal 
bleeding and case-fatality of major bleeding events (MBE) with DOACs 
than with warfarin.
11
 Another meta-analysis showed that patients with a 
creatinine clearance (CrCl) between 50-80 ml/min who received DOACs 
had significantly fewer MBE than those receiving Vitamin K antagonists 
(VKAs). For patients with CrCl <50ml/min, the difference in MBE was not 
statistically significant, but using indirect comparisons, apixaban was 
associated with significantly fewer MBE than other DOACs.
12
  
Post-marketing surveillance registries provide real world data on the safety 
and efficacy of DOACs. The Dresden registry found that the routine safety 
profile of dabigatran etexilate (DE) was not worse than that reported in the 
RELY trial even if selection bias might exist.
13
 The Danish national registry 
found a higher bleeding rate in previous VKA users than VKA naive 
patients.
14
 Concerning rivaroxaban, large observational studies as well as 
prospective non-interventional studies showed that the major bleeding rate 
was generally consistent with registration trial results and that fatal bleeds 
were rare. 
15,16,17
 The MBE rate with rivaroxaban from the Dresden registry 
was lower than that for VKAs.
18
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Table 1: Summary of pharmacokinetic properties of direct oral anticoagulants in the European Union 
19-28
 
 Dabigatran  Rivaroxaban Apixaban Edoxaban 
Target Factor lla Factor Xa Factor Xa Factor Xa 
Prodrug Yes No No No  
Tmax (h) 1.5 - 3.0 2.0 - 4.0 3.0 - 4.0 1.0-2.0 
Distribution 
volume (L) 
60 – 70 ± 50 23 107 
Half-life (h) 12 - 17 5 - 9: healthy 
individuals 
11 - 13: elderly 
8 - 15: healthy 
individuals 
10-14 
Bioavailability  3 - 7 %  
pH sensitive 
2.5 mg to 10mg dose: 
80-100% (fasting/fed) 
15 - 20mg dose:  
66% (fasting) 
+- 100% (fed) 
± 50% 62% 
Protein binding 35% >90% 87% 55% 
Metabolism Conjugation CYP-dependent and 
independent  
CYP-dependent  CYP-dependent (<5%) 
and independent (<10%) 
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Active 
metabolites 
Yes - glucuronide 
conjugates 
No No Yes (<15%) 
Elimination 80% renal 33% unchanged via the 
kidney 
27% renal 50% renal 
 20% bile 
(glucuronide 
conjugation) 
66% metabolized in the 
liver into inactive 
metabolites eliminated 
via the kidney (50%) or 
the colon (50%) 
73% through the liver 
while the residue is 
excreted by the 
hepatobiliary route  
50% metabolism and 
biliary/intestinal 
excretion 
  
Effects of food Tmax delayed;  
Cmax & AUC 
unchanged 
Tmax delayed;  
Cmax & AUC 
increased (15-20 mg) 
Tmax delayed;  
Cmax & AUC 
unchanged 
C max increased, but 
minimal effect on total 
exposure 
CYP substrate No CYP3A4, CYP2J2 CYP3A4 CYP3A4 (<5%) 
P-gp substrate DE: Yes Yes Yes Yes 
 
Tmax: time to reach peak concentration; Cmax: peak concentration; AUC: air under the curve; CYP3A4: cytochrome P450 isozyme 3A4;  
P-gp: P-glycoprotein.  
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Table 2. Indication and dose regimens of direct oral anticoagulants in the European Union
29-52
 
VTE Prophylaxis  220 mg/day 
(2 caps 110 mg qd)  
Cmax: 
71 (35 – 162) ng/ml 
(mean; 25-75 PCTL) 
Cmin: 
22 (13 – 36) ng/ml 
(mean; 25–75 PCTL) 
 150mg/day 
(2 caps 75 mg qd) 
 if CrCl 30-50 ml/min, if 
>75 years, if verapamil, 
amiodarone and quinidine 
 
THR: 28-35 days  
TKR: 10 days 
 10 mg/day 
(1 tablet 10 mg qd) 
Cmax: 
125 (91 – 196) ng/ml 
(median; 5–95 PCTL) 
Cmin: 
9 (1 - 38) ng/ml 
(median; 5–95 PCTL) 
 
 
 
 
 
 
THR: 5 weeks  
TKR: 2 weeks 
 5 mg/day 
(1 tablet 2.5 mg bid)  
Cmax: 
77 (41 – 146) ng/ml 
(median; 5–95 PCTL) 
Cmin : 
51 (23– 109) ng/ml 
(median; 5–95 PCTL) 
 
 
 
 
 
 
THR: 32-38 days 
TKR: 10 days 
 (EU) 
Non-valvulal atrial 
fibrillation 
 
 
 
 
 
 
 300 mg/day  
(1 caps 150mg bid) 
Cmax: 
175 (117-275) ng/ml 
(mean; 25-75 PCTL) 
Cmin: 
91 (61-143-200) ng/ml 
(mean; 25-75-90 PCTL) 
 
 
 20 mg/day 
(1 tablet 20 mg qd) 
Cmax: 
249 (184 – 343) ng/ml 
(mean; 5–95 PCTL) 
Cmin: 
44 (12 – 137) ng/ml 
(mean; 5–95 PCTL) 
 
 
 10 mg/day 
 (1 tablet 5 mg bid) 
Cmax : 
171 (91 – 321) ng/ml 
(median; 5–95 PCTL) 
Cmin : 
103 (41– 230) ng/ml  
(median; 5–95 PCTL 
 
 
 60mg/day 
(1 tablet 60 mg qd) 
Cmax : 
+/-170 (165-195) ng/ml 
(median; IQR) 
Cmin : 
36 (19 – 62) ng/ml  
(median; IQR) 
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Non-valvulal atrial 
fibrillation  
 220 mg/day  
(1 capsule 110 mg bid)  
 if >80 y or verapamil 
 
 
 
 15mg/day 
(1 tablet 15 mg qd)  
 if CrCl between  
15-49 ml/min 
Cmax: 
229 (178 – 313) ng/ml 
(mean; 5–95 PCTL) 
Cmin: 
57 (18 – 136) ng/ml 
(mean; 5–95 PCTL) 
 
 5 mg/day 
(1 tablet 2.5mg bid)  
 If at least 2 of the 
following conditions:  
≥80ys, ≤60kg or serum 
creatinine ≥ 1,5 mg/dl; 
 Or if CrCl 15-
29ml/min 
Cmax : 
123 (69 – 221) ng/ml 
(median; 5–95 PCTL) 
Cmin : 
79 (34– 162) ng/ml  
(median; 5–95 PCTL) 
 30mg/day 
(1 tablet 30mg qd) 
 if CrCl between       
15-50 ml/min,  
≤ 60kg or  
concomitant use of 
dronedarone, 
erythromycin, 
ketoconazole, ciclosporin  
Cmin : 
27 (15-45) ng/ml  
(median; IQR) 
VTE treatment  300mg/day  
(1 caps 150mg bid)  
after at least 5 days of 
parenteral anticoagulants 
Cmax: 
175 (117 – 275) ng/ml 
(mean; 25-75 PCTL) 
Cmin:  
60 (39 – 95- 146) ng/ml 
(mean; 25-75-90 PCTL) 
 
 220 mg/day 
(1 caps 110 mg bid)  
 if >80 y or verapamil 
 
Treatment phase:  
 30 mg/day 
(1 tablet 15 mg bid)  
for 21 days 
 followed by 
 20mg/day 
(1 tablet 20 mg qd)  
for 3 to 6 months  
Cmax: 
270 (189 – 419) ng/ml 
(mean; 5–95 PCTL) 
Cmin: 
26 (6 – 87) ng/ml 
(mean; 5–95 PCTL) 
 
Treatment phase:  
 20mg/day  
(2 tablet 5mg bid)  
for 7 days  
Cmax : 
251 (111-572) ng/ml 
(median; 5–95 PCTL) 
Cmin : 
120 (41– 335) ng/ml  
(median; 5–95 PCTL)  
 followed by 
 10mg/day  
(1 tablet 5mg bid)  
for 3 to 6 months 
 
 60mg/day 
(1 tablet 60 mg qd)  
after at least 5 days of 
parenteral anticoagulant 
treatment. 
 30mg/day 
(1 tablet 30mg qd) 
 if CrCl between  
15-50 ml/min,  
BW ≤ 60kg or 
concomitant use of 
dronedarone, 
erythromycin, 
ketoconazole, ciclosporin 
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  15mg/day  
(1 tablet 15 mg qd)  
 if CrCl between  
15-49 ml/min and the risk 
of bleeding outweights 
the risk of recurrent DVT 
or PE 
 
 
 
Cmax : 
132 (59 – 302) ng/ml 
(median; 5–95 PCTL) 
Cmin : 
63 (22– 177) ng/ml  
(median; 5–95 PCTL) 
If high risk of recurrent 
DVT or PE:  
 5mg/day  
(1 tablet 2.5mg bid)  
after 6-months treatment   
Prevention of 
athero-thrombotic 
events after ACS 
with elevated 
cardiac biomarkers  
 
 5 mg/day 
(1 tablet 2.5 mg bid) 
with ASA (75-100 mg) 
or, ASA + clopidogrel (75 
mg) or ticlopidine 
Cmax: 
46 (28 – 70) ng/ml 
(median; 5–95 PCTL) 
Cmin: 
17 (6 – 37) ng/ml 
(mediaan; 5–95 PCTL) 
 
 
 
 
 
 
 
 
 
 Off-label; caps: capsule; qd: once daily; bid: twice daily; CrCl: creatinine clearance; DVT: Deep-vein thrombosis; PE: pulmonary 
embolism; THR: total hip replacement TKR: total knee replacement; ASA: acetylsalicylic acid; ACS: acute coronary syndrome, Cmax and 
Cmin: peak and trough concentrations providing from the clinical trials; PCTL: percentiles, IQR: interquartil range 
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B. Why was it necessary to optimize laboratory assays and perioperative 
management? 
Dabigatran etexilate and rivaroxaban were firstly licensed for the prevention 
of VTE events in a postoperative context of some orthopaedic surgeries 
(total hip and knee surgery in the European Union). This indication has a 
different dose regimen  (see Table 2) than the prevention of stroke in NVAF 
or VTE treatment. 
Laboratory testing is not recommended routinely, as these drugs have a rapid 
onset and offset of action, short half-life, predictable pharmacokinetics and a 
large on-therapy range.  
However, numerous publications came rapidly out to report haemorragic 
complications due to DOACs and pointed out the limit of the clinical phase 
III studies that allowed the license of the drug. 
i. Limit of clinical phase III trials 
A major criticism was that many frail patients who received DOACs in real-
life were excluded from the clinical phase III trials. These patients were 
older, with lowerer body weight and had also several co-medications that 
interact with DOACs’ metabolism. In an cross-sectionnel study conducted in 
2010 including patients hospitalized for NVAF, 42% of these had at least 
one medication affecting P-glycoprotein.
53
 
Sub-studies of these clinical phase III trials aimed at selecting specific 
clinical characteristics that increased the risk of bleeding. A reduced DOAC 
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dosage was recommended when specific medications with high drug-drug 
interaction and/or clinical characteristics based on age, renal clearance and 
body weight (see Table 2) were present.  
 
Reilly et al. were the first to publish a link between adverse events and 
plasmatic concentrations of dabigatran. They described a cut off of 
dabigatran plasma concentrations inside of which patients had the lowest 
risk to present a thromboembolism (TE) or haemorragic event. As DOACs 
have a large therapeutic range, this analysis clearly demonstrated that high 
plasma concentrations of dabigatran could led to severe bleeding and 
suggested a follow up for specific patient populations such as frail patients 
or patients presenting haemorragic complications.  
 
The debate around DOAC monitoring was intense, as a key strength of the 
marketing policy of these medications was the “no need of routine 
monitoring”. Furthermore, reduced dosages were not validated according to 
specific plasma concentrations.  
However, it rapidly became evident that coagulation testing could be of 
value in emergency situations to determine the presence or absence of 
DOACs, to plan the best timing of an invasive procedure since last DOAC 
administration, for the assessment of adherence, and to help evaluating the 
cause of ischemic stroke or bleeding.
54
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ii. Issues with routine coagulation assays  
The DOACs have different effects on routine coagulation tests, such as the 
activated partial thromboplastin time (aPTT), the thrombin time (TT), and 
the prothrombin time (PT). Moreover, the responsiveness of these tests to 
the DOACs is coagulometer and reagent dependent [12,13]. 
Guidances based on routine tests were rapidly published as specific 
coagulation assays were not widely available and requested specialized 
laboratories and staff.  
However, these proposals were not adequate as most of these routine tests 
were not sufficiently sensitive to measure quantitatively DOACs plasma 
concentration. Routine coagulation tests have a qualitative value that can 
inform about a range of DOACs plasma concentration.  
 
For example, a normal aPTT was initially recommended to exclude the 
absence of a significant dabigatran effect.
54
 However, normal aPTT do not 
systematically exclude dabigatran concentrations up to 60 ng/ml. 
Cuker showed in a recent review that dabigatran prolonged the aPTT in a 
concentration-dependent manner in both ex vivo and in vitro studies.
55
 The 
dose response was curvilinear, with a linear response up to a concentration 
of 200 to 300 ng/ml and then a flattening of the response for higher drug 
levels
56,57
. This relationship does not enable quantitative assessment of 
dabigatran levels, particularly at higher concentrations. Furthermore, the 
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sensitivity of dabigatran to commercial aPTT reagents differs widely, and 
therefore laboratories should perform dose-response studies using calibration 
standards to determine the sensitivity of their aPTT reagent and 
communicate the results to clinicians. When insensitive reagents are used, 
the aPTT may not be prolonged in the presence of typical on-therapy trough 
levels.  
Thrombin time is the most sensitive coagulation test for dabigatran. 
However, it is not standardized between the laboratories and, depending on 
the reagent, dabigatran concentrations of as little as 25 and up to 150 ng/ml 
may exceed the limits of detection
56-59
. 
However, irrespectively of the reagent used, its normal range can exclude 
presence of clinically relevant concentrations of dabigatran. 
55,60
 
 
Both aPTT and TT suffer from several biological and clinical variables that 
need to be taken into account in the interpretation of the tests results.
60
 
For direct anti-Xa agents like rivaroxaban and edoxaban, the PT is more 
prolonged than the aPTT in therapeutic ranges, but normal test results do not 
exclude a significant drug effect.
55
 
Rivaroxaban and edoxaban prolonged the PT in spiked plasma in a 
concentration dependent and linear way.
61,62
 
63
 
For rivaroxaban, typical trough (41 to 60 ng/ml) and peak (219 to 305 
ng/ml) concentrations increased PT (in seconds) by 6% to 19% and 50% to 
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135%, respectively.
64-66
 Thromboplastin reagents have variable sensitivities 
to rivaroxaban and edoxaban.
61,63,67
  
An in vitro study showed that the interassay variability can be reduced by 
the use of an international sensitivity index specific for rivaroxaban, but not 
by conversion to an International Normalized Ratio (INR) used for the 
monitoring of VKA therapy.
68
  
Laboratories should perform dose-response studies using calibration 
standards to determine the sensitivity of their particular PT method for 
rivaroxaban and edoxaban, and communicate the results to clinicians.
55
 
 
For apixaban, the PT is not sensitive enough as a normal PT cannot exclude 
therapeutic ranges even at peak time, except for the reagent Triniclot PT 
Excel S®.
69
 To detect rapidly high anticoagulant effect of apixaban in 
patients with bleeding complications and normal routine coagulation tests, 
some publications proposed the use of the dilute Russell’s Viper Venom 
Time (dRVVT).
70
 
 
There are no routine tests that have a comparable sensitivity for direct anti-
Xa agents such as TT has for dabigatran. Therefore, laboratories need to use 
specific calibrated chromogenic assays to exclude clinically relevant 
presence of these agents.  
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When specific tests are not available, management of emergencies are based 
on routine coagulation tests, on the last timing of DOACs intake and on 
patient’s renal clearance. The aim is to estimate roughly if the residual 
DOAC activity may potentially lead to bleeding or to guide the timing to 
emergent surgery. Using routine coagulation tests to follow the effect of 
bleeding treatment or antidotes administration is not accurate enough as 
normal ranges cannot exclude DOAC concentrations of 50-60 ng/ml (except 
TT for dabigatran). Furthermore, some studies on dabigatran with 
prothrombin complex administration did not show an improvement of 
aPTT,
71,72
 and prolonged routine coagulation tests could also partly reflect an 
additional coagulopathy due to severe bleeding or polytrauma.
73
 
 
Clinical trials using routine coagulation assays to screen for DOAC’s 
presence need to provide detailed informations about the methodology and 
reagent used to allow potential comparison between their results and to 
enable some recommendations. 
 
iii. Issues with specific tests for quantitative estimation of DOACs 
To allow quantitative measurements of DOACs, the use of different specific 
coagulation assays have been largely validated in several publications.   
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These include the diluted TT (dTT), the ecarin clotting time (ECT), or the 
ecarin chromogenic assay (ECA) for dabigatran, and chromogenic anti-FXa 
assays for rivaroxaban, apixaban, and edoxaban.  
On-therapy plasma concentration ranges of DOACs for VTE treatment and 
SPAF are presented in Table 2. The DOACs plasma concentration range 
varies according to the indication and dosing regimen. This needs to be 
taken into account when interpreting the test results. The elimination half-
life of DOACs is relatively short compared with vitamin K antagonists. 
Therefore, the time of the last DOAC dose relative to blood sampling time 
must also be considered.  
 
These specific assays are not widely available as it requested specialized 
laboratories and staff, and furthermore, its turnaround time (TAT) may be 
too long to guide rapidly clinicians who are faced to critical situations 
involving DOACs.  
These tests showed a limit of detection with standard methodology and 
calibrators around 30 and 50 ng/ml, which is not accurate enough to guide 
experts’ proposals based on DOACs plasma concentration.74-79 
Furthermore, many specific assays (e.g. the dTT or most chromogenic 
assays for anti-Xa agents) are not specific to DOACs, as that they can falsely 
estimate higher DOACs plasma concentrations in the presence of heparin.  
 51 
This interference is especially high with chromogenic assays using the same 
reagent for direct anti-Xa agents and heparins.  
 
iv. Issues with different perioperative management proposals 
An increasing number of patients are receiving a DOAC. In Belgium, the 
number has tripled in two years (i.e. 33000 patients in 2012 and 100 000 
patients in 2014).
80
  
Annually approximately 10-15% of such patients will require a DOAC 
interruption for an elective procedure.
81
 Several reviews provided guidances 
regarding the perioperative management of patients on DOACs.
82-84
 Their 
aim was to ensure mimimal to no anticoagulant effect at the time of the 
procedure, and to minimize the period without protection against 
thromboembolism.  
Although this was an important step, especially for clinicians with a poor 
knowledge of these drugs, many proposals had a different strategy to guide 
the best timing to surgery.  
 
The main approach to guide perioperative management in elective surgery 
was based on the elimination half-life of the drug, which is highly influenced 
by renal clearance in patients taking dabigatran. Despite drug-drug 
interactions that are frequently found in patients treated with NVAF, only 
few proposals add some extra delay to the surgery.
85
 For rivaroxaban, there 
 52 
is no guidance for patients with altered liver metabolism in the perioperative 
setting. 
Many proposals integrated the bleeding risk of the surgery in the 
perioperative algorithm, allowing some low bleeding risk procedures to be 
realized with clinically significant residual anticoagulant effect of DOACs, 
without consequences on the patient’s outcome. 
For elective surgery, a good understanding of drug’s elimination half-life 
may prevent DOAC monitoring. However, some patients may have 
unexpected health conditions that can prolong DOAC elimination, and a 
quantitative measurement of DOAC can be requested before a high bleeding 
risk procedure.  
This is different for the emergency setting, where the estimation of DOACs 
plasma concentration has rapidly revealed to be crucial in guiding patients’ 
management at a time where antidotes were not available, e.g. when an 
emergent surgery needed to be rapidly planned or the patient required 
aggressive transfusion of blood products.  
 
The first proposals on DOACs plasma concentration in the emergency 
setting were provided by the Groupe d’Intérêt en Hémostase Périopératoire 
(GIHP). They proposed that the threshold of 30 ng/ml plasma concentration 
of dabigatran and rivaroxaban should provide adequate haemostasis for high 
bleeding risk procedures. If possible a delay to emergent surgery was 
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recommended, and a new estimation of DOACs plasma concentration was 
suggested before allowing the invasive procedure.
75-78,86
 The threshold of 30 
ng/ml was defined as the expected concentrations reached after three half-
lives, when 87.5% of the Cmax has been eliminated, assuming that the mean 
Cmax is 215 and 175 ng/ml (Summary of Products Characteristics (SmPC) 
values for NVAF patients) for rivaroxaban and dabigatran, respectively. 
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In the same idea, a report of the European Medecines Agency (EMA) 
recommended a dabigatran plasma concentration below 48 ng/ml before a 
surgery, which would correspond to 25% of the mean Cmax, reached after 
two half-lifes. 
87
 
It can be hazardous to consider only the elimination half-life of DOACs to 
estimate their residual concentration in emergency settings, as it does not 
take into account the high inter-individual variability of DOAC 
concentrations, which has recently been shown to have a poor correlation 
with patient’s renal function, except for dabigatran concentrations at 
trough.
88
 
 
However, the measurement of DOACs plasma concentration requires the 
most accurate laboratory tests for the suspected plasma range, which in turn 
depends on the clinical setting that need a monitoring (see Table 3). It is 
important to note that the proposed tests for each of the DOACs are subject 
to limitations with regard to their sensitivity, specificity, the experience 
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within the laboratory, the availability, the inter-reagent variability, the 
linearity of the response, as well as the current existence or absence of a 
known cut-off level for bleeding risks (see Table 3).  
Accurate laboratory tests and exclusion of important biological or clinical 
interferences, may allow clinicians to take the best decision for the 
management of their patients. 
This research project aimed at improving the use of some routine and 
specific coagulation assays frequently used in the perioperative context. 
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Table 3. Laboratory monitoring of direct oral anticoagulants 
Drugs Laboratory tests Utility Availability Sensitivity/ 
Specificity 
Dependence of 
the reagent 
Linearity of the 
response 
Dabigatran 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPTT Limited: 
Bleeding event/ 
Emergencies 
 
Reflects poorly the 
intensity of 
anticoagulation 
 
24/7 – all 
laboratories 
± 100 ng/ml 
/ No 
Yes No 
TT Limited: 
Exclude the presence of 
dabigatran in the peri-
operative setting 
24/7 – all 
laboratories 
Very 
sensitive -
LOD 1ng/ml 
LOQ 2ng/ml 
/ No 
Yes Depend on the 
reagent – until 50 
ng/ml 
dTT 
 
High and low 
calibrators 
Bleeding or thrombotic 
event/ emergencies 
 
Accurate estimation of 
plasma concentrations 
(ng/ml)  
 
Requires trained 
staff – only in 
specialized 
laboratories 
± 10 ng/ml  
/ No 
No  Yes 
ECT Limited:  
Standardisation and 
validation required  
Requires trained 
staff – only in 
specialized 
laboratories 
 
± 15 ng/ml  
/ No 
Probably not but 
an inter-lot 
variability has 
been reported 
Yes 
 56 
Dabigatran ECA Bleeding or thrombotic 
event/ emergencies 
 
Accurate estimation of 
plasma concentrations 
(ng/ml)  
 
Requires trained 
staff – only in 
specialized 
laboratories 
± 10 ng/ml  
/ No 
No No 
Rivaroxaban/ 
(Edoxaban) 
PT Limited: 
Bleeding event/ 
Emergencies 
 
Reflects poorly the 
intensity of 
anticoagulation 
 
24/7 – all 
laboratories 
from ±100 to 
> 500 ng/ml 
(depending 
on the 
reagent)  
/ No 
Yes Yes 
Rivaroxaban 
/ Apixaban / 
Edoxaban 
Chromogenic 
anti-Xa assays 
 
High and Low 
calibrators 
Bleeding or thrombotic 
event/ emergencies 
 
Accurate estimation of 
plasma concentrations 
(ng/ml)  
 
Requires trained 
staff – only in 
specialized 
laboratories 
± 10 ng/ml / 
Yes-No 
(depend on 
the anti-Xa 
assay) 
No Depends on the 
reagent 
Dabigatran/ 
Rivaroxaban 
/ Apixaban / 
Edoxaban 
 
 
 
LC-MS/MS Not for emergencies  
 
Accurate estimation of 
plasma concentrations 
(ng/ml)  
 
 
Requires trained 
staff – only in 
specialized 
laboratories 
LOD and 
LOQ around 
1 and 3 
ng/ml 
Not applicable Yes 
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Dabigatran/ 
Rivaroxaban 
/ Apixaban / 
Edoxaban 
DRVV-T 
 
 
Partially proven: 
Confirmation needed in 
plasma samples from 
patients treated with 
apixaban and edoxaban.  
 
Detection of apixaban in 
bleeding or thrombotic 
events/ emergencies. 
Only in 
specialized 
laboratories 
± 100 to 200 
ng/ml 
(depend on 
the reagent 
and the 
molecule)  
/ No 
Yes, but < to PT 
or aPTT 
No 
 
 
 
 
58 
 
  
59 
 
II. Objectives 
 
Research questions 
A. How can we improve the use of thrombin time in the perioperative 
management of patients on dabigatran etexilate? 
B. Which specific assays are more accurate for the perioperative 
setting of patients on DOACs? 
i. Comparison of the performance of coagulation tests 
specifically developed for the measurement of low plasma 
dabigatran concentrations with the reference LC-MS/MS 
method. 
ii. Case series showing the discrepancy of dabigatran plasma 
concentrations estimation with the different coagulation 
assays in a perioperative context.  
iii. Comparison of the performance of chromogenic assays 
specifically developed for the measurement of low 
rivaroxaban concentrations with the reference LC-MS/MS 
method. Impact of heparin bridging on their performance. 
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III. Results 
 
Part 1 
 
How can we improve the use of thrombin time in the 
perioperative management of patients on dabigatran etexilate? 
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Guidance regarding dabigatran monitoring has been published
56,89
, but 
the specific assays are not all targeted to low levels of dabigatran 
encountered in the preoperative setting. For example, the Hemoclot® 
Thrombin Inhibitor (HTI) and the ecarin chromogenic assay (ECA) 
have a limit of detection and quantification (LOD and LOQ) between 
30 and 50 ng/ml 
90-92
. In our recent study, a modified HTI (HTI LOW) 
and ECA (STA®-ECA II) adapted for low dabigatran concentrations 
showed better performances than conventional HTI to assess plasma 
dabigatran concentrations below 50 ng/ml 
93
, but these assays are not 
widely available. The activated partial thromboplastin time should not 
be used to assess dabigatran in plasma as it has only a modest 
correlation with dabigatran levels and is affected by factor 
deficiencies, lupus anticoagulant or elevated FVIII in inflammatory 
conditions 
94
.  
Some recent publications have suggested that thrombin time (TT) 
could be useful to assess the presence of dabigatran to guide the peri-
procedural management 
55,57
. However, TT is affected by many 
variables 
95
 and there is a lack of standardization between laboratories 
96
.  
Therefore, we decided to analyse TT following validation methods 
published by Marlar et al. and Chandler 
97,98
 in plasma samples 
66 
 
containing dabigatran.  We assessed the TT of different spiked 
dabigatran concentrations with intra- and inter-assay precision, its 
stability in time (at 2, 4 and 24 hours) and at different temperatures 
(room temperature and 4°C), its LOD and LOQ for dabigatran, the 
linearity of the results, and finally, the sensitivity of TT to different 
spiked concentrations of unfractionated heparin (UFH) (Leo Pharma, 
Ballerup, Denmark) and enoxaparin (Clexane®, Sanofi-Aventis, 
Diegem, Belgium) compared to HTI.  Afterwards, we analysed TT in 
24 plasma samples from dabigatran treated patients expected to be in 
the low ranges.  
The stability of TT was compared using the Wilcoxon signed-rank 
test. We used Medcalc software version 6.0 for Windows® and 
GraphPad Prism® version 6.0 for Mac OSx®.  
The study was approved by the Medical Ethical Committee of the 
CHU Dinant Godinne UcL Namur (BU3920096633). We prepared 
normal pool plasma (NPP) and platelet-poor-plasma (PPP) samples 
and stored them as described previously 
56
. Dabigatran was purchased 
from Alsachim® (Strasbourg, France) and spiked at increasing 
concentrations (0, 10, 20, 30, 40, 50, 100 and 200 ng/ml) in NPP as 
described previously 
56
. These concentrations were designed to cover 
pre-procedural ranges (from 0 to 50 ng/ml) 
86,99
 and trough therapeutic 
67 
 
ranges (from 50 to 200 ng/ml). The limits of the trough therapeutic 
range represent the range in which ischemic stroke/systemic embolic 
events and major bleeding events are lowest 
100
. Two thrombin 
reagents were tested (a bovine thrombin: HemosIL® TT, 
Instrumentation Laboratory, Lexington, KY, USA, and a human 
thrombin: STA®-Thrombin, Diagnostica Stago, Asnière, France) on 
two coagulometers (STA-R® Evolution and ACL TOP®700). We 
prepared 6 different concentrations of bovine thrombin (3.33, 3.75, 
3.90, 4.05, 4.28 and 5.00 NIH/ml) and 4 different concentrations of 
human thrombin (1.36, 1.50, 1.76 and 2.00 NIH/ml). We defined the 
optimal thrombin concentration (OTC) for three arbitrarily selected 
conditions, as the minimal concentration that gave a reproducible TT: 
 less than 120 seconds at 50 ng/ml;  
 less than 300 seconds at 200 ng/ml;  
and higher than the minimum TT measurable with the coagulometer at 
0 ng/ml of dabigatran (e.g. > 8 seconds for ACL TOP®). 
We set TMAX at 300 seconds (instead of the recommended 120 
seconds on STA-R® and 100 seconds on ACL TOP®) to allow 
measurement of dabigatran concentration up to 200 ng/ml. This was 
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technically not possible to achieve for the combination STA®-
Thrombin on ACL TOP®.  
As shown, in Fig.1. the OTCs were 1.76 NIH/ml for STA-R® with 
STA®-Thrombin, 4.28 NIH/ml for STA-R® with HemosIL® TT, 
3.75 NIH/ml for ACL TOP® with HemosIL® TT and we found no 
OTC for ACL TOP® with STA®-Thrombin (TMAX = 100 seconds). 
The type of coagulometer (different mechanism of clot detection, i.e. 
mechanical (STA-R®) versus optical (ACL TOP®) clot detection) 
and, especially, the thrombin origin were two important variables. We 
decided afterwards to use a homogeneous system for the validation 
methods and chose two OTCs for each coagulometer (1.50 and 1.76 
NIH/ml of STA®-Thrombin for STA-R®; 3.75 and 3.90 NIH/ml of 
HemosIL® TT for ACL TOP®). For STA®-Thrombin, the 
concentration recommended by the manufacturer is 1.50 NIH/ml. At 
this thrombin concentration, TT was sometimes > 120 seconds for 
dabigatran concentrations of 50 ng/ml, so that it failed to respect one 
of the OTC’s arbitrary conditions, but for routine facilities we tested it 
further. For HemosIL® TT, the manufacturer’s recommendations 
(1.9, 3.0 and 7.5 NIH/ml) were never optimal following our arbitrary 
definitions (preliminary tests not shown). 
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Fig 1. Optimization of thrombin time on different coagulometers 
and with different reagents 
 
 
A) STA-R Evolution
®
, STA
®
-Thrombin; B) STA-R Evolution
®
, HemosIL
®
 
TT; C) ACL TOP
®
700, HemosIL
®
 TT; D) ACL TOP
®
700, STA
®
-Thrombin.  
Thrombin times < 8 seconds were placed at zero in images C and D.  
Thrombin time > 300 seconds (A-C) or 100 seconds (D)* were set at 300 and 
100 seconds, respectively.  
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Our repeatability experiments showed an acceptable variability (below 
10% for intra-assays and below 12% for inter-assays) 
97
. ACL TOP® 
with HemosIL® TT showed higher CV% than STA-R® with STA® 
Thrombin. This may be explained by the mechanism of clot detection. 
Mechanical clot detection (STA-R®) may be preferable to optical clot 
detection (ACL TOP®) due to its increased sensitivity 
101
 and greater 
precision 
102
.  
Stability experiments were tested for one OTC on each coagulometer. 
A slight increase of TT appeared after 2 hours of storage at room 
temperature. For 1.50 NIH/ml on STA-R®, the stability tests showed 
a statistically significant increase in TT for all dabigatran 
concentrations when plasma samples were stored at room temperature 
for 4 or 24 hours. For plasma samples stored at 4°C, we observed 
statistically and clinically significant increases in TT for samples with 
dabigatran concentrations > 30 ng/ml that were stored for 24 hours.  
For 3.75 NIH/ml on ACL TOP®, only plasma samples stored at room 
temperature showed a statistically and clinically significant increase in 
TT for dabigatran concentrations > 30 ng/ml and stored for 24 hours. 
The stability for the different dabigatran concentrations at room 
temperature and 4°C is shown in Fig. 2.  
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Fig 2. Stability of plasma samples containing low and high 
dabigatran concentrations, at 4°C and room temperature. 
 
A, C, E and G correspond to the measurements of TT (mean + SD) on STA-
R
®
 Evolution with STA
®
-Thrombin at 1.50 NIH/ml. B, D, F and H 
correspond to the measurements of TT (mean + SD) on ACL TOP
®
 700 with 
HemosIL
® 
TT at 3.75 NIH/ml. 
72 
 
This time-related increase in TT may be due to platelet and soluble 
coagulation factor activation 
103
. These findings should be validated 
on samples from patients treated with dabigatran. We suggest to 
measure TT as soon as possible (within 2 hours of sampling) in 
plasma containing dabigatran. If this is not possible, samples should 
be rapidly stored at 4°C.   
We tested TT and HTI in the presence of UFH and enoxaparin both in 
NPP at 0, 0.15, 0.30, 0.60, 0.90, 1.20, 1.50 and 2.00 UI/ml. Thrombin 
time was above the reference range at a concentration of 0.15 UI/ml of 
UFH, 0.30 UI/ml of enoxaparin whereas the HTI gave a false positive 
result at 0.60 UI/ml of UFH and 1.20 UI/ml of enoxaparin on STA-
R®. The aim of this comparison was to show the differences in 
sensitivity of TT to two different heparins and to underline the limit of 
HTI in patients bridged with heparin. A commercially available 
heparinase can be added to the blood sample to detect the presence of 
heparin 
104
. 
Limit of detection and LOQ were lower than 0.9 and 3.0 ng/ml 
respectively for STA®-Thrombin on STA-R®, and lower than 2.2 and 
7.2 ng/ml for HemosIL® TT on ACL TOP®. As stated in previous 
publications 
55,56
, TT is a reliable test to exclude clinically relevant 
dabigatran presence in the blood. 
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Following the linear regressions presented in Table 1, TT measured 
with STA®-Thrombin concentration proposed by the manufacturer 
(1.5 NIH/ml) can also detect dabigatran concentrations < 50 ng/ml (R-
square = 0.97). In addition, optimised HemosIL® TT on ACL TOP® 
is a reliable qualitative test for dabigatran concentrations up to 200 
ng/ml (R-squares = 0.98), which is not the case for STA®-Thrombin 
on STA-R® (R-squares = 0.78 and 0.75 for 1.5 NIH/ml and 1.76 
NIH/ml respectively).  
Table 1. Linearity of thrombin time and dabigatran 
concentrations following optimized thrombin concentrations 
 1.50 NIH/ml 
STA®-
Thrombin 
STA-R
® 
Evolution 
1.76 NIH/ml 
STA®-
Thrombin 
STA-R
® 
Evolution 
3.75 NIH/ml 
HemosIL
®
 TT 
ACL TOP
®
700  
3.90 
NIH/ml 
HemosIL
®
 
TT 
ACL 
TOP
®
700 
For  dabigatran concentrations: 0, 30, 50, 100 and  200 ng/ml  
R-square 0.78 0.75 0.98 0.98 
For  dabigatran concentrations: 0, 30 and 50 ng/ml  
R-square 0.97 0.99 0.98 0.99 
 
Therefore, we do not support the suggestion of Chin et al. 
105
 to use 
TT to assess trough dabigatran concentrations and adjust treatment 
doses. Furthermore, other studies are needed to validate the 
improvement in outcomes with dose adjustment related to plasma 
levels and patient characteristics 
100,106
. 
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In plasma samples from patients treated with dabigatran etexilate, TT 
was measured under routine conditions (1.50 NIH/ml of STA®-
Thrombin on STA-R®). Most samples (12/13) with a TT < 120 
seconds had a dabigatran concentration < 50 ng/ml (confirmed by 
liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS)). The only exception was a sample with a free dabigatran of 
76 ng/ml and a TT of 110.3 seconds, collected in a context of an 
inflammatory syndrome. Seven samples had a normal TT with a LC-
MS/MS measuring maximum 4 ng/ml. One sample had a TT of 64.3 
seconds and no dabigatran measured, but this patient was switched to 
therapeutic enoxaparin.  
Most samples (10/11) with a TT ≥ 120 seconds had a dabigatran 
concentration > 50 ng/ml, except for one patient (free dabigatran: 28 
ng/ml) who was admitted to the intensive care unit with a medical 
history suggesting presence of fibrin/fibrinogen degradation products. 
These results emphasize the importance of taking into account the 
clinical context in the interpretation of TT.  
In terms of limitations, the conclusions might not be generalizable to 
other coagulometers and our ex vivo results should be confirmed in a 
larger population.  
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We conclude that TT may be used as an alternative in assessing low 
dabigatran concentrations (< 50 ng/ml), especially for laboratories that 
do not have access to specific assays. However, clinicians also need to 
consider all the different variables affecting TT. Thrombin time 
should not be used to assess dabigatran concentrations in the normal 
therapeutic range.  
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Part 2 
 
Comparison of the performance of two coagulation tests 
specifically developed for the measurement of low plasma 
dabigatran concentrations with the reference LC-MS/MS method. 
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ABSTRACT 
Background 
The perioperative management of dabigatran is challenging and 
recommendations based on activated partial thromboplastin time 
(aPTT) and thrombin time (TT) are unsatisfactory. Dedicated 
coagulation tests have limitations at plasma concentrations <50ng/ml. 
Therefore, a more sensitive test, which is available 24/7, is required. 
Aim 
To investigate the performance of the Hemoclot Thrombin Inhibitors
®
 
LOW (HTI LOW) kit, a diluted thrombin time, and the STA
® 
- ECA II
 
(ECA-II) kit, a chromogenic variant of the ecarin clotting time, that 
were developed to measure low dabigatran concentrations, compared 
to reference dabigatran analysis by liquid chromatography tandem 
mass-spectrometry (LC-MS/MS).  
Materials 
This study included 33 plasma samples from patients treated with 
dabigatran etexilate who had plasma concentrations <200ng/ml. HTI 
LOW and ECA-II were performed along with HTI, aPTT (STA
®
-
C.K.Prest
®
 and SynthasIL
®
) and TT (STA
® 
- Thrombin). All 
procedures were performed according to recommendations by the 
82 
 
manufacturers. Linear (or curvilinear) correlations and Bland-Altman 
analyses were calculated. 
Results and discussion 
For free dabigatran concentrations <50ng/ml, the R
2
 of linear 
correlations were 0.69, 0.84 and 0.61, with HTI, HTI LOW and ECA-
II, respectively. The R
2
 for TT, STA
®
-C.K.Prest
®
 and SynthasIL
®
 
were 0.67, 0.42 and 0.15. For HTI, HTI LOW and ECA-II, Bland-
Altman analyses revealed mean differences of -6ng/ml (95%CI: -25 – 
14ng/ml), 1ng/ml (95%CI: -18 – 19ng/ml) and -1ng/ml (95%CI: -25 – 
23ng/ml), demonstrating that tests dedicated to measuring low 
concentrations are more accurate than HTI.  
Conclusions  
The use of HTI LOW or ECA-II to assess low plasma dabigatran 
concentrations is supported by our findings.  
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INTRODUCTION 
Pradaxa
®
, dabigatran etexilate, has received its market authorization 
for various indications worldwide and was developed and marketed to 
be used in fixed dose regimens without a need for regular monitoring. 
However, assessments of drug plasma levels are desired to ensure a 
safe use of the product in several specific situations 
107
. In this context, 
the perioperative management of dabigatran is quite challenging 
especially in the absence of a specific reversal agent. During the two 
years of follow-up in the RE-LY study, approximately 25% of the 
patients underwent at least one invasive procedure. Compared with 
warfarin, dabigatran is associated with similar rate of perioperative 
bleeding and thrombotic complications, even among patients having 
major or urgent surgery 
108
. However, in patients who had treatment 
withdrawn > 3 days before the intervention dabigatran was associated 
with more bleeds, perhaps at least in part due to accumulation of the 
drug in patients with poor renal function. Furthermore, the equality of 
outcomes should be viewed in relation to how warfarin-related bleeds 
or risk of bleeding were handled in the study. Thus, vitamin K was 
given perioperatively to fewer than 5% of warfarin-treated patients. 
Fresh-frozen plasma was given to 2%, and prothrombin complex 
concentrate treatment was apparently not used at all. The comparison 
84 
 
of bleeding problems might have been less favourable for dabigatran 
if patients taking warfarin would more often have received treatments 
that are recommended by expert opinion and guidelines 
109
. This 
underlines the necessity to implement risk minimization strategies in 
the perioperative management of dabigatran in absence of specific 
antidote, especially for high-risk surgery, e.g. major interventions or 
neurosurgery.  
 
In the initial assessment report of the European Medicines Agency 
(EMA), the marketing authorization holder informed that a dabigatran 
concentration below 48 ng/ml is equivalent to elimination of at least 
75% of dabigatran and should be reached before invasive intervention 
110
. The “Groupe d’Intérêt en Hémostase Périopératoire (GIHP)” is 
much more conservative and put the threshold at 30 ng/ml 
86
. A 
diluted Thrombin Time (dTT, i.e. the Hemoclot Thrombin Inhibitors
®
, 
Hyphen BioMed, Neuville-Sur-Oise, France) has been proposed for 
accurate determinations of dabigatran in plasma, but this test was not 
intended for measurements of low levels of dabigatran 
111
. Other 
studies have assessed the performance of this test, but also of a 
chromogenic variant of the well-established ecarin clotting time 
112
. 
Both tests had lower limits of quantitation between 30 and 50 ng/ml 
89-
85 
 
92
. Therefore, a specific laboratory test, which is accurate in the low 
concentration range and available 24/7, is highly requested. So far, 
most routine coagulation tests for assessments of dabigatran 
concentrations or effects in the lower concentration range have been 
too insensitive. This limits their usefulness in the perioperative setting, 
and the use of the undiluted thrombin time test (TT) is currently 
presented as an alternative due to its very high sensitivity to 
dabigatran 
56,95,105
. This approach, although interesting, has some 
limitations because TT is affected by several analytical and biological 
variables making its standardization difficult 
113
.  
 
In this study, we investigated the performance of two coagulation tests 
specifically developed for measurements of low plasma dabigatran 
concentrations (the Hemoclot Thrombin Inhibitors
®
 LOW (HTI 
LOW), a diluted thrombin time (Hyphen BioMed
®
, Neuville-sur-Oise, 
France) and the STA
®
-ECA II (ECA-II), a chromogenic variant of the 
ecarin clotting time (Diagnostica Stago
®
, Asnière-sur-Seine, France)) 
and to compare their results to direct measurements by a reference 
liquid chromatography coupled with a tandem mass-spectrometry 
(LC-MS/MS) method 
89
. We also assessed the performances of the 
standard procedure of HTI (Hyphen BioMed
®
) and the activated 
86 
 
partial thromboplastin time (aPTT), which are recommended in the 
EMA documents 
110,114
, as well as of the TT. 
 
MATERIALS AND METHODS 
The study was performed in accordance with the Declaration of 
Helsinki and was approved by the Medical Ethics Committee of the 
Centre Hospitalier Universitaire Dinant Godinne UcL Namur in 
Yvoir, Belgium. Written informed consent was obtained from each 
donor.  
Clinical samples and normal pooled plasma 
Thirty-three plasma samples from patients treated with dabigatran 
etexilate for stroke prevention in non-valvular atrial fibrillation were 
included in the study. Blood was taken by venipuncture in the 
antecubital vein and collected into 0.109 M sodium citrate (9:1 v/v) 
tubes (Venosafe®, Terumo, Heverlee, Belgium) using a 21-gauge 
needle (Terumo). Platelet-poor plasma (PPP) was obtained from the 
supernatant fraction after double centrifugation for 15 minutes at 
1500g at room temperature. Afterwards, plasma was aliquoted and 
frozen at –80°C without delay. Frozen plasma samples aliquots were 
thawed and heated to 37°C for at least 5 minutes just before 
experiments. Plasma samples were taken randomly and included in 
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this study after a first assessment of plasma dabigatran concentrations 
using the HTI to select samples with plasma concentrations <200 
ng/ml. The exact plasma level of dabigatran was measured using a 
reference LC-MS/MS method, as described below 
89
. 
Normal pooled plasma (NPP) was obtained from the PPP of 27 
healthy individuals which was prepared as for the clinical samples. 
The exclusion criteria for the healthy individuals were: thrombotic 
and/or haemorrhagic events, pregnancy, and use of antiplatelet and/or 
anticoagulant medication and/or drugs potentially affecting platelet 
and/or coagulation factor functions during two weeks prior to 
sampling.  
Liquid chromatography coupled with tandem mass 
spectrometry   
This method has been described previously 
89
. Briefly, plasma 
concentrations of free dabigatran were determined after sample 
preparation by protein precipitation of 50 μL citrated plasma with 150 
μL acetonitrile containing dabigatran-d3 as an internal standard. The 
calibration curve for dabigatran in plasma was linear over the range 1-
400 ng/ml and the limit of detection (LOD) was estimated to be <0.5 
ng/ml. Validation experiments with three levels of control samples 
(8.1, 202 and 393 ng/ml) on three different occasions (six 
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determinations per concentration), showed an inter- and intra-assay 
precision between 6.0% and 9.2% and between -0.9% and 3.6%, 
respectively.  
Coagulation assays 
For the ordinary HTI assay, a diluted thrombin time (dTT), the tested 
plasma was diluted 1:8 in Owren-Koller
®
 buffer. Fifty μL of diluted 
plasma were mixed with 100 μL of NPP and were incubated during 
240 seconds. One hundred μL of highly purified human thrombin, in 
the α-form pre-incubated at 37°C was then added to start the reaction. 
The procedure was calibrated with a 3-calibrators kit at 35, 240 and 
470 ng/ml (Hyphen BioMed
®
). For HTI LOW, the methodology of 
the test was the same (i.e. it used the same reagent than HTI) except 
that 1) the dilution of the sample was reduced to 1:2 compared to 1:8 
for the normal procedure, and that 2) specific calibrators (and 
controls) at lower concentrations (0, 57 and 110 ng/ml) were required 
(Hyphen BioMed
®
) to establish a new calibration curve. All 
calibrations were defined by linear correlation. 
 
For ECA-II, the tested plasma was diluted 1:5 in Owren-Koller
®
 
buffer. Fifty μL of diluted plasma were mixed with 140 μL of 
prothrombin and then 70 µL of chromogenic substrate were added and 
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incubated during 240 seconds. Seventy μL of ecarin, pre-incubated at 
37°C, was then added to start the reaction. Optical density was 
followed during 40 seconds (from 70 to 110 seconds after ecarin 
addition) and the result was expressed as the difference of OD/min. 
The procedure was calibrated with a 5-calibrator kit at 0, 50, 96, 177 
and 240 ng/ml (Diagnostica Stago
®
) and results were fitted by an 
exponential decay equation model. For results above 230 ng/ml, the 
ECA-II proposed an automatic re-dilution of the sample (1:10 instead 
of 1:5). Thrombin Time (TT), using STA
®
-Thrombin
 
at 1.5 NIH 
units/ml, with an upper limit of measurement (ULM, i.e. the maximal 
clotting time for which the coagulometer provides a numerical result) 
extended to 300 seconds (Diagnostica Stago
®
; NPP baseline clotting 
time: 16.8 seconds; standard deviation: 0.3 seconds; local acceptable 
range: 13.5 – 20.5 seconds) and the activated partial thromboplastin 
time (aPTT), using STA
®
-C.K.Prest
®
 (Diagnostica Stago
®
; NPP 
baseline clotting time: 30.3 seconds; standard deviation: 0.2 seconds; 
acceptable range: 26.4 – 37.6 seconds) and SynthasIL® 
(Instrumentation Laboratory
®
; NPP baseline clotting time: 31.4 
seconds; standard deviation: 0.2 seconds; local acceptable range 26.0 
– 38.0 seconds) reagents were also measured to compare the 
performance of each of these tests in presence of low concentrations 
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of dabigatran.All procedures were performed on a STA-R Evolution
®
 
coagulometer (Diagnostica Stago
®
), according to the 
recommendations of the manufacturers.  
Statistical analyses 
Statistical analyses were performed using GraphPad Prism version 
5.00 (GraphPad Software, San Diego California, USA, 
www.graphpad.com) for Windows. Results for coagulation tests 
expressed in ng/ml were compared to the LC-MS/MS method by 
linear regression. Bland-Altman analyses were also performed and 
were calculated as follows: Difference (A-B)/average, where A was 
the result of the corresponding coagulation test and B, the result of the 
LC-MS/MS.  
Thrombin time showed a linear regression while aPTT is better fitted 
by a curvilinear (first-order) relation described by the following 
model: Y=Y0 + (Plateau-Y0)*(1-exp(-K*x)). 
Sensitivity was defined as the concentration in dabigatran in the 
original sample required to double the clotting time or halve the 
optical density per minute (OD/min). For the coagulation assays, the 
lower limit of detection (LOD) and the lower limit of quantitation 
(LOQ) were calculated as follows: LOD = [(3*standard deviation of 
Y0)/ slope] and LOQ = [(10*standard deviation of Y0/ slope]. The 
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standard deviation of Y0 was calculated by running the tests 10 times 
with NPP.  
 
RESULTS  
The plasma concentration range of free dabigatran was from 0 to 200 
ng/ml according to LC-MS/MS measurements. ►Table 1 summarises 
data on plasma drug concentrations according to the time elapsed 
since dabigatran etexilate administration. Among these samples, 17 
were between 0 and 50 ng/ml. For assays that express results in ng/ml 
(i.e. HTI, HTI LOW and ECA-II) the linear correlation parameters 
and the Bland-Altman analyses versus exact plasma concentrations 
are provided in ►Table 2 and represented in ►Figure 1 for 
concentrations between 0 and 200 ng/ml. A stratification for results 
between 0 and 50 ng/ml is also provided in the same table and figure. 
►Figure 2 shows the results for TT and aPTT. 
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Table 1: Median plasma drug concentrations according to the time elapsed since dabigatran etexilate 
administration. 
 
LC-
MS/MS 
(ng/ml) 
HTI 
 
(ng/ml) 
HTI 
LOW 
(ng/ml) 
STA
®-
ECA-II 
(ng/ml) 
STA
®
-
Thrombin 
(s) 
SynthasIL
®
 
 
(s) 
STA
®
-
C.K.PREST
®
 
(s) 
Time elapsed since the last dose: 0 hours† (n=2) 
Median 0 0 0 0 18.8 31.7 32.5 
Range  
(min – max) 
0 to 0 0 to 0 0 to 0 0 to 0 18.6 to 19.0 31.5 to 31.8 27.5 to 37.5 
 Time elapsed since the last dose: 2 hours (n=4) 
Median 133 122 138 153 229.2 56.8 52.9 
Range  
(min –max) 
65 to 185 64 to 191 87 to 168 77 to 204 
18.1 to M > 
MMax‡ 
32.6 to 59.3 27.5 to 56.9 
 Time elapsed since the last dose: 3 hours (n=4) 
Median 125 119 132 146 235.4 51.1 48.3 
Range  
(min – max) 
49 to 200 68 to 194 79 to 179 77 to 161 
215.5 to 
292.5 
42.1 to 57.7 42.2 to 57.1 
 Time elapsed since the last dose: 12 hours (n=5) 
Median 76 46 76 83 157.8 48.2 42.9 
Range  
(min – max) 
52 to 88 22 to 83 61 to 103 65 to 118 
103.3 to 
233.5 
38.3 to 56.5 38.7 to 54.6 
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 Time elapsed since the last dose: 20 hours (n=8) 
Median 41 17 42 34 91.7 39.5 40.4 
Range  
(min – max) 
0 to 76 0 to 56 0 to 95 0 to 83 19.9 to 189.2 24.8 to 52.5 24.2 to 46.5 
 Time elapsed since the last dose: Unknown (n=10) 
Median 
9 0 1 8 26.5 
 
 
32.0 28.7 
Range  
(min – max)  
0 to 40 0 to 30 0 to 41 0 to 37 16.7 to 80.2 21.9 to 55.2 22.7 to 35.5 
 
Table 1. Two hours and 3 hours correspond to the expected Cmax of the drug while 12 hours corresponds to the Cmin. Plasma samples 
taken more than 20 hours after the last intake of dabigatran etexilate were grouped together. For 11 samples, the exact time elapsed 
since the last intake was unknown.  
†
 0 hours correspond to baseline value (before the first intake of dabigatran etexilate)  
‡
 M>MMax means that the upper limit of measurement (ULM) of the test (i.e. 300 seconds) was exceeded 
HTI: Hemoclot Thrombin Inhibitors
®
;
 
LC-MS/MS: Liquid chromatography coupled with tandem mass-spectrometry
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Figure 1. Results of the linear correlation (A) and the Bland-Altman analyses for the entire concentration range 
(B) for HTI, HTI LOW and ECA-II compared to LC-MS/MS. 
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Fig 1. Bland-Altman analyses were also extracted for concentration specifically <50 ng/ml (C). Bland-Altman analyses were 
calculated as follow: Difference (A-B)/average, where A was the result of the corresponding coagulation test and B, the result of the 
LC-MS/MS. HTI: Hemoclot Thrombin Inhibitors
®
 - HTI LOW: Hemoclot Thrombin Inhibitors
®
 - ECA-II: STA
®
-ECA II  
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Linear and curvilinear correlations  
For concentrations between 0 and 200 ng/ml, the R
2
 of the linear 
correlations were 0.94, 0.94 and 0.85 for HTI, HTI LOW and ECA-II, 
respectively. For STA
®
-Thrombin, the R
2
 of the linear correlation was 
0.79 and the clotting time ranged from 16.7 to 292.5 seconds. For 
aPTT, the R
2
 were 0.62 and 0.43 for STA
®
-C.K.Prest
®
 and 
SynthasIL
®
, respectively. The clotting times ranged from 22.7 to 57.1 
seconds for STA
®
-C.K.Prest
®
 and from 21.9 to 59.3 seconds for 
SynthasIL
®
.  
 Figure 2 
 
Fig 2. Results of the linear correlation for TT (STA
®
-Thrombin at 1.5 
NIH/ml; NPP baseline clotting time: 16.8 seconds; standard deviation: 0.3 
seconds; acceptable range: 13.5 – 20.5 seconds) and the curvilinear 
correlation for aPTT (STA
®
-C.K.Prest
®
; NPP baseline clotting time: 30.3 
seconds; standard deviation: 0.2 seconds; acceptable range: 26.4 – 37.6 
seconds and SynthasIL
®
; NPP baseline clotting time: 31.4 seconds; standard 
deviation: 0.2 seconds; acceptable range 26.0 – 38.0 seconds), respectively.
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For concentration below 50 ng/ml, the R
2
 of the linear correlations 
were 0.69, 0.84 and 0.61 for HTI, HTI LOW and ECA-II, 
respectively. The R
2
 of the linear correlation for TT was 0.67 and the 
longest clotting time for this range of concentrations was 248.7 
seconds for a sample with 49 ng/ml. For aPTT, linear correlation R
2
 
values of 0.42 and 0.15 were found for STA
®
-C.K.Prest
®
 and 
SynthasIL
®
, respectively.  The highest clotting times in this 
concentration range were 57.1 and 57.7 seconds for STA
®
-C.K.Prest
®
 
and SynthasIL
®
 for the sample with a plasma concentration of 49 
ng/ml. 
 
Bland-Altman analyses 
For concentration between 0 and 200 ng/ml, the Bland-Altman 
analysis showed a mean difference of -10 ng/ml (95%CI: -38 to 18 
ng/ml), 1 ng/ml (95%CI: -25 to 28 ng/ml) and 4 ng/ml (95%CI:-41 to 
48 ng/ml) for HTI, HTI LOW and ECA-II, respectively.  
For concentration below 50 ng/ml, the Bland-Altman analysis showed 
a mean difference of -6 ng/ml (95%CI: -25 to 14 ng/ml), 1 ng/ml 
(95%CI: -18 to 19 ng/ml) and -1 ng/ml (95%CI:-25 to 23 ng/ml) for 
HTI, HTI LOW and ECA-II, respectively.  
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Table 2. Summary of results obtained with the different analyses as 
related to direct measurements of dabigatran in plasma by LC-MS/MS. 
 
HTI HTI LOW STA
®
-ECA-II 
STA
®
- 
Thrombi
n 
0 to 200 ng/ml (n=33) 
R-square 0.94 0.94 0.85 0.79 
slope 0.9748 0.9663 1.002 
 
95% CI 
(0.8803 to 
1.069) 
(0.8773 to 
1.055) 
(0.8490 to 
1.154) 
intercept -8.633 3.204 3.635 
95% CI 
(-15.93 to -
1.336) 
(-3.672 to 
10.08) 
(-8.159 to 
15.43) 
Bland-
Altman  
(in ng/ml) 
-10 1 4 
95% CI (-38 to 18) (-25 to 28) (-41 to 48) 
 0 to 50 ng/ml (n=17) 
R-square 0.69 0.84 0.61 0.67 
slope 0.8740 1.219 0.9403 
 
95% CI 
(0.5516 to 
1.197) 
(0.9268 to 
1.511) 
(0.5302 to 
1.351) 
intercept -4.03 -2.629 -0.2403 
95% CI (-11.60 to 3.00) 
(-8.994 to 
3.736) 
(-9.182 to 
8.701) 
Bland-
Altman 
(in ng/ml) 
-6 1 -1 
95% CI (-25 to 14) (-18 to 19) (-25 to 23) 
 
Table 2. Results are given for the linear regression (R
2
, slope, intercept) and the 
Bland-Altman analyses. Results are also stratified for dabigatran concentrations up 
to 200 ng/ml and <50 ng/ml.  
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Sensitivity and Limits of Detection/Quantitation 
The concentrations of dabigatran in the sample required to double 
the clotting time of HTI, HTI LOW, TT, aPTT (STA
®
-C.K.Prest
®
) and aPTT 
(SynthasIL
®
) were 298, 67, 6, 585 and 551 ng/ml, respectively. For ECA-II, 
the concentration of dabigatran required to halve the DO/min was 102 
ng/ml. The LOD and LOQ were 8 and 25, respectively, for HTI compared to 
2 and 7 ng/ml for HTI LOW. For ECA-II the entire calibration curve is not 
defined by a linear correlation but by a second order polynomial relation. 
Therefore, we took only the 3 first points of the calibration curve, i.e. 0, 50 
and 96 ng/ml, to calculate the LOD and LOQ for ECA-II. These 3 points 
were well defined by a linear correlation model (R
2
 = 1.00), thus. The LOD 
and LOQ for ECA-II in this concentration range were 14 and 46 ng/ml while 
for TT, the LOD and LOQ were 1 and 2 ng/ml, respectively.  
 
DISCUSSION  
Currently, there is no clear consensus regarding the perioperative 
management of patients treated with dabigatran etexilate, especially not 
among patients with impaired renal function in whom longer time periods 
are required to eliminate the drug 
115
. While several authors recommend the 
use of a dTT, such as HTI, or an aPTT in the perioperative context 
54,116
, 
their insufficient sensitivity 
89-92
 limits their utility in patients with low 
plasma levels of dabigatran 
100,113
. The inaccuracy of HTI at low 
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concentrations may not change the clinical outcomes in invasive 
interventions with low bleeding risk. However, in connection with high-risk 
surgery, such as neurosurgery, a more accurate assessment may be needed 
and risk minimization strategies should be provided.  
Thrombin time is an alternative in this context due to its very high sensitivity 
towards dabigatran 
117
. However, it is influenced by several biological and 
analytical variables 
57
. Thus, up to now, anaesthetists, surgeons and doctors 
involved in critical care units are so far ill-equipped to cope with situations 
requiring accurate evaluations of residual dabigatran effects and/or plasma 
concentrations and a specific laboratory test which is accurate in the low 
concentration range and available 24/7 is highly requested. 
 
 Performance of dedicated coagulation tests compared to global 
ones 
Our results show that HTI LOW performs better than HTI and ECA-II in the 
concentration range assessed in this study, i.e. from 0 to 200 ng/ml. It 
provides a steeper correlation compared with ECA-II and a lower systematic 
difference compared to LC-MS/MS with a narrower 95% confidence 
interval (►Table 2). However, ECA-II provides less systematic deviation 
than HTI (4 ng/ml versus -10 ng/ml) for assessments of plasma 
concentrations in the 0-200 ng/ml range. For concentrations below 50 ng/ml, 
HTI LOW correlates better with LC-MS/MS than HTI or ECA-II, which 
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were equivalent at these low concentrations. Regarding the systematic 
deviation, both HTI LOW and ECA-II performed very well with a small 
preference for HTI LOW due to a narrower 95% confidence interval.  
Regarding sensitivity, HTI LOW was the most sensitive assay followed by 
ECA-II and HTI. Surprisingly, ECA-II did not perform better than 
previously shown for the “non-dedicated” methodology 91,92. However, both 
HTI LOW and ECA-II reflect plasma dabigatran concentrations <50 ng/ml 
reasonably well with a slight preference for HTI LOW due to narrower 
confidence intervals. However, HTI LOW requires a new calibration curve 
and a new set of controls which further increases the turn-around time in an 
emergency situation. This is not required for ECA-II which directly 
introduces a calibration curve for the low concentrations and an automatic 
re-dilution of the sample if the result exceeds 230 ng/ml. However, if the test 
is already calibrated on the coagulometer, our proposal for sample 
management (see below) can reduce the turn-around time by choosing 
directly the right procedure to use between HTI and HTI LOW. 
 
As expected, the lowest LOD and LOQ were obtained with TT, i.e. 1 and 2 
ng/ml, respectively. With the normal procedure (with an upper limit of 
measurement (ULM) of 120 seconds with STA
®
-Thrombin
 
at 1.5 NIH 
units/ml on a STA-R Evolution
®
 coagulometer), concentrations above 50 
ng/ml frequently exceed the ULM making the evaluation of the degree of 
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anticoagulation impossible. For example, in our study, one sample with 49 
ng/ml dabigatran gave a TT of 248.7 seconds while in another sample, TT 
reached 86.2 seconds for a plasma concentration of dabigatran of 54 ng/ml 
(► Figure 2).  Thus, thrombin time may be less useful than dedicated 
assays to provide estimates of dabigatran effects. Initial recommendations on 
the peri-procedural management of patients taking dabigatran etexilate stated 
that a normal aPTT indicated the absence of a significant dabigatran effect. 
It was also recommended that surgery should be delayed for ≥1 half-life 
after the last dose of dabigatran or until the aPTT is normal or “near normal” 
54
. However, aPTT reacts differently depending on reagents, coagulometers 
and their combinations, and a normal aPTT may be found in the presence of 
therapeutic dabigatran concentrations making these recommendations too 
simplistic 
56,118,119
. In the present study, one sample was within the normal 
range of the STA-C.K.Prest
®
 (35.5 seconds; normal range: 26.4 to 37.6 
seconds) and SynthasIL
®
 (32.1 seconds; normal range: 26 to 38 seconds), 
despite a dabigatran concentration of 40 ng/ml. Two samples exhibited 
normal Synthasil
®
 and STA
®
-C.K.Prest
®
 values despite concentrations of 76 
and 34 ng/ml, respectively. Thus, the aPTT alone is not reliable and 
decisions based on aPTT should be avoided. Dedicated coagulation tests 
should be preferably used to guide the perioperative management. In the 
absence of dedicated coagulation tests, the aPTT may be used but, only 
concomitantly with the TT, as proposed previously 
57,117
.  
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 Proposal for sample management 
The laboratory can be guided by TT regarding which dedicated coagulation 
assay to use. We propose the following approach for the rational 
management of plasma samples from patients on dabigatran etexilate: For 
TT that exceeds the ULM (i.e. a TT < 120 seconds or ± 6-times the upper 
limit of normal on a STA-R Evolution
®
 coagulometer using the 
recommendations of the manufacturer), we propose the use of the standard 
HTI assay which has demonstrate a sufficient accuracy in estimating plasma 
concentrations of dabigatran above 50 ng/ml 
89,91,92,111
. Following our 
experiments, if TT is between the baseline clotting time and the ULM, a 
dedicated method should be employed. The HTI LOW or the ECA-II assays 
both provide good estimates of the plasma concentrations but HTI LOW 
seems to be more accurate thanks to narrower confidence interval. This 
simple paradigm may avoid unnecessary costs and ensure the best estimation 
of the plasma concentrations when required, e.g., in the perioperative setting. 
  
 Bridging therapy? The advantage of generating meizothrombin 
A recent prospective and non-interventional registry revealed that heparin 
bridging did not reduce cardiovascular events in the perioperative context 
but lead to a significantly higher rate of major bleedings. However, the use 
of heparin bridging increased with the severity of the procedure (30% of 
patients in this registry received heparin bridging compared with 16% in the 
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RE-LY analysis). The authors conclude that patients at cardiovascular risk 
who need to undergo major procedures may benefit from heparin bridging 
120
. In case of heparin bridging, the anticoagulant effect is transiently 
affected by low molecular weight heparins to the effect of dabigatran. 
Despite being less accurate than HTI LOW, one of the main advantage of 
ecarin based assays is that in case of switching or bridging therapy, 
meizothrombin, i.e. the intermediate product released by ecarin from 
prothrombin, is unaffected by the presence of heparin and derivatives. This 
allows an accurate assessment of the direct thrombin inhibitor in plasma. 
This was demonstrated in one of our patients who was bridged from 
dabigatran etexilate to enoxaparin. While LC-MS/MS and ECA-II revealed 
no residual dabigatran in plasma (0 ng/ml) the HTI LOW assay yielded a 
dabigatran plasma concentration of 8 ng/ml. The TT and the SynthasIL
® 
were 53.9 and 52.9 seconds, respectively. Thus, HTI LOW may be 
influenced by the presence of heparin or LMWH and laboratory tests should 
be interpreted in conjunction with the clinical history. Another advantage of 
the ECA-II method is that the user must not choose between a “LOW” or a 
“normal” procedure since the test is intended to perform both by itself on a 
Stago
®
 platform. However, this is at the expense of higher reagent 
consumption. 
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LIMITATIONS 
Our study has some limitations. First, the LC-MS/MS method proposed in 
this study only measured free dabigatran and does not include the conjugated 
form. However, the latter only contributes approximately to 20% of the total 
dabigatran in plasma and is most likely of minimal importance at these low 
concentrations of dabigatran 
113,121
. The second limitation concerns the low 
number of samples assessed that did not allow us to provide strong 
recommendations on whether HTI LOW or ECA-II should be used at the 
lowest plasma concentrations. Nevertheless, Bland-Altman analyses 
revealed that both HTI LOW and ECA-II perform better than HTI in the 
concentration range tested in this study and that they should be preferred to 
the standard procedure of HTI for evaluations of assess plasma 
concentrations between 0 and 50 ng/ml. This single center pilot study with a 
small patient material was not designed and powered to address clinical 
outcomes. Consequently, the implementation of a second-tier assay for 
dabigatran testing in routine practice should be further investigated to 
confirm clinical benefits in a large, multicentric study. 
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CONCLUSIONS 
So far, TT has been the only functional test sufficiently sensitive to guide the 
management of patients in the perioperative context since both the Hemoclot 
Thrombin Inhibitors
®
 (HTI) and the Ecarin Chromogenic Assay (ECA) 
showed weak performances when assessing low dabigatran concentrations. 
Measurements of such low plasma concentrations may have clinical 
implications for high-risk surgery and dedicated coagulation tests are 
therefore required. The HTI LOW and the ECA-II assays, specifically 
adapted to evaluate low dabigatran concentrations, performed well with 
dabigatran concentrations in plasma <50 ng/ml. We therefore recommended 
the use of HTI LOW or ECA-II to assess the plasma concentrations when 
they are suspected to be low, such as those encountered in the perioperative 
context. HTI LOW seems to be more accurate due to a narrower confidence 
interval but this should be confirmed in a larger study. However, screening 
of such samples by TT may be useful when choosing dedicated coagulation 
tests in order to avoid unnecessary costs and ensure the best estimation of 
dabigatran plasma concentrations, when required. The clinical benefit of 
such a procedure should be confirmed in a large multicentric study that 
addresses its impact on clinical outcomes. 
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EXTRA TABLE 
What is known about this topic? 
 The perioperative management of dabigatran is quite challenging 
especially in the absence of a specific reversal agent and 
possibilities to evaluate the intensity of the treatment are therefore 
valuable. 
 The use of dTT or an aPTT has been recommended in the 
perioperative context but their insufficient sensitivity limits their 
utility in patients with low plasma levels of dabigatran. 
 Thrombin time is an alternative in this context due to its very high 
sensitivity but it is influenced by several biological and analytical 
variables. 
What does this paper add? 
 The performance of two coagulation tests specifically developed 
for measurements of low plasma dabigatran concentrations (the 
Hemoclot Thrombin Inhibitors
®
 LOW (HTI LOW) (Hyphen 
BioMed
®
, Neuville-sur-Oise, France) and the STA
®
-ECA II 
(ECA-II) (Diagnostica Stago
®
, Asnière-sur-Seine, France) has 
been assessed and compare to direct measurements by a reference 
LC-MS/MS method. 
 The HTI LOW and the ECA-II assays, specifically adapted to 
evaluate low dabigatran concentrations, performed well with 
dabigatran concentrations in plasma <50 ng/ml. 
 Screening by the thrombin time test may be useful in choosing the 
dedicated coagulation tests (i.e. HTI or HTI LOW/ECA-II) in 
order to avoid unnecessary costs. 
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Part 3 
 
Case series showing the discrepancy of dabigatran plasma concentrations 
estimation with the different coagulation assays in a perioperative context. 
 
The manuscript is currently under rewiewing in the journal Blood 
Coagulation & Fibrinolysis 
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ABSTRACT 
Introduction 
Management of emergencies and invasive procedures in patients on 
dabigatran etexilate may request a ponctual assessment of dabigatran plasma 
concentrations.  
Methods 
Two dedicated coagulation assays for low dabigatran concentrations (the 
Hemoclot Thrombin Inhibitor® with low calibrators and the STA®-ECA II) 
and a standard methodology (the Hemoclot Thrombin Inhibitor® with 
standard calibrators) have been used to assess residual dabigatran plasma 
concentrations in three patients in a peri-procedural context. The results 
were compared with the reference method liquid chromatography coupled 
with a tandem mass-spectrometry. We raised the difference in residual 
dabigatran plasma concentrations’ estimation depending on the coagulation 
assay and on the different perioperative management available in the 
literature.  
Results 
The Hemoclot Thrombin Inhibitor® with low calibrators and the STA®-
ECA II assays were more accurate for low dabigatran plasma concentrations 
than the Hemoclot Thrombin Inhibitor® with standard calibrators. The 
different periprocedural management may lead to large differences in 
residual dabigatran concentrations at the time of the procedure. 
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Conclusions 
This case-series illustrates the interest of using appropriate coagulation 
assays for the expected range of dabigatran plasma concentration in 
situations requiring accurate measurements (e.g. serious bleeding, urgent 
procedure at high risk of bleeding). Furthermore, this case-series highlights 
the need for a unique periprocedural management policy for patients on 
dabigatran etexilate.  
  
114 
 
  
115 
 
Introduction  
With the growing number of patients treated with direct oral anticoagulants 
(DOACs), clinicians are increasingly confronted with challenging situations 
where an estimation of their anticoagulant effect may be required. 
78,122
  
In the last 5 years, the impact and clinical relevance of the anticoagulant 
effect of DOACs on several coagulation assays have been reported. 
55,61,62,66,93,123-127
 For dabigatran, the activated partial thromboplastin time 
(aPTT) and the thrombin time (TT) are routine coagulation tests that may be 
used to estimate dabigatran plasma level, while more specific coagulation 
assays such as the diluted thrombin time (dTT) or ecarin-based assays such 
as the ecarin chromogenic assay (ECA) are used to provide accurate 
measurements of dabigatran plasma concentrations. 
55,125
 
However, the aPTT can be normal in the presence of therapeutic 
concentrations of dabigatran 
89,91,92,128
 and is not accurate at high dabigatran 
concentrations. 
95
 Inversely, the TT is very sensitive to dabigatran and 
therefore useful to exclude its presence at clinically relevant concentrations 
before invasive procedures. 
55
 However, its lack of standardisation makes it 
unsuitable for quantitative measurements. 
60
 Moreover, both aPTT and TT 
are not specific to dabigatran and may be influenced by pre-analytical and 
analytical variables.  
Of the commercially available specific tests, dTTs such the Hemoclot
®
 
Thrombin Inhibitor (HTI) (Hyphen BioMed
®
, Neuville-sur-Oise, France) or 
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ecarin-based assays such STA® ECA II (ECA II) (Diagnostica Stago
®
, 
Asnière-sur-Seine, France) are validated for the quantitative measurement of 
dabigatran plasma concentrations. However, the HTI with standard 
calibrators and the preceding version of ECA II have previously shown a 
limit of quantitation between 30 and 50 ng/ml 
89-92
 precluding accurate 
measurements of the low plasma concentrations often encountered in the 
perioperative setting after dabigatran has been stopped 
79
. To date, the gold 
standard method for measuring such low concentrations is liquid 
chromatography coupled with a tandem mass-spectrometry (LC-MS/MS) 
56,89,129
 but this is  available only in highly specialized centers and not in 
routine practice. 
Therefore, improved specific assays, i.e. the HTI with low calibrators (HTI 
LOW) and the ECA II, have been developed to cover this range. We 
demonstrated in an earlier ex-vivo analytical study using 33 plasma samples 
from patients treated with dabigatran etexilate (DE), that the estimation of 
low dabigatran concentrations was more accurate with the adapted 
methodologies than with the conventional HTI for dabigatran concentrations 
below 50 ng/ml. 
93
  
For some challenging situations requiring a measurement of dabigatran 
plasma concentration, we use the HTI LOW and ECA II methodologies 
systematically when the plasma range is expected to be low.  
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This case series describe three peri-procedural settings of patients on DE 
with a serious bleeding or requiring the planning of an urgent procedure, and 
for whom the anticoagulant effect of dabigatran was monitored. Through 
these three illustrations, we first aimed at highlighting the potential impact 
on patients’ management according to the difference in residual plasma 
concentrations obtained with the specific tests HTI, HTI LOW and ECA II. 
Secondly, we aimed at demonstrating that the different periprocedural 
recommendations proposed in the current literature lead to significant 
different residual plasma concentrations at the suggested time of the invasive 
procedure.  
 
Methods  
The study was performed in accordance with the Declaration of Helsinki and 
was approved by the Medical Ethics Committee of the CHU UCL Namur in 
Yvoir, Belgium (number B039201524384). All patients provided written 
informed consent.  We selected three patients for whom a coagulation 
screening was realized at different times before and after an urgent invasive 
procedure.  
For urgent dabigatran plasma concentration measurement, only the standard 
method HTI was realized when on-therapy range was suspected (e.g. 
prolonged routine coagulation assays aPTT and TT > 120 s). Some blood 
samples were collected in the follow-up of these patients for observational 
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studies, without impacting patients’ management. In these samples, impact 
of dabigatran on coagulation were estimated with  routine coagulation assays 
(aPTT and TT) and plasma concentrations were measured using specific 
tests (conventional HTI, HTI LOW and ECA-II). All these procedures were 
performed on a STA-R Evolution
®
 coagulometer (Diagnostica Stago®) 
following the manufacturer’s recommendations.  
To compare our results with the reference method, the samples were sent for 
LC-MS/MS measurements to the Department of Clinical Pharmacology, 
Karolinska University Hospital and Clinical Pharmacology Unit, Stockholm, 
Sweden. 
 
Diluted Thrombin Time 
For the conventional method of the Hemoclot
®
 Thrombin Inhibitor (HTI), 
the tested plasma was diluted in a 1:8 ratio in Owren-Koller
®
 buffer with an 
incubation time of 240 s. Purified human thrombin, in the α-form, was added 
to start the reaction. Calibration was performed using a commercial kit of 3 
standards at concentrations of 35, 240 and 470 ng/ml from Hyphen 
BioMed®. For the low procedure, the methodology was the same except that 
the initial dilution was reduced (1:2) and a new calibration curve using 
commercially available calibrators from the same manufacturer, with lower 
concentrations (0, 57 and 110 ng/ml) was used.
93
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Chromogenic assay 
For the STA®-ECA-II, the tested plasma was diluted in a 1:5 ratio in 
Owren-Koller
®
 buffer and mixed with prothrombin and a chromogenic 
substrate. After an incubation time of 240 s,  purified ecarin was added to 
start the reaction. The optical density (OD) was assessed for 40 s (from 70 to 
110 s) and the result was expressed in OD/min. The procedure was 
calibrated with a 5-level calibration kit at concentrations of 0, 50, 96, 177 
and 240 ng/ml (Diagnostica Stago
®
). If the estimated plasma concentration 
exceeded 230 ng/ml, as measured by the test, the STA®-ECA-II procedure 
automatically re-diluted the sample by increasing the initial dilution step 
(1:10 instead of 1:5).  
 
Routine coagulation assays 
For the TT, we used the STA®-Thrombin,
 
which contains human thrombin 
at a concentration of 1.5 NIH/ml (Diagnostica Stago
®
; baseline clotting time 
between 13.5 – 20.5 s; higher limit of measurement of 120 s) on a STA-R 
Evolution
®
 coagulometer (Diagnostica Stago
®
).  
For the aPTT, we used the STA
®
-C.K.Prest
®
 (Diagnostica Stago
®
; baseline 
clotting time between 26.4 – 37.6 s) on a STA-R Evolution® coagulometer 
(Diagnostica Stago
®
).  
All tests were performed according to the manufacturers’ recommendations 
using appropriate controls.  
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Results 
Case description 1 
A 65-year-old man weighing 79.5 kg was admitted to the emergency 
department with left lower lobe pneumonia. His medical history included 
hypertension, hypercholesterolemia, previous smoking, ischemic heart 
disease with angioplasty, and ablation for atrial flutter. He was receiving 
amiodarone 200 mg/day for 5 days/week, DE 150 mg twice a day (bid), 
molsidomine, quinapril with hydrochlorothiazide, acetylsalicylic acid (80 
mg) and rosuvastatin (10 mg). He was hospitalized and treated with 
amoxicillin clavulanate. Clarithromycin was introduced three days later. 
Dabigatran plasma concentration was measured to exclude supratherapeutic 
levels, as both amiodarone and clarithromycin are strong inhibitors of P-
glycoprotein. The Cockcroft-Gault (C-G) equation gave a creatinine 
clearance (CrCl) of 82 ml/min and the dabigatran trough concentration (22 
hours after the last intake - see Table 1: patient 1 - sample 1) estimated with 
HTI was 66 ng/ml, which is not associated with an increased risk of major 
bleeding. This assertion is based on a substudy of the RELY trial, in which a 
trough plasma dabigatran concentration of 210 ng/ml doubled the rate of 
major bleeding compared with median concentrations of 88 ng/ml, measured 
10-16 h after the last dabigatran intake (for 150 mg of DE bid).
100
 
The cardiologist advised that anticoagulation should be continued as the 
patient had had several episodes of atrial fibrillation (AF) after his ablation. 
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As his oxygen requirement increased despite treatment, broncho-alveolar 
lavage (BAL) by fibroscopy was performed to test for the presence of 
Legionella antigen. The BAL was carried out 4 hours after DE intake and 
the fibroscopy revealed an alveolar hemorrhage. Afterwards, the patient 
mentioned that he had coughed up blood before the fibroscopy. 
Anticoagulants were stopped and the patient received rapidly intravenous  
four-factor prothrombin complex concentrate (PCC) 50 UI/kg. 
Unfortunately, the clinicians did not request a dabigatran monitoring before 
fibroscopy or PCC infusion. However, the first sample realized the day 
before did not show supra-therapeutic dabigatran concentrations. 
Furthermore, the patient was symptomatic before the procedure and with 
acute deterioration of its respiratory function, the clinicians decided to 
decrease rapidly the anticoagulant effect of DE as the diagnosis of alveolar 
hemorrhage came short after peak time. In order to assess the decrease in 
anticoagulant level after PCC infusion, further estimations of dabigatran 
plasma concentration were realized as illustrated in Table 1. The Legionella 
antigen test was positive and the patient was admitted to the intensive care 
unit (ICU) two days later with acute respiratory distress syndrome. He was 
discharged from hospital three months later.  
Case description 2 
A 77-year-old man weighing 77.0 kg attended the emergency department 
because of  bradycardia, discomfort with dizziness, and a short loss of 
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consciousness. His medical history included hypertension, type 2 diabetes, 
previous smoking, dyslipidemia and cardioversion for AF one month before. 
He was receiving DE 150 mg bid, sotalol 40 mg bid, ramipril, gliquidone, 
furosemide and simvastatin. He had been receiving clarithromycin, but had 
stopped the day before admission. The patient was conscious. An 
electrocardiogram showed a third degree atrioventricular block with a heart 
rate of 20 beats/min and ventricular escape rhythm.  
His CrCl was 71 ml/min according to the C-G equation.  HTI indicated 360 
ng/ml of dabigatran 6 hours after the last intake. In the RE-LY trial, the 90
th
 
percentile of dabigatran plasma concentration at peak time was 383 ng/ml 
measured at 1 to 3 hours after last oral intake 
19,100
. The patient was paced 
with external patches during his transfer to ICU. As the external patches 
were not sufficient, the patient received cardiac massage intermittent 
compression and had to be intubated and sedated for his comfort. He 
received 25 IU/kg of PCC before the placement of an internal pacemaker 
through an echo-guided femoral access with chest X-ray control. The 
following day, the cardiologist decided  to place a permanent pacemaker. As 
the patient had such a high peak plasma concentration, dabigatran levels 
were monitored to ensure elimination before surgery (see Table 1: patient 2 
- samples 2-4). Unfortunately, the patient developed a respiratory tract 
infection after 2 days, postponing the procedure 6 days later. The patient was 
discharged from ICU the day after pacemaker insertion.  
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Case description 3 
A 76-year-old woman weighing 62.0 kg was hospitalized for a femoral neck 
fracture. Her medical history revealed AF with left atrial appendix 
thrombosis, severe aortic stenosis, sub-dural hematomas within the past year 
and 10 years before, type 2 diabetes, hypertension, hypercholesterolemia, 
smoking, and chronic obstructive pulmonary disease. She was taking DE 
110 mg bid, amiodarone, metformin, aldactazine, pantoprazole (20 mg) and 
ezetimibe (10 mg). Her CrCl on the day of admission was 75 ml/min 
according to the C-G equation. Surgery was delayed for 5 days after the last 
intake of DE, because of DE anticoagulation and operating room 
availability. Because of a high CHA2DS2-VASc score (6/9), the patient was 
bridged with enoxaparin 60 mg bid the second day after her admission. As 
HTI and HTI LOW can be falsely elevated in the presence of enoxaparin, 
dabigatran measurements were made before the next enoxaparin 
administration (see Table 1: patient 3 – samples 2-4).  
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Table 1: Coagulation screening in three patients on dabigatran etexilate in a peri-procedural setting 
 Time after 
last 
intake of 
dabigatran 
(hours) 
Time 
after PCC 
trans-
fusions 
(hours) 
HTI 
(ng/ml) 
HTI 
LOW 
(ng/ml) 
ECA II 
(ng/ml) 
LC-
MS/MS 
(ng/ml) 
aPTT 
(s) 
aPTT 
ratio 
TT 
(s) 
Fib 
(mg/dl) 
 Patient 1 
Sample 1 22 / 66 / / / 46.0 1.5 >120 1,129 
Sample 2 24 16 19 / / 50 39.8 1.3 79.1 1,382 
Sample 3 50 42 0 0 4 4 33.5 1.1 20.9 1,005 
Patient 2 
Sample 1 5 / 360 / / / 52.7 1.7 >120 415 
Sample 2 27 20 102 / / / 26.4 0.8 >120 396 
Sample 3 44 37 34 75 62 65 33.3 1.1 >120 470 
Sample 4 54 47 / / / / 27.4 0.9 73.1 558 
Patient 3 
Sample 1 18 / / / / / 50.1 1.7 >120 355 
Sample 2 40 
 
/ 27 60 61 67 38.0 1.3 >120 / 
Sample 3 84 / 6 0 0 10 27.5 0.9 29.5 / 
Sample 4 138 / 0 0 0 4 31.5 1.0 19 737 
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Table 1. HTI: Hemoclot Thrombin Inhibitor®, HTI LOW: Hemoclot Thrombin Inhibitor® LOW, ECA II: Ecarin Chromogenic Assay II®  
LCMS-MS: Liquid chromatography coupled with a tandem mass-spectrometry  
aPTT: activated partial thromboplastin time ( normal range: 26.4 – 37.6 s), TT: Thrombin Time (normal range: 13.5 – 20.5 s) 
Fib: fibrinogen (normal range: 180-400 mg/dl), PCC: Prothrombin complex concentrate, /: coagulation assays not asked  
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Discussion  
Issues with non standardized periprocedural managements…  
The threshold for plasma concentrations of dabigatran allowing safe 
hemostasis for procedures carrying a high risk of bleeding has not been 
studied in clinical trials, but is currently based on expert opinion. The French 
Group of Perioperative Hemostasis (GIHP) has proposed a cut-off value of 
30 ng/ml 
86
 which corresponds to the expected plasma DOAC concentration 
reached after 3 half-lives, when 87.5 % of the assumed Cmax (175 ng/ml) 
100
 
has been eliminated. This threshold is now also proposed by the 
International Society of Thrombosis and Hemostasis. 
130
 Based on this 
threshold, conventional tests, such as HTI, do not provide sufficient 
accuracy compared with specific methods for assessing low concentrations. 
In patients 2 and 3 (who had measurements taken 40 to 44 hours after 
stopping dabigatran), values obtained via HTI LOW and ECA-II were closer 
to the LC-MS/MS values than those obtained with HTI, which 
underestimates dabigatran concentrations. These differences in dabigatran 
measurements might influence decisions about perioperative management 
for procedures carrying a high risk of bleeding by allowing surgery for 
patients who actually have therapeutically relevant dabigatran plasma 
concentrations (in our cases,  65 and 67 ng/ml in patients 2 and 3, 
respectively).  
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Considering another type of perioperative management, based on the timing 
of last dabigatran intake according to a procedure’s bleeding risk and the 
patient’s renal function, as proposed by Schulman et al. 131, these three 
patients would have undergone low risk procedures with residual dabigatran 
plasma concentrations ranging from 66 to 120 ng/ml.  
On the same basis, for a procedure carrying a high risk of bleeding (for 
which a CrCl >50 ml/min at 48 hours after stopping dabigatran is 
recommended), patients 2 and 3 would have had residual dabigatran plasma 
concentrations of around 60 ng/ml.  
A sub-analysis of the prospective study on the perioperative management of 
patients on dabigatran was conducted by Douketis et al. It analyzed the 
residual anticoagulant effect of dabigatran found in plasma from patients the 
day of the elective invasive procedure using the HTI and a validated LC-
MS/MS method. 
132
 Blood samples were frozen and laboratory tests were 
performed later, ensuring that results of the coagulation tests and the LC-
MS/MS did not influence the perioperative management of these patients. 
The conventional HTI used in the study of Douketis et al. estimated that 
13% of the patients had a residual dabigatran concentrations > 20 ng/ml, 
which corresponded to the limit of detection of the test, as described by the 
authors. The LC-MS/MS measured around 16% over 20 ng/ml. The TT, 
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which demonstrated a high sensitivity towards dabigatran 
56,60,93
, was higher 
than the upper limit of the normal range (20 to 30 s, as described by the 
authors) in 43% of these blood samples. These results strengthened the 
hypothesis that a longer period of interruption might be required before high 
bleeding-risk procedures. 
132
 In addition, their results underlined the 
difference with the conventional HTI method in detecting concentration > 20 
ng/ml compared with LC-MS/MS (13% versus 16%, respectively), 
suggesting that conventional HTI is not optimal to assess low dabigatran 
concentrations. These data are in agreement with a recent multicenter study 
showing that waiting 48 hours after the last dose did not guarantee residual 
plasma concentrations ≤ 30 ng/ml, as 14% of patients did not achieve this 
cut-off value. 
79
 
Another issue with the different proposals for perioperative management are 
the differences in the definition of high and low bleeding risk procedures. 
For example, Schulman et al. consider  pacemaker placement to carry a high 
risk of bleeding because of the risk of pocket hematoma 
131
; while 
Heidbuchel et al. consider it to have a low risk of bleeding. 
24
 Obviously, 
these different categorizations influence the timing of surgery, especially in 
patients with poor renal function. This was confirmed in a recent multicenter 
study where the CrCl showed significant correlations with dabigatran at 
trough concentrations. 
88
 In addition, Douketis et al. showed that the 
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proportion of patients with dabigatran levels > 20 ng/ml in the high bleeding 
risk procedure arm was doubled in patients with a CrCl between 30 and 50 
ml/min compared with patients with a CrCl > 50 ml/min. However, due to 
the small number of bleeding outcomes, they could not perform any 
clinically meaningful correlation analyses between the clinical outcomes and 
the pre-procedural residual anticoagulant effect.  
 
How can DOAC measurements improve the periprocedural management? 
Periprocedural estimation of dabigatran plasma concentration will be most 
of the time realized in emergency settings carrying a high risk of bleeding, 
or when a patient presents an unexpected impaired renal function before a 
high bleeding procedure.  
Elective periprocedural management of patients treated with DE does not 
require routine dabigatran monitoring. However, a cautious assessment of 
the procedures’ bleeding risk and patients’ renal function is required to 
determine a safe period of DE interruption. 
In this case-series, some measurements of dabigatran concentration had no 
impact on their management. However, measurements realized for 
observational studies enable us to confirm the results of our previous studies 
60,93
 and to raise concern about current perioperative recommendations. 
Indeed, Testa et al. demonstrated high intra-inter variability of DOAC 
plasma concentrations in patients on DOACs. They warn clinicians about 
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higher than expected circulating dabigatran levels in clinical conditions such 
as surgery or invasive procedures. 
88
 Along the same lines, experts in 
regional anesthesia recommand further research studies including DOAC 
periprocedural estimation to validate a safe DOAC interruption before 
procedures at high bleeding risk, such as neuraxial anesthesia. 
133
  
Such research studies strengthen decisions concerning DOACs perioperative 
management. Indeed, the recent update on periprocedural management 
published by Spyropoulos et al.
134
 proposes a longer interruption of  DOAC 
than the one proposed by Schulman et al.
131
 (i.e. DE interruption before 
procedures carrying a high bleeding risk in patients with ClCr > 50 ml/min 
at day 3 instead of day 2). 
 
How to deal with heparin bridging in patients treated with dabigatran 
etexilate… 
The HTI and HTI LOW are not specific to dabigatran. Spiked unfractionated 
heparin (UFH) and enoxaparin at 0.60 IU/ml and 1.20 IU/ml respectively, 
gave false positive results with HTI, according to previous data. 
60
 Thus, for 
patients bridged with low molecular weight heparins (LMWH) when 
dabigatran is interrupted, the HTI should be realized just before the next 
administration of LMWH and care should be taken in the interpretation of 
the result. Importantly, the HTI LOW will have increased sensitivity towards 
heparins due to lower dilution step, as set in the procedure. The ECA-II 
131 
 
assay has the advantage to be specific to direct thrombin inhibitors and 
effective in assessing low concentrations. Therefore, it should be preferred 
to estimate preoperative dabigatran plasma concentrations in bridged 
patients. 
93
  
 
Decision tree for urgent dabigatran monitoring in different clinical settings  
Monitoring the anticoagulant effect of dabigatran has a clear added value 
when it can guide patients’ management, e.g. in case of bleeding or 
thrombotic events or in case of emergencies with high bleeding risk.  
For example, recent guidelines for the administration of idarucizumab 
130
, 
the high-costly antidote of DE, are partially based on dabigatran plasma 
concentrations. As the threshold to consider administration of idaricuzimab 
is 50 ng/ml for serious bleeding and 30 ng/ml for urgent invasive procedures 
carrying a high risk of bleeding, decision to administer the antidote should 
be guided with accurate coagulation assays. Conventional coagulation tests 
are not appropriate in this context. Interestingly, in this case-series, the 
difference in dabigatran measurements of dedicated assays for low 
concentrations (HTI LOW and ECA II) and standard methodology  (HTI) 
can strongly influence the management of serious bleeding. Indeed, the 
plasma concentrations measured with standard HTI (in patient 1 - sample 2,  
patients 2 and 3 – sample 2) would not suggest to use the antidote, as the 
ones measured with HTI LOW and ECA II (confirmed with LCMS-MS) 
132 
 
would suggest to use the antidote. As yet, the benefit of idarucizumab has 
not been proved on patient outcomes. However, clinicians need to rely on 
accurate tools to guide antidote’s administration. 
Table 2 proposes an algorithm of the laboratory tests to use in relation to the 
different clinical contexts that may require dabigatran monitoring.  
Nowadays, clinicians sometimes have to make do with routine coagulation 
assays to estimate the residual anticoagulant effect of dabigatran. The use of 
sensitive aPTT reagents and an optimized TT (i.e. a TT using a thrombin 
concentration able to detect dabigatran plasma concentrations up to 50 ng/ml 
within its limits of analytical range) can provide qualitative estimation of 
dabigatran plasma levels. Moreover, both routine tests can guide the 
laboratory in choosing the most accurate coagulation assays to measure the 
expected dabigatran plasma concentration.  
Although expert’s raise concerns of the urgent need to ensure access to 
specific coagulations assays for DOAC monitoring in emergency settings, 
these are not always available within an appropriate turnaround time. Efforts 
should be performed by laboratories and manufacturers to reduce the 
turnaroun time of specific assays (i.e by reducing the time of centrifugation 
and/or by reducing the time required to reconstitute controls and reagents) 
and make the specific assays widely available. 
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Table 2: Appropriate coagulation assays to use in clinical situations that 
may require a monitoring of dabigatran 
Emergencies 
that cannot be delayed 
or 
need to be rapidly 
plannified 
Periprocedural  
bleeding events 
Suspicion of insufficient 
perioperative arrest before  
a high bleeding risk 
procedure 
 
If TT < 120 s and/or normal aPTT : 
Use HTI LOW or ECA II 
 
If TT < 120 s 
and/or normal aPTT : 
 
Use HTI LOW or 
ECAII  
 
 
If TT > 120 s and prolonged aPTT : 
 
Use  HTI or ECA II  
 
 
In case of heparin bridging : 
Use ECA II 
 
Table 2. TT: Thrombin Time, aPTT: activated partial thromboplastin time, HTI: 
Hemoclot® Thrombin Inhibitor from Hyphen BioMed
®
 ECA II: ecarin chromogenic 
assay from from Diagnostica Stago
®
, DE: dabigatran etexilate. 
Our laboratory uses a TT with optimized conditions (STA®-Thrombin,
 
1.5 NIH/ml; 
baseline clotting time between 13.5 – 20.5 s; higher limit of measurement of 120 s) 
on a STA-R Evolution
®
 coagulometer (Diagnostica Stago
®
), allowing a 
measurement of TT within its analytical range for spiked dabigatran concentration in 
normal pool plasma between 0 and 50 ng/ml. 
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Conclusions 
The optimal time to stop a direct oral anticoagulant to minimize 
thromboembolic or bleeding complications remains unclear. 
136
 We need 
further prospective studies to standardize an optimal periprocedural 
management policy for patients on DE and to validate a safe cut-off of 
plasma concentration for procedures carrying a high risk of bleeding. When 
patients require a point measurement of dabigatran plasma concentration, 
laboratories should use the coagulation assay that has the best performance 
for the expected concentration ranges and patients’ specific clinical context. 
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Part 4 
 
Comparison of the performance of chromogenic assays specifically 
developed for the measurement of low rivaroxaban concentrations  
with the reference LC-MS/MS method.  
Impact of heparin bridging on their performance. 
 
The manuscript has been accepted in September 2016 in the journal  
Clinical and Applied Thrombosis/Hemostis 
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ABSTRACT 
Introduction 
Estimation of residual rivaroxaban plasma concentrations may be requested 
before invasive procedures and some patients at high thrombo-embolic risk 
will have a bridging therapy with heparins when rivaroxaban is interrupted. 
The objective of this study was to assess the performance of the STA®-
Liquid Anti-Xa assay (STA®LAX) and the low and normal procedures of 
the Biophen®Direct Factor Xa Inhibitors (DiXaI) assay, in patients with and 
without bridging with low-molecular weight heparins (LMWH). 
Material and Methods 
Seventy-nine blood samples were collected from 77 patients on rivaroxaban 
at CTROUGH or before an invasive procedure. Rivaroxaban plasma 
concentrations were estimated using Biophen®DiXaI, Biophen®DiXaI 
LOW and STA®LAX and compared with liquid chromatography coupled 
with mass spectrometry (LC-MS/MS) measurements.  Stratifications were 
performed according to heparin bridging.  
Results 
The Biophen®DiXaI LOW and STA®LAX showed better correlation with 
LC-MS/MS measurements than Biophen®DiXaI in patients not bridged with 
LMWH (R: 0.97, 0.96 and 0.91, respectively). However, the performance of 
Biophen®DiXaI LOW and STA®LAX decreased when residual LMWH 
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activity was present (R: 0.18 and 0.19 respectively) demonstrating that these 
tests are not specific to rivaroxaban. 
Conclusions 
In patients not bridged with LMWH, we suggest to use the Biophen®DiXaI 
LOW and STA®LAX for the estimation of rivaroxaban concentrations <50 
ng/ml. These results should be confirmed on a larger cohort of patients. 
Patients bridged with LMWH have inaccurate estimates of low levels of 
rivaroxaban and the three assays studied should not be used to estimate if it 
is safe to perform a procedure.  
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Introduction 
The management of rivaroxaban in the perioperative context requires 
specific expertise in both clinical and laboratory aspects 
137
. In the ROCKET 
AF trial, treatment interruptions occurred in 33% of participants, and 45% of 
the interruptions were in patients treated with rivaroxaban. Approximately 
8% of these patients were bridged, and a low molecular weight heparin 
(LMWH) was used in 98% of these patients. Surgical procedures accounted 
for 39% of the treatment interruptions in the rivaroxaban arm 
138
. A similar 
pattern was also reported from the Dresden registry in which 27% of the 
participants underwent a surgical procedure, of whom 30% were bridged 
with a LMWH after the pre-procedural interruption of their direct oral 
anticoagulant (DOAC)
120
.  The median duration of DOAC interruption 
before surgery was 2 days
120
. However, a prospective observational study on 
the periprocedural management of patients treated with dabigatran etexilate 
or rivaroxaban showed that 2 days of interruption may not be sufficient to 
eliminate the entire residual effect of these drugs. Indeed, in 14% of patients, 
although DOACs had been discontinued for 48 h, DOAC concentrations 
remained above 30 ng/ml which was defined as the safe threshold for 
invasive procedures
79
. Thus, some situations will require an assessment of 
the residual effect of rivaroxaban to guide therapeutic decisions, for 
example, before selecting fibrinolytic treatment in a patient on rivaroxaban 
presenting with an acute ischemic stroke
139
.  
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Specific coagulation assays are now available that can reliably estimate 
rivaroxaban plasma concentrations within its therapeutic range 
55,61,66,140,141
. 
Nevertheless, as shown for dabigatran 
142
, two previous studies have 
demonstrated the need for coagulation assays sensitive to low (<30 ng/ml) 
plasma concentrations of rivaroxaban 
143,144
. These studies used blood 
samples collected in real-life conditions, but none of them dealt with the 
problem of measuring plasma rivaroxaban concentrations in patients bridged 
with heparins when rivaroxaban is stopped.  
Some tests used to estimate the plasma concentration of rivaroxaban are also 
used to estimate heparin concentrations by applying appropriate 
calibrators.
70
 The STA®-Liquid Anti-Xa assay from Diagnostica Stago® 
(Diagnostica Stago®, Asnière, France) is a global anti-Xa assay designed to 
estimate low and on-therapy plasma concentrations of rivaroxaban and to 
measure LMWH anti-Xa activity. As a consequence, the presence of heparin 
when estimating rivaroxaban concentrations might affect the result and vice 
versa.  
To avoid this interference, Samama et al. have developed an optimized 
chromogenic assay (Biophen®Direct Factor Xa Inhibitors (DiXaI) from 
Hyphen BioMed®, Neuville-Sur-Oise, France). This test uses a specific 
buffer allowing the measurement of the sole anti-Xa activity from 
rivaroxaban even in the presence of heparins or fondaparinux 
145
. Its limit of 
quantitation (LOQ) of around 50 ng/ml is not appropriate for the 
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perioperative setting, and an adaptation of the procedure is proposed to 
allow the estimation of lower rivaroxaban plasma concentrations.  
We hypothesized that low residual heparin plasma concentrations found the 
day of the invasive procedure may interfere with some assays used to 
quantify rivaroxaban.
70
  
The objective of this study was to assess the performance (limit of detection, 
limit of quantitation and accuracy) of the low and the high procedure of the 
Biophen®DiXaI assay, and the STA®-Liquid Anti-Xa assay from 
Diagnostica Stago® (Diagnostica Stago®, Asnière, France), using real-life 
samples from patients with or without bridging with LMWH.  
Materials and methods 
The study was performed in accordance with the Declaration of Helsinki and 
was approved by the Medical Ethics Committee of the CHU UCL Namur, 
Yvoir, Belgium. Written informed consent was obtained from each donor.  
Clinical samples  
Eighty-six plasma samples from 84 patients on rivaroxaban were collected 
from April 2014 until the end of July 2015 in the CHU UCL Namur, Yvoir, 
Belgium.  
The inclusion criteria were patients receiving rivaroxaban for secondary 
prevention of thrombo-embolic events in atrial fibrillation or treatment of 
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venous thromboembolism, and collection of blood samples at trough 
concentrations or just before an invasive procedure.  
The only exclusion criterion was the absence of result for one of the three 
chromogenic assays. Seven blood samples were excluded from the study, 
which was realized on the remaining 79 blood samples collected from 77 
patients.  
We aimed at collecting at least thirty samples from patients bridged and not 
bridged with LMWH. Blood was taken by venipuncture in the antecubital 
vein using a 21-gauge needle (Terumo™) or through a peripheral venous 
catheter (BD Insyte-W®, 18 or 16-gauge) and collected into 0.109 M 
sodium citrate (9:1v/v) tubes (Venosafe®, Terumo™, Heverlee, Belgium). 
Platelet-poor plasma (PPP) was obtained from the supernatant fraction after 
double centrifugation at 1,500 G for 15 min at room temperature. Samples 
were then aliquoted and frozen immediately at -80°C. Plasma sample 
aliquots were thawed and heated to 37°C for at least 5 min before running 
the experiments.  
We measured the creatinine clearance with the Cockcroft-Gault equation, 
using the actual body weight. 
Distribution of collected blood samples following LMWH presence and last 
administration  
Some blood samples came from patients bridged with LMWH after 
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cessation of rivaroxaban. As residual heparin might interfere with the 
estimation of plasma concentrations of rivaroxaban by anti-Xa assays, we 
divided patients into three groups (➤Figure 1).  
- Group A represents the patients who were not bridged with LMWH 
(n=31). These blood samples were collected from patients at CTROUGH (n=28; 
timing of last administration between 21 and 48 h) outside a perioperative 
context or within a perioperative context without the use of heparin bridging 
(n=3; timing of last administration between 42 and 72 h).  
- Group B represents the patients who were bridged with LMWH (n=48; 
timing of last administration between 65 and 158 h). 
- Group C was a subdivision of group B and included patients bridged with 
therapeutic LMWH whose last administration of LMWH was ≥ 24 hours ago 
(n=26). The group C was designed to analyze the effect of low LMWH 
levels (last administration of LMWH was ≥ 24 hours) on rivaroxaban 
estimation. 
This stratification of the time interval between blood sampling and last 
LMWH administration is based on the international recommendations for 
safe hemostasis before an invasive procedure (e.g. neuraxial anesthesia), 
when therapeutic LWMH bridging is established preoperatively 
84,146,147
. 
Therapeutic LMWH was defined as enoxaparin 1 mg/kg twice a day (bid) or 
nadroparin calcium 171 international units (IU) anti-Xa/kg once a day (qd).    
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Figure 1. Distribution of the collected blood samples following LMWH 
presence and last administration.  
 
Fig 1. The 79 blood samples included in the analyses were collected from patients 
receiving rivaroxaban at trough concentrations (CTROUGH) or before an invasive 
procedure. For these samples, an estimation of rivaroxaban plasma concentrations 
with three chromogenic assays (Biophen®DiXaI, Biophen®DiXaI LOW and 
STA®LAX) was performed and compared with measurements obtained by LC-
MS/MS.  Stratifications were performed according to heparin bridging.  
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Estimation of the anti-Xa activity of LMWH administered ≥ 24h ago  
To assess the impact of residual anti-Xa activity from LMWH on the 
estimation of rivaroxaban concentrations, samples from Group C were used 
(n=26). In these samples, the residual rivaroxaban plasma concentrations 
were below the LOQ of the LC-MS/MS (i.e. 1.0 ng/ml). Thus, residual 
LMWH anti-Xa activity can be measured without interference from the anti-
Xa activity of any residual rivaroxaban. 
Normal pooled plasma 
Normal pooled plasma (NPP) was obtained from the platelet poor plasma 
(PPP) of 49 healthy individuals. The exclusion criteria for the recruitment of 
healthy individuals were: thrombotic or hemorrhagic events, pregnancy, or 
use of antiplatelet, anticoagulant agent or any drug potentially affecting 
platelet or coagulation factors within two weeks of blood sampling. Blood 
was taken by venipuncture in the antecubital vein using a 21-gauge needle 
(Terumo™). The sample preparation steps were the same as for the clinical 
samples.  
Chromogenic anti-Xa assays  
Biophen®Direct Factor Xa Inhibitors. We incubated 200 µl of diluted 
plasma (1:50 with the Tris-NaCl-EDTA buffer at pH 7.85) with 75 µl of 
human FXa (Hyphen BioMed) for 120 s at 37°C, then 75 µl of a specific 
FXa substrate [CS-11(65)] (Hyphen BioMed) were added to start the 
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reaction on a STA-R®Evolution coagulometer (Diagnostica Stago). The 
concentrations of calibrators for the normal therapeutic range of rivaroxaban 
(Biophen®Rivaroxaban Plasma Calibrator, Hyphen BioMed) were 50, 250 
and 500 ng/ml in the initial samples after reconstitution.  
The low procedure (Biophen®DiXaI LOW) was the same as the normal one 
except that plasma was diluted 1:8 in the buffer and the calibration was 
performed with standards for low plasma concentrations of rivaroxaban 
(Biophen®Rivaroxaban Calibrator Low). The standard rivaroxaban 
concentrations were 0, 52 and 110 ng/ml.  
STA®-Liquid Anti-Xa. We mixed 30 μl of diluted plasma (1:4 in STA® - 
Owren-Koller) with 150 μl of chromogenic substrate (CBS 02.44 consisting 
of MAPA-glycine-arginyl-p-nitroanilide, HCl) and incubated this for 240 s. 
We then added 150 μl of bovine FXa (pre-warmed at 37°C), starting the 
reaction on a STA-R®Evolution coagulometer (Diagnostica Stago). The 
concentrations of calibrators (STA®-Rivaroxaban Calibrator, Diagnostica 
Stago) were 0, 94, 236 and 472 ng/ml in the initial samples after 
reconstitution.  
Anti-Xa measurement of LMWH. The anti-Xa activity of LMWH was 
measured with the Biophen®Heparin Liquid Reagent Technology (LRT) 
assay (Hyphen BioMed). We mixed 50 μl of diluted plasma (1:2 in 
STA®Owren-Koller) with 125 μL of pre-warmed specific chromogenic 
substrate of factor Xa (SXa-11) and incubated this for 240 s at 37°C. We 
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then added 125 µl of bovine FXa (pre-warmed at 37 °C) and measured the 
color development. Results were expressed in OD/min. Calibration curves 
were realized with Biophen®Heparin Calibrators (Hyphen BioMed) (5 
plasma samples with LMWH concentrations ranging from 0.0 to 1.6 IU/ml). 
The LOQ of the anti-Xa activity is 0.05 UI/ml, according to the 
manufacturer. 
Liquid chromatography coupled with tandem mass spectrometry 
All chemical reagents and solvents were used as obtained from commercial 
sources (Sigma Aldrich, Acros, Biosolve). Rivaroxaban and [
13
C6]-
rivaroxaban-d5 were purchased from Alsachim. The LC-MS/MS method 
was adapted from the procedures described by Douxfils et al. 
62
 and Rohde 
et al. 
148
. All LC-MS/MS measurements were carried out on an Ultra 
Performance Liquid Chromatography (UPLC) (Acquity H-Class system, 
Waters) coupled to a tandem-quadrupole mass spectrometer (Xevo TQ-S, 
Waters). Chromatographic separation was achieved using a Waters 
Cortecs® UPLC® C18 column (2.1 x 100 mm, 1.6 μm) at a temperature of 
40°C and a flow rate of 500 μl/min. The mobile phase was composed of 
ammonium formate buffer (10 mM, pH 3) (A) and acetonitrile (B). Gradient 
started at 20% B and linearly ramped up to 55% B in 4 min.  The proportion 
of B was then set to 90 % for 1 min before returning to 20% B. All 
experiments were carried out with an injection volume of 2 μl, the 
autosampler was set to 10°C.  The MS/MS detection was done with 
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electrospray ionization (ESI) in the positive mode and multiple reaction 
monitoring (MRM). The capillary voltage was set to 0.5 kV, the source 
block temperature was 150°C and the nitrogen desolvation gas was heated to 
600°C with a flow rate of 1000 l/h. Four transitions were monitored: 
436.00>145.05 with cone voltage at 50.0 V and collision energy at 30.0 ev 
(rivaroxaban, quantitative ion product); 436.00>231.20 with cone voltage at 
50.0 V and collision energy at 20.0 ev (rivaroxaban, qualitative ion product); 
442.00>145.05 with cone voltage at 50.0 V and collision energy at 30.0 ev 
([
13
C6]-rivaroxaban, quantitative ion product); 442.00>237.20 with cone 
voltage at 50.0 V and collision energy at 20.0 ev ([
13
C6]-rivaroxaban, 
qualitative ion product). The dwell time was set to 0.038 sec. Preparation of 
the sample was realized according the following procedure: 50 μl of plasma 
was added to an Ostro
TM
 plate (Waters); 350 μl of 1% formic acid containing 
internal standard (2.0 ng/ml) was mixed with each sample for protein 
precipitation. The plate was then placed on a vacuum manifold (Waters) and 
the samples were collected in a Waters® 2 ml square collection plate. 
Weighted (1/x) linear calibration was done using calibration standards 
prepared by spiking blank plasma at 1, 3, 6, 10, 50, 125, 250 and 500 ng/ml. 
Validation standards were prepared by spiking blank plasma at 1, 3, 9, 200, 
400 ng/ml. Validation with the QCs on three different days showed 
repeatability relative standard deviation (RSD) below 5.0%, an intermediate 
precision RSD below 9.8 % and a relative bias below 11.1 %. The limit of 
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detection (LOD) and the LOQ were 0.5 and 1.0 ng/ml, respectively. The 
method was validated according to FDA Guidelines 
149
. 
Statistical analyses 
GraphPad Prism® version 6.0c for MacOSx (GraphPad Software, San 
Diego, CA, USA, www.graphpad.com) was used for the statistical analyses. 
Due to the fact that little is known about the combined impact of Xa-
Inhibitors and LMWHs on Xa-Assays, this study is of exploratory nature 
and not formally powered. Results for the rivaroxaban anti-Xa assays 
(Biophen®DiXaI, Biophen®DiXaI LOW and STA®LAX) and those 
obtained using LC-MS/MS were compared by Spearman correlation, linear 
regression and Bland-Altman analyses. The coefficients of correlation of 
group A were compared with those of group B and C. A p-value lower than 
0.05 was considered as statistically significant. Bland-Altman was calculated 
as the difference (A-B)/average, where A was the result of the corresponding 
coagulation test and B, the result of the LC-MS/MS. Limits of agreement of 
the Bland-Altman analyses were calculated as the mean difference – or + 
1.96*standard deviation for the 5
th
 and the 95
th
 limit of agreement, 
respectively. The lower limit of detection (LOD) was calculated as 
[(3*standard deviation of Y0)/ slope] and the lower limit of quantitation 
(LOQ) was calculated as [(10*standard deviation of Y0/ slope]. The 
standard deviation of Y0 was calculated by running the tests 10 times with 
NPP. For STA®LAX, the calibration curve is better defined by a second 
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order polynomial relation. Therefore, the three first points of the calibration 
curve (value of the intrapolation: 8.6 ng/ml, 85.2 ng/ml and 233.9 ng/ml) 
that can be fitted by a linear regression (R
2
 ≥ 0,98) were taken to calculate 
the LOD and LOQ. 
Results 
Plasma concentrations of rivaroxaban in the blood samples ranged from 0.0 
ng/ml to 108.2 ng/ml according to LC-MS/MS. ➤Table 1 shows the 
statistical characteristics of the rivaroxaban plasma concentrations of the 
different groups. All the patients had a creatinine clearance estimated with 
the Cockcroft-Gault equation above 50 ml/min. 
Spearman and linear correlations  
For Group A, the Spearman r was 0.91, 0.97 and 0.96 for Biophen®DiXaI, 
Biophen®DiXaI LOW and STA®LAX, respectively. The linear regression 
gave an R-square of 0.82, 0.94 and 0.95 for Biophen®DiXaI, 
Biophen®DiXaI LOW and STA®LAX, respectively (➤Table 1).  
The difference in correlation with the LC-MS/MS measurement of 
Biophen®DiXaI LOW and Biophen®DiXaI was clinically significant (95% 
confidence interval (CI) of Spearman coefficient (r): 0.81 to 0.96 vs 0.94 to 
0.99, respectively (Table 1). For STA®LAX and Biophen®DiXaI, this 
difference tended towards significance (95% CI of Spearman r: 0.92 to 0.98 
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vs 0.81 to 0.96, respectively). 
For Groups B and C, the Spearman r and the linear regression showed only a 
weak correlation between chromogenic assays and LC-MS/MS 
measurements.   
For Biophen®DiXaI, Biophen®DiXaI LOW and STA®LAX, the 
coefficients of correlation obtained with group A are significantly higher 
than the coefficients of correlation obtained with group B (e.g for 
Biophen®DiXaI the 95% CI was 0.81 to 0.96 for group A vs -0.03 to 
0.52 for group B). The same results were obtained when comparing the 
coefficients of correlation of groups A and C (➤Table 1). 
Bland-Altman analyses 
➤Figure 2 and ➤Table 1 present the Bland-Altman analyses.  
In the absence of bridging (group A), the mean difference between specific 
assays and LC-MS/MS was less than 10 ng/ml. 
In bridged patients (group B), the mean difference between Biophen®DiXaI 
LOW, STA®LAX and LC-MS/MS increased (from 4.7ng/ml to 13.5ng/ml 
for Biophen®DiXaI LOW and from -1.5 ng/ml to 20.9 ng/ml for 
STA®LAX) whereas it remains similar from Biophen®DiXaI (8.8 ng/ml for 
group A, 12.4 ng/ml for group B). 
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Table 1. Statistical characteristics, Spearman correlation, linear regression and Bland-Altman analyses of the 
rivaroxaban plasma concentrations in the different groups.  
 Biophen®DiXaI Biophen®DiXaI LOW STA®-Liquid Anti-Xa 
 
Group A: Patients not bridged  (n=31) 
Range of rivaroxaban plasma concentration 
(ng/ml) 
median (ng/ml) 
interquartile range (ng/ml) 
2.1 to 108.2 
 
32.6 
13.4 to 71.30 
Bland-Altman 
mean bias (ng/ml) 
 
8.8 
 
4.7 
 
-1.5 
SD (ng/ml) 16.8 8.4 10.7 
95% limits of agreement (ng/ml) -24.1 to 41.8 -11.8 to 21.2 -22.4 to 19.5 
R square 0.82 0.94 0.95 
Spearman r 0.91 0.97 0.96 
95% CI 0.81 to 0.96 0.94 to 0.99 0.92 to 0.98 
 
Group B: Patients bridged with LMWHs (n=48) 
 
Range of rivaroxaban plasma concentration 
(ng/ml) 
median (ng/ml) 
interquartile range (ng/ml) 
< 1.0 to 10.1 
 
1.0 
0.0 to 1.0 
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Bland-Altman 
mean bias (ng/ml) 
 
12.4 
 
13.5 
 
20.9 
SD (ng/ml) 9.7 14.5 12.6 
95% limits of agreement (ng/ml) -6.6 to 31.5 -14.8 to 41.8 -3.7 to 45.5 
R square 0.05 0.01 0.00 
Spearman r 0.26 0.18 0.19 
95% CI -0.03 to 0.52 -0.11 to 0.45 -0.11 to 0.45 
 
Group C: Patients bridged with therapeutic LMWH with a last administration of LMWH ≥ 24 hours before 
(subgroup of group B) (n=26) 
Range of rivaroxaban plasma concentration 
(ng/ml) 
median (ng/ml) 
interquartile range (ng/ml) 
< 1.0 to 10.1 
 
0.5 
0.0 to 1.0 
Bland-Altman 
mean bias (ng/ml) 
 
11.4 
 
10.2 
 
17.6 
SD (ng/ml) 10.4 7.0 6.6 
95% limits of agreement (ng/ml) -8.9 to 31.7 -3.6 to 24.0 4.7 to 30.6 
R square 0.01 0.10 0.10 
Spearman r 0.04 0.25 0.29 
95% CI -0.37 to 0.43 -0.16 to 0.59 -0.12 to 0.62 
Table 1. Bland-Altman was calculated as the difference (A-B)/average, where A was the result of the corresponding coagulation test and B, the result of the 
LC-MS/MS. Limits of agreement of the Bland-Altman analyses were calculated as the mean difference – or + 1.96*standard deviation for the 5th and the 
95th limit of agreement, respectively.  
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Figure 2. Bland-Altman analyses of the estimation of rivaroxaban plasma concentrations of Biophen®DiXaI, 
Biophen®DiXaI LOW and STA®LAX with LC-MS/MS measurements.
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Figure 3. Influence of LMWHs on the estimation of rivaroxaban plasma 
concentration with the three chromogenic anti-Xa assays. 
 
Fig 3. Biophen®DiXaI LOW and STA®LAX are influenced by the presence of 
LMWH. Up to 0.12 UI/ml, Biophen®DiXaI LOW performs better than 
Biophen®DiXaI but above this threshold, the overestimation of the Biophen®DiXaI 
LOW is higher than that of Biophen®DiXaI which is not influenced by LMWH at 
these concentrations. Samples with LMWH concentrations below the LOQ of the 
heparin assay were not included. 
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Limit of detection and quantitation 
The LOD and LOQ were 16 and 53 ng/ml respectively for Biophen®DiXaI, 
4 and 12 ng/ml for Biophen®DiXaI LOW and 11 and 36 ng/ml for 
STA®LAX. 
Interference of the anti-Xa activity of LMWH administered ≥ 24h ago with 
Biophen®DiXaI, Biophen®DiXaI LOW and STA®LAX 
Among patients in Group C, the residual LMWH activity could not be 
estimated in 4 samples because of insufficient plasma. For the remaining 22 
samples, the LMWH activity was below the LOQ of the anti-Xa assay (i.e. 
Biophen®Heparin LRT) in 4 samples, and between 0.05 UI/ml and 0.25 
UI/ml in 18 samples. ➤Figure 3 shows the impact of residual LMWH anti-
Xa activity on the estimation of rivaroxaban in these 18 samples. The 
correlation was non-significant for Biophen®DiXaI (Spearman r: 0.09; 95% 
CI: -0.41 to 0.55) but was significant for Biophen®DiXaI LOW (Spearman 
r: 0.76; 95% CI: 0.44 to 0.91) and STA®LAX (Spearman r: 0.73; 95% CI: 
0.39 to 0.90).  
 
Discussion  
These results demonstrate the value of the low version of the 
Biophen®DiXaI assay (Biophen®DiXaI LOW) for the estimation of low 
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rivaroxaban concentrations. Due to its higher sensitivity compared with the 
standard procedure, the LOD and LOQ of Biophen®DiXaI LOW were 
roughly 4-times lower than those of the standard procedure, allowing 
accurate measurements of plasma concentrations <50 ng/ml, which is a 
limitation of the standard Biophen®DiXaI 
62
. We found that STA®LAX was 
also reliable for the estimation of rivaroxaban plasma concentrations at 
CTROUGH. However, and importantly, agreement with LC-MS/MS depended 
on the presence of LMWH. Indeed, the performance of Biophen®DiXaI 
LOW and STA®LAX decreased when residual LMWH activity was present, 
demonstrating that these tests are not specific to the direct factor Xa 
inhibitors (➤Table 1, ➤Figure 2&3). To our knowledge, this study is the 
first that enables the assessment of the performance of chromogenic anti-Xa 
assays with high- and low- procedures in blood samples containing both 
residual rivaroxaban and LMWH.  
However, some limitations concerning this study need to be discussed. First, 
the range of rivaroxaban plasma concentration in patients bridged with 
LMWH (group B and C) was quite limited (from 0 to 10 ng/ml) and was 
also below the LOQ of the more sensitive chromogenic anti-Xa assay, the 
Biophen®DiXaI LOW. Samples from patients bridged with LMWH in the 
10 to 50 ng/ml rivaroxaban concentration range would have been needed to 
assess the performance of the specific chromogenic tests in the concentration 
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range for which they are designed. However, due to the design of our study, 
which followed the initial perioperative management protocol proposed by 
the French Working Group on Perioperative Haemostasis (Groupe d’Intérêt 
en Hémostase Périopératoire - GIHP 
86
), patients stopped their rivaroxaban 
well before the invasive procedure with high bleeding risks, resulting in very 
low residual rivaroxaban concentrations at the time of the intervention 
compared with samples recruited at CTROUGH in patients outside the 
perioperative context (➤Table 1). Furthermore, the number of samples 
recruited in group A could only suggest a tendency to a statistical significant 
difference between Biophen®DiXaI and STA®LAX. Therefore, these 
findings need to be confirmed in a larger cohort, preferably within a 
multicenter study also using coagulometers from different manufacturers 
since it is recognized that this may affect the sensitivity 
150
. According to the 
previous findings of Harenberg et al., a similar study should also be 
performed with other chromogenic assays available on the market to analyze 
the inter-assay variability and reduce it using a mathematical modeling 
140
. 
Lastly, our conclusions cannot be extrapolated to blood samples of patients 
receiving prophylactic bridging, where 12 h discontinuation of LMWH is 
considered sufficient to undergo an invasive procedure with appropriate 
hemostatic conditions.  
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Report of previous findings  
Mani et al. have already published the interest of using low calibrators for 
the measurement of low rivaroxaban concentrations with three other 
chromogenic anti-FXa assays (COAMATIC®Heparin from Chromogenix, 
Instrumentation Laboratory, and Technochrom®anti-Xa with and without 
exogenous anti-thrombin (AT) from Diagnostica Stago®). The LOQ was 
decreased from 25 ng/ml to 10 ng/ml, when the low calibrators were used 
instead of the high calibrators. Therefore, they recommended to re-run 
plasma samples with the low calibrators when rivaroxaban was estimated < 
25 ng/ml with the high calibrators. They demonstrated also that anti-Xa 
assays including exogenous AT were unsuitable for the measurement of 
rivaroxaban levels as AT falsely elevates rivaroxaban plasma concentrations. 
This was explained by the ability of AT in excess to complex residual factor 
Xa. The ex vivo samples came all from patients who had received 
rivaroxaban 10 mg once daily for postoperative prevention of deep venous 
thromboembolism (DVT) after elective hip or knee replacement, so none 
had residual heparin 
143
. 
Königsbrügge et al. have also used high and low commercial standards of 
rivaroxaban to calibrate the Biophen®DiXaI and Biophen®Heparin LRT, 
two chromogenic anti-Xa assays which are and aren’t, respectively, specific 
to rivaroxaban. For the low procedure of the Biophen®DiXaI, they used a 
different dilution of the plasma samples in the buffer (1:20 instead of 1:8 in 
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our methodology). They demonstrated that the use of the low calibrators 
improved the LOD, the LOQ, the mean difference and the standard deviation 
(in ng/ml) of the two anti-Xa assays compared with high calibrators, for 
rivaroxaban concentrations below 102 ng/ml 
144
. For the Biophen®DiXaI, 
the LOD and LOQ decreased from 35 ng/ml and 107 ng/ml to 9 ng/ml and 
28 ng/ml, respectively. For the Biophen®LRT assay, the LOD and LOQ 
decreased from 49 ng/ml and 149 ng/ml to 2 ng/ml and 6 ng/ml, 
respectively. All their samples came from patients treated with rivaroxaban 
without LMWH bridging. Therefore, we cannot evaluate if the difference in 
their methodology of the Biophen®DiXaI LOW (dilution 1:20) would have 
less interference with LMWH than our methodology (dilution 1/8). We can 
only observe an expected decrease in the LOD and LOQ with the dilution 
1:8 compared with the dilution 1:20 (i.e. 4 and 12 ng/ml compared with 9 
and 28 ng/ml, respectively). The dilution 1:8 might be more appropriate in 
the perioperative setting, as some experts group recommend reaching a 
rivaroxaban plasma concentration ≤ 30 ng/ml before an emergency 
procedure with high bleeding risk 
86
.   
Proposal for sample management 
Low concentrations of rivaroxaban can only be assessed properly with 
chromogenic anti-Xa assays 
61,62,137,151
. However, most of these anti-Xa 
assays have a LOQ around 30 to 50 ng/ml, making them unreliable for 
assessing concentrations below the LOQ. Measurements of residual 
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rivaroxaban concentrations in the perioperative setting are currently 
recommended before emergencies that cannot be delayed (e.g. thrombolysis 
in the setting of an acute cerebral thrombosis) or emergencies with high 
bleeding risks. If a patient is suspected to have an insufficient preoperative 
interruption of rivaroxaban (e.g. a clinical context with suspected supra-
therapeutic plasma concentration), the measurement of rivaroxaban is 
arguable, especially if the invasive procedure is at high bleeding risk 
78
.  
Without LMWH bridging, the Biophen®DiXaI LOW showed a better 
correlation than Biophen®DiXaI with the LC-MS/MS measurement (➤
Table 1). This difference of correlation with LC-MS/MS between 
STA®LAX and Biophen®DiXaI tended toward significance. However, one 
of the advantages of the STA®LAX is its wide application range since the 
operator does not have to choose between a low and a normal procedure, 
simplifying the management of samples for the estimation of residual 
rivaroxaban concentrations. Therefore, we suggest that Biophen®DiXaI 
LOW and STA®LAX may be used for the estimation of low rivaroxaban, 
e.g. when rivaroxaban has been stopped for more than 24 h.  
The problem of bridging therapy 
Recent publications demonstrated the increase risk of major bleedings 
without a decrease of thrombotic events in patients group bridged with 
heparins during the perioperative interruption of oral anticoagulants 
120,152-154
. 
164 
 
The most recent updated guidelines recommend to bridge only patient who 
are at high risk of thromboembolic events, especially as those were 
underrepresented in clinical trials analyzing the benefit or harm of bridging 
therapies (e.g. the BRIDGE clinical trial) 
155-157
.  
With the exception of the Biophen®DiXaI and its specific buffer, LMWH 
anti-Xa activity leads to an overestimation of the rivaroxaban concentration 
145
. We expected that the low procedure of the Biophen®DiXaI would also 
have this specificity since it is directly derived from the Biophen®DiXaI 
assay. Unfortunately, this study reveals that in the absence of any 
rivaroxaban effect, increasing concentrations of residual LMWH 
overestimated rivaroxaban plasma concentrations measured by 
Biophen®DiXaI LOW (➤Figure 2&3). From our data, above 0.12 IU/ml of 
LMWH, there is no benefit from the low procedure of Biophen®DiXaI (➤
Figure 3). These findings may be explained by the fact that, in order to 
improve the sensitivity, the LOD and the LOQ, the sample is less diluted in 
the high ionic strength buffer which is less apt to inhibit the catalytic action 
of LMWHs. The overestimation of rivaroxaban by STA®LAX was 
predictable as it is not specific for rivaroxaban, however it had no advantage 
compared with Biophen®DiXaI even in samples with 0.05 IU/ml of 
LMWH. Therefore, both Biophen®DiXaI LOW and STA®LAX are not 
suitable for the measurement or the exclusion of residual rivaroxaban 
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concentrations in bridged patients. The standard Biophen®DiXaI was, as 
expected, not influenced by the presence of LMWH, even at therapeutic 
LMWH concentrations (data not shown), but its lack of precision at low 
levels of rivaroxaban precludes its use for the accurate estimation of residual 
rivaroxaban in this concentration range.  
Some manufacturers have proposed the use of a global anti-Xa plasma 
activity calibrated with heparin. However, these assays are affected by a 
high inter-assay variability and the absence of correlation between anti-Xa 
concentration and heparin anti-Xa IU/ml, except for the low anti-Xa 
concentrations.
158,159
 In case of a patient initially on rivaroxaban and bridged 
with LMWH, the result will reflect the activity of residual rivaroxaban and 
LMWH. These assays are thus suitable to exclude presence of anti-Xa 
activity but should not be used to quantify direct anti-Xa activity or to 
predict the bleeding risk of the patients receiving LMWH after rivaroxaban 
suspension. 
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Perspectives 
This study represents real-life conditions, without routine access to LC-
MS/MS. Thus, a chromogenic anti-Xa assay that is not sensitive to heparin 
and is more accurate than Biophen®DiXaI for the low concentrations of 
rivaroxaban should be developed. Our findings should help to improve the 
performance of these dedicated tests in the presence of heparins. These 
results suggest that both STA®LAX and Biophen®DiXaI LOW could be 
tested with a high ionic strength buffer which, in the case of 
Biophen®DiXaI LOW, should be six times more concentrated than the 
current buffer to recover the specificity of Biophen®DiXaI. Secondly, as 
suggested by Asmis et al., the use of a heparin-neutralizing agent such as 
polybrene or heparinase, could be tested to evaluate if it improves the 
specificity to rivaroxaban 
141
. Meanwhile, clinicians need to inform their 
laboratory about the timing and dose of the last LMWH and rivaroxaban 
administration, so that the most reliable test can be used depending on the 
patient’s specific situation and the clinical question.  
 
Conclusion 
This study confirms previous data and recommendations about the use of 
low methodologies to estimate low rivaroxaban concentrations. However, 
the main point is that it highlights important limitations of the chromogenic 
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tests currently available for the management of patients bridged with 
LMWHs. While the low procedures may be preferred for the estimation of 
rivaroxaban concentrations below 50 ng/ml, these methods are sensitive to 
LMWHs and may be influenced even 24 h after of the last LMWH 
administration. Currently clinicians and laboratories are ill-equipped to 
assess bridged patients when a reliable estimate of the residual rivaroxaban 
concentration is required. Even if bridging therapies with heparins will 
decrease in the near future, there will still be patients at high 
thromboembolic risks who will benefit from it. Therefore, the development 
of a chromogenic anti-Xa assay accurate at low rivaroxaban concentrations 
and insensitive to heparins is required to optimize their perioperative 
management.  
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IV. Discussion and perspectives 
 
A. Why, when and how to assess the anticoagulant effect of DOACs  in a 
perioperative setting 
i. The preoperative assessment for elective invasive procedures 
Throughout this thesis, the clinical utility of accurate DOAC 
measurement could be tested in several situations encompassing the 
perioperative management of patients treated with DOACs. 
First of all, optimizing the TT in our institution enabled us to use the TT 
outside the actual recommended situation which is to confirm the 
absence of dabigatran when a TT is within its normal range. Despite TT 
had a good correlation of variation on both coagulometers for 
concentrations up to 50 ng/ml, we do not recommend to use it as a 
quantitative tool but either as a qualitative tool. This is due to the impact 
of the clinical and biological variables on TT that we cannot exclude 
with certainties, especially in emergent situations. However, knowing 
that the range of dabigatran plasma concentrations is below 50 ng/ml 
when TT is below 120 s (with STA®-Thrombin, 1.5 NIH/ml on a STA-R 
Evolution
®
 coagulometer (Diagnostica Stago
®
), can guide the laboratory in 
estimating the range of dabigatran concentrations and in choosing the 
more accurate coagulation assay for its range of plasma concentrations.  
Another way to use TT in a preoperative assessment is to estimate if the 
patient has a good elimination of dabigatran. Knowing his last intake 
174 
 
(e.g. the morning of the preoperative assessment) and having a TT below 
120 s can guarantee that the patient is not accumulating dabigatran. If 
the TT would be higher than 120 s, clinicians can only estimate a 
dabigatran concentration probably over 50 ng/ml. Therefore, a sensitive 
aPTT reagent would give further informations. If the aPTT was normal, 
the dabigatran range would be probably close to 50-60 ng/ml, as these 
concentrations can show a normal aPTT in real life. If the aPTT was 
increased, only a specific coagulation assay would estimate accurately 
the plasma concentration of dabigatran. 
A TT > 120 s after several days of dabigatran arrest can also indicate 
that the patient is within a supratherapeutic range, when other 
interferences with TT have previously been excluded. 
A well-optimised TT is a coagulation assay that can give useful 
informations about patient’s pharmacokinetics when it is related to its 
timing of last drug intake. 
In our institution we take profit of the preoperative assessment to spot 
patients that could be in supra therapeutic concentrations. Following a 
careful anamnesis of patient’s medical history, we aimed at detecting 
patients that have DOACs prescribed in an off-label use (e.g. incorrect 
doses), or whom clinical characteristics may enter the patient in a 
subpopulation that are at increased risk of bleeding. 
160
 In these cases, a 
point measurement of the DOACs plasma concentration is prescribed 
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the day of the preoperative assessment. Except for emergencies, this 
allows to have a result within a week and to contact the patient and the 
prescriber if the estimation is sub- or supra-therapeutic.
161
 However, in 
situations where the plasma concentration is outside the on-therapy 
range, a second analysis at peak and trough should confirm the first 
statement. Indeed, a recent multicentric study showed a wide inter-
individual variability for dabigatran, rivaroxaban and apixaban at peak 
(mean CV = 46%) and at trough (mean CV= 63%) that could not be 
accounted for the CrCl only. The correlation with the renal function was 
poor, except for dabigatran plasma concentrations at trough. The mean 
CV% of intra-individual variability was 36.6% at trough and 34.0% at 
peak. 
88
 
Except in a context of adverse event (thrombosis or bleeding), cautious 
should be advised before changing the dose, as currently there are no 
recommendations based on DOACs plasma concentration, except for 
some sub-populations (i.e. extreme obese patients).
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The estimation of DOACs plasma concentration during a preoperative 
assessment in patients at risk of being in a supra-therapeutic 
anticoagulant level allows, if needed, to adapt the time of DOAC’s 
interruption before an invasive procedure. 
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ii. Emergencies 
Emergencies that cannot be delayed, with a recent DOAC intake or with 
a severe bleeding, are examples of indication for a measurement of 
DOACs residual plasma concentrations to guide patient’s management.  
Even if rapidly available (on site), it takes still 45 minutes to 1 hour 
before a specific laboratory is able to deliver a result, as these specific 
reagents are not daily prepared. A new calibration is only required when 
the lot of reagents changes or the control is not in the validated range. 
However, the TAT for DOACs plasma concentration estimation is 
limited with the timing of reconstitution of reagents and controls, which 
currently takes 30 minutes. A decrease in the TAT could be obtained 
when specific procedures are in place for emergencies with severe 
bleeding, such as for example, warning the laboratory about the type of 
DOAC before samples are collected, bypassing login and re-labelling of 
blood samples,
163
 or reducing the time of blood samples centrifugation
164
 
or reagent/control’s reconstitution and analysis. However, this needs to 
be validated in an adequate study.  
This has already been evaluated for standard coagulation assays where 
an emergency haemorrhage panel (prothrombin time, fibrinogen, platelet 
count, haematocrit) was used for transfusion decisions on bleeding 
patients and where the TAT was reduced to less than 20 minutes.
165 
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For patients presenting a TE on DOAC therapy, as for example an acute 
ischemic stroke, a rapid TAT for specific coagulation assays can 
optimize the management of these patients in allowing a thrombolysis 
within the 3 hours of the beginning of the event, when residual DOAC 
plasma concentration is low.  
The question of which threshold of DOACs plasma concentration is safe 
for a thrombolysis or whether an antidote should be administered before 
a thrombolysis of an acute ischemic stroke remains currently 
unanswered. Mechanical thrombectomy is an alternative to intravenous 
thrombolysis. However, every cerebral embolism cannot benefit from 
this technique, and furthermore, this requires an extra organisation to get 
the interventional radiologist and anaesthetist rapidly ready for the 
thrombectomy. Every minute counts in this critical situation and 
therefore improving the TAT of the specific laboratory tests may speed 
up the access to different treatment option of acute ischemic strokes. 
Furthermore, even if a thrombolysis cannot be administered, having the 
initial DOACs plasma concentration can help in the follow up of the 
patient, e.g. when a haemorragic component due to an important cerebral 
infarct appears after the ischemic stroke. It can also assess the level of 
anticoagulation when the TE happened, which is of interest for post-
marketing reports and further management of the patient’s 
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anticoagulation (e.g. TE with a correct anticoagulation level or TE 
because of poor drug adherence). 
Recent guidances commented the decision to administer thrombolytic 
therapy based on the last intake of DOAC, which is an arbitrary 
recommendation that has not yet been tested.
24
 However, this 
information can be missing (e.g. unconscious patients). Furthermore, 
with the high inter-individual variability of DOACs plasma 
concentrations
88
 it can be hazardous to perform a thrombolysis only 
guided by the rough estimation of the last intake.  
Therefore, the very sensitive TT has the advantage to rapidly inform 
about dabigatran’s presence. Yet, no residual plasma concentration is 
validated before a thrombolysis and an elevated TT requires a specific 
test accurate in low plasma concentrations to manage emergencies, 
especially if the TT is not optimized. Optimizing the TT inside each 
laboratory would give rapidly a rough estimation of dabigatran’s plasma 
concentration, as it would have a limit of measurement around a 
predefined dabigatran concentration. However, care should be advised in 
emergency settings where the TT can be falsely reduced or prolonged.  
A recent study analysed the predictive value of PT, aPTT and TT to 
detect DOAC concentrations of 30, 50 and 100 ng/ml in an emergency 
setting (abstract published during the last International Society of 
Thrombosis and Haemostasis (ISTH) congress in May 2016). They used 
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the same TT as in our study (i.e. the reagent STA®-Thrombin, 
Diagnostica Stago, Asnière, France), which had a negative predictive 
value (NPV) of 100% to exclude clinically relevant concentrations of 
dabigatran (≥ 30 ng/ml) in emergency situations (813 samples collected 
in 660 patients).
166
 
For the direct anti-Xa agents, a similar sensitive routine test is not 
available, and even a sensitive reagent of PT cannot exclude clinically 
relevant concentrations of these drugs. Indeed, in the previous described 
study using sensitive reagents of PT and aPTT, a combined normal PT 
and aPTT excluded rivaroxaban concentrations ≥100 ng/ml in 100% of 
patients, but not ≥50 ng/ml. For apixaban, the NPV did not exceed 
70.6% for concentrations of 100 ng/ml.
166
 
If a center decides to thrombolyse only patients with no residual effect 
of anti-Xa agents, a specific coagulation assay accurate in the low 
plasma concentrations is required. 
Kepplinger J et al. published recently their decision making protocol 
based on routine and specific coagulation assays. Their higher threshold 
of DOACs plasma concentration before a thrombolysis should be 
validated in a large clinical trial. 
139
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It is thus essential to validate an acute stroke management based on 
several steps: 
1. Which DOAC, timing of last intake, warn rapidly the laboratory 
(Which coagulation test to use? Improve the TAT for standard and 
specific coagulation assays) 
2. Haemorrhagic component at the cerebral scanner (antidote?) 
3. Is a mechanical thrombo-embolectomy feasible?  
4. Is a thrombolysis feasible? Centers should fix a threshold for 
residual DOAC concentrations allowing thrombolysis and validate 
the safety of their procedure. 
The laboratory tests should not delay a mechanical thrombo-
embolectomy. The rapid measurement of initial anticoagulant level may 
authorize the addition of a thrombolysis to the procedure, which can be 
useful if mechanical thrombo-embolectomy fails.  
 
iii. Outside the perioperative or emergency setting 
In our recent publication “Minimisation of Bleeding Risks Due to Direct 
Oral Anticoagulants”9, which is an updated version of our previous 
manuscript “Preventive Strategies Against Bleeding Due to Nonvitamin 
K Antagonist Oral Anticoagulants”160, we focused on several clinical 
characteristics or situations (e.g. dehydration, loss of weight) that might 
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increase the plasmatic concentrations of DOACs in patients outside a 
perioperative context and who are chronically on DOACs. 
Several publications described sub-groups for which the dose tailering 
could be based on their individual DOACs plasma concentration.
106
 
Currently, clinical characteristics guide the dose tailoring to keep a 
patient within the wide therapeutic range of DOACs. As no routine 
monitoring was realized during the phase III clinical trials, it is difficult 
to give strong evidence that adapting the dosage to DOACs plasma 
concentrations is safe. However, Reilly and collaborators were the first 
to demonstrate a correlation between ischemic strokes and bleeding 
outcomes with dabigatran plasma concentrations. Age was the most 
important covariate. A main limitation of the study conclusions was the 
lack of dabigatran plasma concentration measurements at the moment of 
the advert event.
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However, the marketing authorization holder of DE (Boehringer 
Ingelheim Gmbh) has since filed a patent describing a safety profil using 
monitoring of DE in a patient suffering from NVAF.
61
 For dabigatran 
etexilate 150 mg bid, the company found that plasma concentrations at 
trough (i.e. 12 h after the last intake) between 90 and 140 ng/ml after one 
week of DE intake, provided the best benefit risk ratio between 
prevention of stroke and occurrence of bleedings.
5
 Following that DE 
plasma concentration is below, within or higher than the recommended 
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plasma concentration, the company proposes different dose adaptations. 
The simulation found in this dose adjustement, a comparable risk of SSE 
with a significant reduction of major bleeding.
167
 This highlight the 
interest of screening a plasma level of anticoagulation that improves the 
benefit risk ratio of DOACs.
106 
In the clinical practice, physicians are regularly confronted to patients 
with brutal changes in their physiological conditions or medications. 
There are many examples supporting the usefulness of measuring 
DOACs plasma concentration in some routine settings. We had recently 
a patient on dabigatran who had a laryngectomy for several years. He 
presented difficulties in swallowing the capsule of dabigatran and tried 
to crush the capsule with its tongue to swallow it more easily. Opening 
dabigatran’s capsule can increase its bioavailability up to 75% instead of 
6-8%, putting the patient at risk to be chronically in supratherapeutic 
plasma concentrations.  A dabigatran plasma concentration within high 
therapeutic ranges would guide the clinicians in prescribing another oral 
anticoagulant that may be safer for the patient (e.g. rivaroxaban or 
apixaban which can be safely administered crushed through a 
nasogastric tube).
168,169
 
Another issue is the lack of available data on the extremes of weight and 
the number of patients in these extremes. The available pharmaco-
kinetic and –dynamic evidence suggests decreased drug exposures, 
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reduced peak concentrations and shorter half-lives with increasing 
weight, which raises concerns about underdosing this population.
161
 
Current guidances from the SSC of the ISTH do not recommend the use 
of DOACs in patients with a BMI of >40 kg/m
2 
or a weight of >120 kg. 
If DOACs are used in this population, the SSC suggest measuring drug-
specific peak and trough level (anti-FXa for apixaban, edoxaban, and 
rivaroxaban; ecarin time or dilute thrombin time with appropriate 
calibrators for dabigatran; or mass spectrometry drug level for any of the 
DOACs). If the anticoagulant level is in the on-therapy range, 
continuation of the DOAC seems reasonable. However, if the level is 
found to be below the expected range, they suggest changing to a VKA 
rather than adjusting the dose of the DOAC.  
The off-label use of DOACs is not unusual too. For apixaban for 
example, the dose reduction criterions of 2.5 mg bid of apixaban were 
chosen because pharmacokinetic modelling identified them as predictors 
of increased apixaban exposure when combined. In the Apixaban for 
Reduction of Stroke and Other Thromboembolic Complications in Atrial 
Fibrillation (ARISTOTLE) trial, only 4.7% patients of the apixaban 
group were concerned by the dose reduction. However, the current 
global prescription data revealed the use of the lower dose of apixaban 
in at least 25% of patients.
170
 The inappropriate use of the lower dose of 
apixaban may reflect concern about the risk for bleeding, but this can put 
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patients in an increased risk for stroke. Indeed, a recent sub-study from 
the ARISTOTLE trial, showed that the 5 mg bid dose of apixaban was 
safe, efficacious, and appropriate for patients with only 1 dose-reduction 
criterion. Even if patients with atrial fibrillation and 1 dose-reduction 
criterion (isolated advanced age, low body weight, or renal dysfunction) 
(n=3,966) had a higher risk of stroke or systemic embolism (HR, 1.47; 
95% CI, 1.20-1.81) and major bleeding than patients without dose 
reduction criterion (HR, 1.89; 95% CI, 1.62-2.20), both groups showed 
consistent benefits with the 5 mg twice daily dose of apixaban vs 
warfarin.
171
  
Moreover, a recent observational study demonstrated, through an 
electronic questionnaire sent by email to prescribers, the lack of 
awareness of the nature of DOACs.172 Indeed, on the 143 responders, 
88%, 80% and 50% respectively recognised rivaroxaban, dabigatran 
and apixaban. But when a routine clinical situation was provided, 
only 13.5%, 17.5% and 16.8% respectively recognised that the 
hypothetical patient was anticoagulated and only 55 to 58% 
recognised that it was unsafe to proceed with an invasive procedure. 
These results indicate a significant risk for patient harm related to 
lack of knowledge about this new group of frequently used drugs. 
Additional education and training is required for prescribers and this 
concerns certainly the role and understanding of laboratory assays.
172
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B. Perspectives of laboratory tests 
The performance of specific methodologies able to measure low plasma 
concentrations of dabigatran (the Hemoclot Thrombin Inhibitors
®
 LOW 
(HTI LOW) from Hyphen BioMed
®
, Neuville-sur-Oise, France and the 
STA
®
-ECA II (ECA-II) from Diagnostica Stago
®
, Asnière-sur-Seine, 
France) and rivaroxaban (Biophen®Direct Factor Xa Inhibitors
®
 LOW from 
Hyphen BioMed
®
, and STA®-Liquid Anti-Xa from Diagnostica Stago
®
) 
should be validated in a larger perioperative prospective cohort study, 
including emergencies and elective invasive procedures.  
The same studies need to be performed for low plasma concentrations of 
apixaban and edoxaban in a perioperative setting. 
A recent ex vivo study showed a better performance of a homemade dTT 
than the conventional HTI in the low to intermediate range of dabigatran 
plasma concentration (<100 ng/ml). They used the same reagent than their 
TT and calibrators from Hyphen BioMed
®
 and homemade NPP (0 ng/ml of 
dabigatran).
173
  
To improve the inter-laboratory precision, the development of 
an international reference calibrator and the use of specific calibrators for 
low DOAC concentrations should be advised. Indeed, in a recent European 
external quality control for normal to high concentration of dabigatran and 
rivaroxaban, the interlaboratory variation ranged from 5.0% to 27.4% for 
dabigatran and depended on the combination reagent-instrument. 
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Homemade dabigatran calibrators differed from commercially available 
calibrators. There are only few data about inter-laboratory precision in the 
low range of DOACs.
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For dabigatran, the STA
®
-ECA II assay can give accurate measurements for 
patients bridged with heparins with low residual DOAC plasma 
concentrations. However, as shown in our last study on rivaroxaban, this is 
not the case for the specific anti-Xa assays, as the specific Biophen®Direct 
Factor Xa Inhibitors (DiXaI) (from Hyphen BioMed®, Neuville-Sur-Oise, 
France) has a limit of detection of 30-50 ng/ml and its adapted methodology 
for low concentrations gives falsely increased measurements of rivaroxaban 
with small quantities of residual LMWH found at > 24 hours of last 
administration of therapeutic LMWH. 
 
The recent published perioperative guidelines should drastically decrease the 
number of patients that need a bridging therapy. However, there will still be 
patients on rivaroxaban, apixaban or edoxaban that might receive a heparin 
bridge in a perioperative setting due to their high TE risk profil, prolonged 
fasting conditions, or even patients who require an initial LMWH treatment 
before starting edoxaban in the acute treatment of a VTE.  
For this category of patients, laboratories need to adapt or develop assays 
specific for low plasma concentrations of direct anti-Xa agents that are not 
sensitive to other anticoagulants.  
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Gosselin et al. studied the potential utility of UFH or LMWH-calibrated 
heparin assays to screen the presence (or absence) of significant levels of 
FXa DOAC. Their anti-Xa assay data suggest that most LMWH- or UFH-
calibrated methods can exclude significant levels of anti-Xa DOACs. 
All tested LMWH-calibrated methods were able to detect the lowest 
concentration of drug (e.g. 21 ng/ml of edoxaban), and only in the AT-
supplemented Berichrom UFH method, the concentration of 21 ng/ml of 
edoxaban fell below the LOQ.  
Most coagulation analyzers have the capability to run the heparin assays, 
and FDA-approved heparin calibrators and controls are commercially 
available, which is not the case for direct anti-Xa agents. 
Heparin assays are not specific and cannot distinguish between heparins and 
direct anti-Xa agents, but their use could assist clinicians in patient 
management in emergent situations, especially when the clinical history is 
not available.  
 
Figure 1 illustrates the current performances of laboratory assays in the 
measurement of DOACS.  
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Figure 1. Current performances of laboratory assays in the measurement of DOACS
55,63,70,159
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 Fig 1. Sensitivity and Linearity of Coagulation Assays to Below, Within, and Above Typical On-therapy Concentrations of 
Dabigatran, Rivaroxaban, Apixaban and edoxaban. Horizontal bars correspond to the approximate range of detectability (i.e., 
sensitivity) of each assay to below, within, and above typical on-therapy concentrations of dabigatran, rivaroxaban, apixaban and 
edoxaban. Hatching corresponds to the linearity of each assay to below, within, and above typical on-therapy concentrations of 
dabigatran, rivaroxaban, apixaban and edoxaban. Ranges are approximations and may vary based on choice of reagent. Typical on-
therapy drug levels are shown in Table 2. APTT = activated partial thromboplastin time; ECA = ecarin chromogenic assay; ECT = 
ecarin clotting time; PT = prothrombin time; TT = thrombin time. 
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Coagulation assays in emergency settings are the most efficient when their 
TAT is short. Point-of-care (POC) monitoring and other global assays have 
been tested for different DOACs.  
A recent review described the limit and interest of these tests for each 
DOAC.
175
 They concluded that for dabigatran, global assays (Thrombin 
generation assay (TGA), Prothrombinase induced clotting time (PiCT), 
Thromboelastography (TEG), Thromboelastometry (TEM), and Activated 
clotting time (ACT) lack standardization, are insufficiently studied and are 
not available in clinical practice. For rivaroxaban the dPT, DRVVT, 
modified PiCT and modified HepTest methods have no advantage over PT. 
Furthermore, the TGA, TEG and TEM are not routinely available and costly. 
However, they can be useful to assess the efficacy of reversal agents. For 
apixaban, the TGA can measure the intensity of apixaban anticoagulation 
and assess the effectiveness of reversal agents. For edoxaban, further studies 
of specialized and global tests are required.
175
 
However, as previously discussed, it has more sense to give priority to 
research studies that improves the TAT of the specific assays measuring 
accurately low to high plasma concentrations of DOACs than to improve 
high costly POC monitoring that are less acurate and may have high 
intravariability in their plasma concentration estimation.
163
  
Reducing the TAT of specific test to 20 minutes would supplant any POC 
monitoring. 
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Other research project including the monitoring of DOACs concerns the 
impact of DOACs on ACT measurements during catheter ablation of AF. 
During this procedure, it is recommended to achieve and maintain an 
activated clotting time (ACT) of 300 to 400 seconds in order to reduce the 
risk of systemic thromboembolism. Uninterrupted oral anticoagulation has 
become the standard protocol. However the ACT is affected by a lot of pre-
analytical and analytical variables, and a target ACT has not yet been re-
determined for the peri-procedural use of DOACs in AF ablation.
176-181 
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C. Perspectives in the perioperative management and implication of 
laboratory tests 
Outside the benefit of accurate tests for the measurements of DOACs, there 
is a clear need to standardize the peri-procedural management of patients on 
DOACs.  
Even if in the last years the recent updated expert’s recommendations 
showed more similarities, the timing of preoperative DOAC interruption is 
still varying and this is partly due to the definition of what is a low, 
moderate and high bleeding risk surgery. 
For the GIHP, the high bleeding risk surgery integrates moderate and high 
risk bleeding procedures, which cannot be realized in patients with 
anticoagulation.
76
 For the European Heart Rhythm Association practical 
guide, the low risk procedures have a low frequency of bleeding and/or 
minor impact of a bleeding and the high-risk procedures have a high 
frequency of bleeding and/or important clinical impact.
24,182
 
Spyropoulos et al. categorize the high bleeding risk procedures by a two-day 
risk of major bleeding ≥ 2% and low procedures by a two-day risk of major 
bleeding < 2%. 
134
 
In any cases, there is sufficient evidence that some procedures may be 
realized on anticoagulant therapy (procedure with minimal risk), as for 
example superficial skin surgeries, parietal surgery, cataract surgery, minor 
dental procedures. It is sometimes suggested to avoid the dose of the 
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morning of the procedure to avoid peak concentrations during these 
procedures. 
 Pacemaker or cardioverter-defibrillator device implantation can be realized 
safely without stopping VKAs, but this should be confirmed for DOACs.
183-
185
  
However, some procedures are categorized in the high bleeding risk 
procedures or low bleeding risk procedures, depending on the experts’ 
proposal. This discrepancy in the categorization of the bleeding risk 
influences the delay of arrest and thus has a clear impact on residual DOAC 
concentrations as shown in the case-series describing patients on dabigatran 
in a perioperative setting. 
Taking the example of the neuraxial anaesthesia or intracranial 
neurosurgery, some experts define these procedures as other conventional 
high bleeding risk procedures
134,182
, while others are more cautious and add 
an extra delay to DOAC interruption.
76
  
DOAC resumption after high bleeding risk procedures are relatively similar: 
therapeutic doses of DOACs should be deferred for 24–72 h.24,76,134,182 If 
necessary the use of a stepwise approach of bridging therapy with 
prophylactic dose of heparins can be considered for patient at high TE 
risks.
24,76,182
 Spyropoulos et al. proposes rather a reduced dose of dabigatran 
(75 mg twice daily), rivaroxaban (10 mg once daily) or apixaban (2.5 mg 
twice daily) on the evening after surgery and on the following day (first 
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postoperative day) after surgery. They recommend bridging therapy with 
heparins only in patients who cannot tolerate oral medications.
134
 If patients 
are at high TE risks and the haemostasis is not under control, mechanical 
VTE prophylaxis should be considered. 
The GIHP recommend a bridge with heparins by the time an indwelling 
catheter is in place after neuraxial anaesthesia.
76
 
For low bleeding risk surgery, some experts recommend to restart DOACs 
6-8 hours after end of the surgery. Spyropoulos et al. recommend 24 hours 
before full dose of DOAC intake. 
Planning a safe resumption of DOAC is essential as a premature re-initiation 
of heparin therapy (within 24 hours after the procedure) is an avoidable-
independent predictor of major bleeding. 
186
  
Table 4 shows recent perioperative guidances. 
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Table 4. Resuming of recent perioperative management of DOACs
24,76,134,182
 
DOAC Dabigatran Rivaroxaban - Apixaban Edoxaban 
Bleeding risk of invasive procedure LOW 
Bleeding 
Risk 
HIGH 
Bleeding 
Risk 
LOW 
Bleeding 
Risk 
HIGH 
Bleeding 
Risk 
LOW 
Bleeding 
Risk 
HIGH 
Bleeding 
Risk 
GIHP 
(Groupe 
d’Intérêt en 
Hémostase 
Péri-
opératoire)  
Preoperative 
interruption 
 
 
 
No bridging  
(except 
patients with 
high risk of 
TE) 
 
 
CrCl ≥ 50 
ml/min 
 
 
 
 
Last dose  
≥ 24h before 
surgery 
Last dose 4 
days before 
surgery 
 
 
 
 
 
Last dose  
≥ 24h before 
surgery 
 
 
 
Last dose 3 
days before 
surgery 
 
 
 
Last dose  
≥ 24h before 
surgery 
 
 
 
Last dose 3 
days before 
surgery 
CrCl > 30 
ml/min 
 
 
 
Last dose 5 
days 
before 
surgery 
For very 
high risk 
procedure  
(neuraxial 
anaesthesia) 
 
 
Last dose 5 days before surgery  
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Resumption 
after 
invasive 
procedure or 
surgery 
 LOW Bleeding risk :  
 resume minimum 6h after invasive procedure or surgery 
HIGH Bleeding risk :  
 prophylactic dose of LMWH, UFH or fondaparinux minimum 6h after invasive 
procedure or surgery if venous thromboprophylaxis is indicated 
 therapeutic dose of DOACs when haemostasis is controlled (24-72 h) 
 
For neuraxial anaesthesia with indwelling catheter: 
 resumption with LMWH or UFH until indwelling catheter is out 
Heidbuchel 
et al. 
 
 
Preoperative 
interruption 
 
 
No bridging  
 
 
 
 
 
 
CrCl ≥ 80 
ml/min 
≥ 24h ≥ 48h ≥ 24h ≥ 48h ≥ 24h ≥ 48h 
CrCl 50-80 
ml/min 
≥ 36h ≥ 72h ≥ 24h ≥ 48h ≥ 24h ≥ 48h 
CrCl 30-50 
ml/min 
≥ 48h ≥ 96h ≥ 24h ≥ 48h ≥ 24h ≥ 48h 
CrCl 15-30 
ml/min 
Not 
indicated 
Not 
indicated 
≥ 36h ≥ 48h ≥ 36h    ≥ 48h 
CrCl < 15 
ml/min 
 
No official indication for use 
 
Resumption 
after 
invasive  
procedure or 
surgery 
 LOW Bleeding risk :  
 DOACs 6-8h 
HIGH Bleeding risk :  
 LOW TE risk  resume DOACs 48-72h after procedure 
 HIGH TE risk  prophylactic or intermediate dose of LMWH 6-8h after 
procedure, resume DOACs when haemostasis is controlled (48-72h) 
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Spyropoulos 
et al. 
Preoperative 
interruption 
 
No bridging 
(except 
patients with 
high risk of 
TE) 
 
CrCl > 50 
ml/min 
Last dose 2 
days before 
surgery 
Last dose 3 
days before 
surgery 
Last dose 2 
days before 
surgery 
Last dose 3 
days before 
surgery 
Last dose 2 
days before 
surgery 
Last dose 3 
days before 
surgery 
CrCl 30-50 
ml/min 
Last dose 3 
days before 
surgery 
Last dose 4-
5 days 
before 
surgery 
Last dose 2 
days before 
surgery 
Last dose 3 
days before 
surgery 
  
CrCl 15-29 
ml/min 
  Depends on 
patient and 
procedural 
factors 
Depends on 
patient and 
procedural 
factors 
  
Resumption 
after 
invasive 
procedure or 
surgery 
 LOW Bleeding risk : DOACs 24h 
HIGH Bleeding risk :  
 LOW TE risk  resume DOACs 48-72h after procedure 
 HIGH TE risk  consider a reduced dose of dabigatran (75 mg twice daily), 
rivaroxaban (10 mg once daily) or apixaban (2.5 mg twice daily) on the evening 
after surgery and on the following day (first postoperative day) after surgery.  
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Surgical aptitudes influence the risk of bleeding of a procedure, as a surgeon 
of great ability and very cautious can balance some high risk bleeding 
surgery to lower bleeding risk surgery, and unfortunately the reverse holds 
true…  
Nevertheless, once this categorization of bleeding risk done, the same 
recommendations of DOAC’s interruption should be recommended. Some 
adaptations to patients at very high risk of thrombosis or bleeding should be 
proposed. 
Outside the availability of experts’ guidances in the literature, every 
institution should have an easy access to their peri-procedural management. 
Written documents should be available and a specific multidisciplinary team 
created to discuss some challenging cases concerning elective surgeries as 
well as different types of emergencies or adverse events due to DOACs. 
The implementation of electronic supports may increase the adherence to the 
perioperative management of DOACs. In addition, regular educational 
support and contact with general practioners or prescribers should offer the 
potential to improve DOAC management. 
In the following sub-chapters some perioperative pending issues are 
addressed with a section concerning DOAC monitoring.  
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i. Timing for neuraxial anaesthesia 
Procedures as neuraxial anesthesia are considered as procedure with high 
bleeding risks. The overall incidences of spinal haematoma in patients 
receiving an epidural or spinal anaesthesia are estimated to be 1/220000 and 
1/320000 patients, respectively. In the presence of risk factors (e.g. multiples 
attempts, spinal abnormalities, inherited or acquired coagulopathies, heparin 
administration), the bleeding risk can be increased up to a two orders of 
magnitude.
187,188
 
Spinal haematomas need to be managed urgently to avoid irreversible 
damages.  
These procedures require a complete haemostatic function and cautious in 
their perioperative management, especially when patients are on 
anticoagulant treatment. Alternatives in anaesthesia techniques should be 
proposed if uncertainties persist on the haemostatic conditions and no 
laboratory monitoring is available. However, as neuraxial techniques may 
improve post surgical outcome
189
, a sufficient preoperative interruption of 
DOACs should be cautiously planned, avoiding unwanted report of 
interventions or change in anaesthetic management that could deprived a 
patient from a technique favourable to manage postoperative pain. 
Different recommendations have been published these last years based on 
DOAC’s estimated half-life.   
Rosencher et al.
35
 and Gogarten et al.
190
 published guidances based on 
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DOAC’s half-life in patients receiving a dose for VTE prevention post joint 
surgery. They consider an interruption of two half-lifes as sufficient before 
neuraxial anaesthesia. The authors assume that a stable clot is formed in 8 
hours, and that the anticoagulant can be administered in a timing of “8 hours 
minus its time to peak concentration (Tmax)” (which is 1 to 4 hours for 
DOACs). They propose this timing for DOAC’s resumption after catheter 
withdrawal, but this applies only for prophylactic doses of DOACs. The 
presence of bleeding during needle puncture and catheter placement should 
delay anticoagulant therapy post surgery for 24 h. 
191
 
 
Recent guidances have been published by the American Society of Regional 
Anesthesia and Pain Medecin
84
 (ASRA) in collaboration with the European 
Society of Regional Anaesthesia and Pain Therapy, as well as other societies 
of Pain Medecine and Neuromodulation. They suggest a 5-elimination half-
life interval between oral anticoagulants discontinuation and intermediate or 
high-risk pain procedures. This corresponds to an interruption of 4-5 days 
for dabigatran (6 days if end-stage renal disease), and 3 days for rivaroxaban 
and 3 to 5 days for apixaban, because of its wide pharmacokinetics 
variability.   
They propose to restart DOACs administration 24 hours after the pain 
intervention, excepted if there is high risk of VTE. In this case, half of the 
usual dose can be given at 12-hours after the pain procedure and should be 
notified to the patient’s treating physician(s).84 
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These guidances are similar to the recent updates of the perioperative 
management of DOACs written by the GIHP. They propose an interruption 
up to 5 days for DOACs to guarantee a normalized haemostasis (less than 
3% of the anticoagulant concentration at peak time). 
76
 
 
Other experts’ proposals have been published and the delay of interruption is 
based on the half-life of the medication and the renal function. 
Heidbuchel et al. published recently a second update of the Europace 
guidances. They consider neuraxial anaesthesia as a conventional high 
bleeding risk procedure and for patients on DOACs with normal renal 
function (= CrCl > 80 ml/m) they suggest at least 48 hours of DOACs 
interruption. This delay increases for dabigatran proportionally to the 
decrease of CrCl (see Table 4). No recommendation is given for dabigatran 
interruption in patients with a CrCl < 30 ml/min, as it is not recommended 
for such renal impairment. For apixaban, edoxaban and rivaroxaban, the 
impact of the CrCl on half-life is lower and therefore they recommended at 
least 48 hours of DOAC interruption, except for CrCl below 15 ml/min 
where these DOACs are not recommended. 
182
 
However, 48 hours of arrest has been proved to be not sufficient to 
guarantee a normal haemostasis for all patients. Indeed, two multicentric 
studies with peri-procedural dosage of DOACs proved that around 15% of 
patients on dabigatran
192
 or dabigatran and rivaroxaban
79
, had over 20 ng/ml 
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and 30 ng/ml, respectively at 48 hours of DOACs arrest.  
Spyropoulos et al. made a recent update of their peri-procedural 
management of DOACs. The delay of interruption is based on DOACs 
respective half-life and patients CrCl. They are almost similar to the 
Europace guidances, as they consider neuraxial anaesthesia as a 
conventional high bleeding risk surgery, but they propose a first delay of 
DOACs interruption for a CrCl below 50 ml/min (including here normal and 
slightly impaired renal function) of minimum 60 hours up to 72 hours. For 
decreased CrCl up to 30 ml/min they recommend a dabigatran interruption 
of 4 to 5 days. For patients with a CrCl of 15 to 30 ml/min treated with 
rivaroxaban and apixaban, the last dose of DOAC should be individualized 
on the basis of patient and procedural factors for bleeding and thrombosis. 
Interestingly, for edoxaban they only give a 60 to 72 hours DOACs 
interruption for patients with a CrCl >50 ml/min. No recommendations are 
given for edoxaban in patients with moderately impaired renal function. This 
is perhaps due to an increased renal metabolism of edoxaban, compared with 
apixaban and rivaroxaban (see Table 1), which can lead to uncertainties 
about half-life elimination of edoxaban with lower CrCl. A focused review 
of edoxaban clinical pharmacology showed that the lower dose (15mg) for 
severe renal impairment (CrCl between 15 and 30 ml/min) had similar 
plasma concentrations as reduced doses (30mg) for normal to mildly 
impaired renal function (CrCl > 50 ml/min). These plasma concentration 
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estimations do not show any drug accumulation with the adapted dose 
administration. However, it cannot guarantee that three days are sufficient to 
reach the recommended threshold in plasma concentration (i.e. 30 ng/ml) 
before a high bleeding risk procedure. Indeed, pharmacokinetic studies of 
edoxaban showed that patients with moderately impaired renal function had 
a decrease in total edoxaban clearance of 1/5 compared to mildly impaired 
renal function. For severely impaired renal function, the total edoxaban 
clearance decreased of ¼ of the clearance of mildly impaired renal 
function.
193
 
 
Douketis et al. commented recently the last ASRA guidances.
132
 They 
suggest that considering only the half-life of a DOAC is insufficient to 
determine the required interruption intervals before neuraxial anaesthesia. 
They put forward the need to define the ideal timing of interruption based on 
residual DOACs plasma concentration measured in the perioperative setting. 
The reply of Benzon et al. concluded with the need of conducting further 
research projects implementing DOAC perioperative measurements, to 
provide sufficient high quality evidences to guide perioperative DOACs 
interruption.
133
 
 
We also commented this point of view in addressing the need to use accurate 
measurements for low DOACs plasma concentrations in such research 
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projects and in remembering the limit of using routine tests to conclude on 
the presence or absence of clinically relevant DOAC concentrations.
194
 
Indeed, as illustrated by our cases-series, conventional HTI measured 
dabigatran level < 30 ng/ml, as adapted methodologies for low 
concentrations of dabigatran (HTI LOW and ECA II) gave much closer 
results to LCMS/MS measurements (which were in the three cases > 30 
ng/ml).  
Observational studies that are realized with accurate perioperative 
measurements will validate a unique perioperative management of DOACs, 
with the best timing of interruption before neuraxial anaesthesia. 
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ii.  Heparin-bridging therapy  
As previously discussed, the issue of residual heparin interfering with the 
estimation of low concentrations of direct anti-Xa agents will decrease in the 
near future as new perioperative recommendations suggest to bridge only 
patients with high TE risk. 
The administration of LMWH after arrest of oral anticoagulants was initially 
recommended to cover the periperative gap with insufficient anticoagulation. 
The 2012 ACCP Antithrombotic Therapy Guidelines recommended with a 
weak Grade 2C the use of heparin bridging (therapeutic doses of UFH or 
LMWH ) in high TE risk patients. No recommendations on the use of 
heparin bridging therapy in moderate TE risk patients were made, but they 
suggested an individual assessment of patient-specific risk factors for 
bleeding and thrombosis to guide the decision to bridge or not.
156
  
The recommendations of the European Society of Anaesthesiology (ESA) 
published in 2013
195
 differed as they suggested that DOACs could be 
stopped 5 days before procedures requiring normal coagulation in patients 
treated with rivaroxaban, apixaban, edoxaban, and in patients treated with 
dabigatran and a CrCl higher than 50 ml/min. Bridging was not suggested 
for low risk low-risk patients (grade 1C), but well for high-risk patients 
including patients with AF and CHADS2 score > 2 (grade 2C). 
In patients treated with dabigatran with a creatinine clearance between 30 
and 50 ml/ min, they suggested 5 days of interruption before surgery with no 
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bridging therapy (grade 2C). Their approach of heparin bridging was 
cautious as they recommended starting LMWH or UFH only at day 3 before 
invasive procedures, avoiding the risk of overlapping high level of two 
different anticoagulants at day 4.
195
 Their last guidances are currently 
available as a draft on the ESA website before definitive publication, and the 
bridging recommendations are hard to find.  
 
In the last decades, LMWHs have largely replaced UFH because they are at 
least equally effective in prevention and treatment of VTEs and have the 
possibility of subcutaneous administration without the need of routine 
laboratory monitoring of the anticoagulant response. Moreover, LMWHs 
have a more predictable anticoagulant response and a longer half-life 
allowing once or twice daily administration. 
196-200
 
Over the past decade, the question of an effective and efficient peri-
procedural bridge has been addressed in several standardized heparin-
bridging regimens.
201-208
 
In a meta-analysis published in 2012
153
 analysing ATE and bleeding risks in 
patients receiving heparin bridging during interruption of vitamin K 
antagonists for elective procedures, thromboembolic events occurred in 
0.9% of bridged patients (95% confidence interval [CI], 0.0.0-3.4) and 0.6% 
of non-bridged patients (95% CI, 0.0-1.2). In eight studies, the risk of 
thromboembolic events in bridged and non-bridged patients was the same 
(OR 0.80; 95% CI, 0.42-1.54). There was an increased risk of overall 
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bleeding in 13 studies (OR 5.40; 95% CI, 3.00-9.74) and major bleeding in 5 
studies (OR 3.60; 95% CI, 1.52-8.50) in bridged patients compared with 
non-bridged patients. In a comparative study of full versus 
prophylactic/intermediate-dose low-molecular-weight heparin bridging, no 
difference in thromboembolic events was seen (OR 0.30; 95% CI, 0.04-2.09) 
but well an increased risk of overall bleeding (OR 2.28; 95% CI, 1.27-4.08) 
in the full heparin-bridging group. The need of a standardized perioperative 
protocol to compare bridged patients versus non-bridged patients was 
necessary to strengthen these results. 
153
 
 
The BRIDGE trial has recently confirmed the hypothesis that forgoing 
bridging anticoagulation was non-inferior to perioperative bridging with 
low-molecular-weight heparin for the prevention of arterial 
thromboembolism, and decreased the risk of major bleeding in patients on 
warfarin.   
Indeed, there was a three-fold to four-fold increased risk of major bleeding 
with the use of therapeutic doses of heparin bridging, and no benefits in 
reducing the rate of TE events. 
155
  
These conclusions are validated for patients on warfarin. For other VKA, the 
timing of last intake should be adapted to each half-life and prospectively 
evaluated in a clinical trial. 
Concerning the perioperative arrest of direct oral anticoagulants, several 
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observational studies have supported similar conclusions concerning the 
benefits of heparin bridging. 
 
The DRESDEN registry was the first perioperative observational study 
including 595 patients who underwent 863 procedures (15.6% minimal, 
74.3% minor, and 10.1% major procedures). Major cardiovascular events 
and major bleeding complications occurred in 1.0% (95% CI : 0.5–2.0) and 
in 1.2% (95% CI 0.6–2.1) of patients, respectively. Both events were highest 
after major procedures (4.6 and 8.0%, respectively). The use of heparin 
bridging significantly increased with the surgical risk (10.4, 27.8, and 74.7% 
for minimal, minor, and major surgery, respectively). 
Multivariate analysis demonstrated that diabetes (OR 13.2) and major 
procedures (OR 7.3) were independent risk factors for cardiovascular events 
and that major procedures (OR 16.8) were an independent risk factor for 
major bleeding. Heparin bridging did not reduce cardiovascular events, but 
increased significantly the rate of major bleeding (2.7%) compared with no 
bridging (0.5%). However, when they assessed major and non-major 
procedures separately, they found that heparin bridging was not an 
independent risk factor for major bleeding.  
They concluded that a short perioperative arrest (three days) of DOACs was 
safe without heparin bridging and that patients at cardiovascular risk 
undergoing major procedures may benefit from heparin bridging, but that 
bleeding risks need to be considered. 
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The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation 
(ORBIT-AF) registry is a prospective, observational registry study of US 
outpatients with atrial fibrillation. They recorded incident temporary 
interruptions of oral anticoagulation for a procedure, including the use and 
type of bridging therapy. In a follow-up of 2 years, including 93% patients 
on warfarin and 7 % on DE, Steinberg et al. found a significant threefold to 
fourfold higher risk of clinically important major bleeding in bridged 
patients than in those who did not receive bridging anticoagulation (5.0% 
versus 1.3%; adjusted OR 3.84, P <0.001). Moreover, bridging 
anticoagulation did not seem to mitigate the risk of thromboembolic events, 
and a trend towards more adverse cardiovascular events was observed with 
bridging compared with no bridging (4.6% versus 2.5%; adjusted OR 1.62, 
P = 0.07). These findings occurred in bridged patients with nominally higher 
CHADS2 score (2.53 versus 2.34; P = 0.04) and CHA2DS2-VASc score 
(4.25 versus 4.03; P = 0.01) than non-bridged patients.
154
 
 
For dabigatran, a sub-study of the RE-LY trial showed that bridging was 
used more during warfarin interruption than dabigatran interruption (27.5 % 
vs 15.4 %; p< 0.001). With dabigatran interruption, bridged patients had 
more major bleeding (6.5 % vs 1.8 %, p< 0.001) than those not bridged. 
Bridged and not bridged groups did not differ for any TE (1.2 % vs 0.6 %, 
p=0.16) and stroke and systemic embolism (SSE) (0.5 % vs 0.3 %, p=0.46).  
With warfarin interruption, bridged patients had more major bleeding (6.8 % 
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vs 1.6 %, p< 0.001) and any TE (1.8 % vs 0.3 %, p=0.007) than those not 
bridged. They did not differ for SSE (0.5 % vs 0.2 %, p=0.321).  
The first prospective trial conducted by Schulman et al. proposed a timing of 
perioperative arrest depending on the renal function and the surgical risk of 
bleeding. There was no bridging with LMWH, except in postoperative 
situations where the patients were fasting or when an indwelling neuraxial 
catheter was in place. They included 541 patients in two years and had only 
one transient ischemic attack (0.2%; 95% CI, 0-0.5). They concluded that 
bridging was not necessary for a standardized arrest of dabigatran in a 
perioperative context. 
 
For rivaroxaban, the ROCKET AF trial compared rivaroxaban (20 mg once 
daily) with warfarin for SPAF. Therefrom, 33% required temporary 
interruption (TI) of study drug, of whom 39.7% required a 
surgery/procedure. Participants with TI were similar to the overall ROCKET 
AF population in regard to baseline clinical characteristics. In most patients, 
rivaroxaban therapy was stopped at least 3 days preprocedure, and heparin 
bridging was used only in 6% (n=483). SSE and risk of major bleeding rates 
during the at-risk period were similar in rivaroxaban-treated and warfarin-
treated participants (0.30% versus 0.41% per 30 days; hazard ratio [CI]=0.74 
[0.36–1.50]; P =0.40) and (0.99% versus 0.79% per 30 days; hazard ratio 
[CI]=1.26 [0.80–2.00]; P =0.32), respectively. 138  
The 30-day rate of stroke or non-CNS embolism which was 0.36% is notable 
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compared with the overall SSE rate in the ROCKET AF trial of 2.2%/y.
50
 
When prorated over a 1-year period, this observed embolic event rates is 
consistent with other findings of patients interrupting anticoagulant 
therapy.
153
 Patients enrolled in the ROCKET AF trial were considered as 
high risk, and the embolic event rate during TI can reflect the intrinsic 
susceptibility of these patients. 
 
In the ARISTOTLE trial comparing apixaban (5 mg twice daily) with 
warfarin for SPAF, around 25% of patients required a procedure, wherefrom 
62.5% had a TI. The rate of heparin bridging was only of 11.7% in both 
groups. During the 30 days postprocedure, stroke or systemic embolism 
occurred after procedures among apixaban-treated patients and warfarin-
treated patients were 0.35% and 0.57%, resepctively. Major bleeding 
occurred in 1.62% procedures in the apixaban group and 1.93% in the 
warfarin group. The risk of death was similar with apixaban and warfarin 
(1.17% and 1.08% respectively). 
Only 10.2% of the procedures were defined as major procedures. This limits 
the generalization of the conclusions of low ATE, death and major bleeding 
rates to all type of surgeries.  
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However, the conclusiveness of these trials should be considered cautiously. 
First, one of the main limitation of these studies is that most of these are 
observational studies where heparin bridging was left to the preference of 
the physicians. Secondly, patients at high TE risks are underrepresented in 
these trials (e.g. BRIDGE trial: only 3% of patients with CHADs2 score of 
5-6), and therefore, these conclusions cannot be extended to these categories 
of patients.  
 
 Which patients may benefit from heparin bridging when 
anticoagulant therapy is interrupted? 
Chronic anticoagulation prevents arterial thromboembolism in patients with 
AF. Kaatz et al. showed that these patients undergoing an elective surgery 
or procedure appear to be at increased risk for perioperative stroke. Indeed, 
in a retrospective population-based study, the 30-day postoperative rate of 
stroke among 69 202 patients with AF was 1.8% compared with 0.6% 
among 2.4 million patients without AF.
209
 
The clinical consequences of a thrombotic or bleeding event must be taken 
into consideration:  
 mechanical heart valve thrombosis is fatal in 15% of patients 
 embolic stroke results in death or major disability in 70% of patients 
 VTE has a case-fatality rate of approximately 5%-9% 
 major bleeding has a case-fatality rate of 8%-10% 
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The more severe clinical consequences of ATE, compared with major 
bleeding, will orient the physicians to opt for a strategy that incurs 3–10 
more major bleeds to prevent one stroke, in theory.
210
 However, heparin 
bridging has only sense when it can reduce the TE risk of the patients, and 
the BRIDGE trial could not prove this benefit in patients with low to 
moderate TE risks, as in both groups (non bridged and standardized heparin 
bridged patients) the overall TE risk was similar.  
 
Patients with high TE risk are underrepresented in clinical trials, and 
therefore it is not possible to draw conclusions on the benefit of heparin-
bridging when anticoagulants are interrupted for longer intervals. 
As already discussed, some procedures can be safely realized on warfarin, as 
for example cardiac implantable electronic devices, as heparin bridging 
confers more bleeding risk than continuing warfarin.
211-213
 However, more 
studies are needed to confirm the safety of continuing DOACs for this type 
of procedures
184
, especially when there are combined with dual antiplatelet 
therapies. 
214,215
 
 
For high bleeding risk procedures, a prolonged DOAC interruption is 
required. High inter-variability of patient’s plasma DOAC concentration has 
been reported in several publications
88,216
, and therefore it is difficult to 
predict if a high TE risk patient will be sufficiently anticoagulated with a 
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prolonged DOAC interruption. As long as there is no evidence of the benefit 
or harm of heparin bridging in this population, the suggestion to bridge them 
should not disappear from the current perioperative proposals. To guide the 
best time to start the heparin bridging before an elective invasive procedure, 
a punctual measurement of DOACs plasma concentration during the 
preoperative assessment can give useful information in anticipating DOAC 
plasma elimination and avoiding an overlap of relevant levels of two 
different anticoagulants. 
 
 Who are the high TE risk patients? 
The 9
th
 edition of the Perioperative management of Antithrombotic Therapy 
published by the American College of Chest Physicians categorized the 
different TE risks patients following Table 5.
156
  
However, the question whether CHADs2 or CHA2Ds2-VAsc score are 
sufficiently sensitive to guide heparin-bridging recommendations in AF 
patients, or whether we should focus on specific biomarkers, past medical 
history of severe TE or repeated TE with underlying conditions increasing 
the risk of recurrent TE (active cancer
217
, prolonged immobilisation) may 
lead to further research projects. 
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Table 5. Suggested Risk Stratification for Perioperative Thromboembolism
156
 
(9
th
 edition of the Perioperative management of Antithrombotic Therapy published by the American College of Chest 
Physicians) 
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 What is the best heparin-bridging regimen? 
Therapeutic bridging and early postoperative reintroduction
186
 of heparin 
have been reported to increase major bleedings. 
Heparin-bridging regimen should be adapted to the bleeding risk of the 
procedure and the TE risk of the patient.  
Schulman et al. published a retrospective study of patients with mechanical 
heart valves (MHV) on long-term VKA receiving perioperative bridging 
with LMWH. Fifty two percent of the patients received prophylactic 
LMWH. Patients with mechanical mitral valves were more frequently 
bridged with therapeutic doses of LMWH (55 %) than those with 
mechanical aortic valves (44 %). The only major predictor for MBE was the 
bleeding risk of the surgery. Other variables, including age, sex, weight, 
renal function, pre-operative INR, concomitant treatment with antiplatelet 
agents or NSAIDs, and dose and timing of LMWH administration were not 
significantly associated with the development of MBE in this population. 
There was no TE event (cardiac valvular, arterial, or venous) recorded 
during 30 days after the invasive procedure/surgery in any of the patients.
218
 
 
Whether a therapeutic or prophylactic regimen is more efficient with 
reduced risk of MBE needs to be evaluated in randomized clinical trials 
including specific populations that might benefit from heparin- bridging. 
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iii. Management with antidotes 
Antidotes for DOACs have been developed these last years to respond to a 
tempered enthusiasm in the use of the anticoagulants among patients and 
physicians because of the perception of a lack of safety without available 
effective reversal strategies.
219
 
 When should antidotes be used? 
Proposals for the administration of antidotes are: 
- Life threatening bleeding 
- Bleeding in a critical organ or closed compartment 
- Prolonged bleeding despite local haemostatic measures 
- High risk of recurrent bleeding because of overdose or delayed clearance 
of DOACs 
- Need for urgent intervention associated with a high risk of bleeding 
 
Reversal is unlikely to be necessary when bleeding can be managed with 
local haemostatic measures, when bleeding has stopped or when 
interventions can be delayed to afford clearance of drugs, especially in 
patients with normal renal function. 
130
 
 Which antidotes are available or ongoing clinical trials? 
1) Idarucizumab 
 For dabigatran
220
, the antidote Idarucizumab is a Fragment Antigen Binding 
(Fab)-fragment of a humanised monoclonal antibody which directly binds 
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and inhibits dabigatran. Its affinity for dabigatran is around 350 times 
greater than the one of thrombin. The Fab-fragment neither bound to various 
clotting factors nor it had an effect on platelets. It has a very short half-life 
of 45 minutes as it is filtered and degraded by the glomerula (bound to 
dabigatran or free). The dabigatran is then eliminated with the urine.
220
 In 
case of renal impairment the Idarucizumab-dabigatran complexes are less 
cleared, but the almost irreversible binding prevents any relevant rebinding 
of dabigatran to thrombin.  
The efficacy and safety of Idarucizumab is currently being evaluated in a 
phase III Study of the Reversal Effects of Idarucizumab on Active 
Dabigatran (REVERSE-AD ; Clinical Trials.gov number NCT02104947) 
which aims to enrol 300 patients. The primary endpoint is the maximum 
percentage reversal of the anticoagulant effect of dabigatran within 4 hours 
of Idarucizumab administration, measured with a dTT or ECT.
130
  
After publication of the first results of the phase III trial testing a 5g 
Idarucizumab infusion (two IV boluses of 2.5 g each administered overs 5-
10 minutes no more than 15 minutes apart) in patients who experienced 
serious bleeding requiring reversal (group A= 51 patients) or who require 
emergency surgery that cannot be delayed for at least 8 hours (group B= 39 
patients) in June 2015, the FDA and EMA have delivered expedited 
approval to have the antidote available in the clinical setting. However, its 
high cost and its potential to induce immunogenic issues should restrict its 
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use to the strict recommended indications. Furthermore, despite the clinical 
trial demonstrate the effect of this antidote to correct anticoagulation induced 
by DE, the benefit in terms of outcome and mortality has still not been 
proved. Whether it should be given before a fibrinolytic therapy in patients 
with acute ischemic stroke and relevant concentrations of dabigatran is still 
unknown. A recent case-report described the administration of Idaricuzimab 
before a thrombolysis in a patient with acute ischemic stroke and 90 ng/ml 
of dabigatran at admission. The authors reported that the patient developed 
further ischemia afterwards and could not conclude about the safety of 
Idarucizumab in such emergent setting.
221
 
2) Andexanet alfa 
For the direct anti-Xa inhibitors, the antidote Andexanet alfa is a modified, 
recombinant activated FXa (rFXa). It is catalytically inactive, but retains the 
ability to bind direct Fxa inhibitors as well as anti-thrombin activated by 
LMWH or fondaparinux. This antidote is currently in a phase III trial, the 
« Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a 
Factor Xa Inhibitor Who Have Acute Major Bleeding » (ClinicalTrials.gov 
number, NCT02329327). The dosing strategies used in the phase II clinical 
trials were different for Rivaroxaban (clinical trial ANNEXA-R) and 
Apixaban (clinical trial ANNEXA-A) due to pharmacokinetic and 
pharmacodynamic models. Bolus infusions resulted in a rapid decrease 
(within 2 to 5 minutes) in both anti-factor Xa and unbound plasma 
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concentrations of apixaban and rivaroxaban, but an increase in both 
measures could be detected within 15 minutes after completion of the bolus. 
Therefore, a 2-hour infusion was necessary to achieve sustained suppression 
of anti-factor Xa activity and plasma concentration of the anticoagulants.  
In a phase II study were Andexanet alfa was given to healthy volunteers 
without anticoagulant, a transient reduction of tissue factor pathway 
inhibitor (TFPI), a slight increase of fibrinogen F1+2 fragments 
(prothrombin fragment 1.2, thrombin-antithrombin complexes)
130
 and of D-
dimer were observed, without associated thrombotic events. This 
phenomenon should be attenuated with the presence of oral FXa inhibitors 
as these last compete with TFPI for Andexanet binding. In the ANNEXA-A 
and ANNEXA-R studies, no serious adverse events nor thrombotic 
complications were recorded in both clinical trials including 101 patients 
receiving andexanet alfa.
219
  
3) Aripazine 
The third approach is the small molecule Aripazine, which antagonize the 
effects of all anticoagulants tested, except VKAs and argatroban.
220
 It has a 
non-covalent binding to anticoagulants and in vitro studies showed no major 
interactions with other coagulation factors or albumin. In an in vivo study 
including healthy volunteers untreated or pre-treated with 60 mg of 
edoxaban, Aripazine did not induce serious adverse events and no 
procoagulant signal (measured by D-dimer, TFPI, prothrombin fragments 
221 
 
1.2). A single bolus of 300 mg of i.v. Aripazine normalised the whole blood 
clotting time in volunteers treated with 60 mg of edoxaban with a stable 
effect remaining 24 hours. Paradoxally, in a rabbit liver laceration model, 
there was a reduction in the blood loss induced with rivaroxaban with 30 
mg/kg of Aripazine, and no effect on clotting assays. This might become an 
issue for the monitoring of the reversal therapy, especially as aripazine can 
reverse citrate.   
 
Why monitoring the anticoagulant effect with antidote administration? 
1) Guiding DOAC administration 
Time of last DOAC intake and laboratory tests (including CrCl) can guide 
clinicians in administering the antidote. 
However, antidote administration should not be delayed until laboratory 
tests results are available when patients have life-threatening bleeding such 
as an intracranial bleeding or patients requiring emergency surgery for life-
threatening conditions such as ruptured aortic aneurysm. 
130
 In this situation, 
some rapidly available routine tests using sensitive agents to DOAC might 
inform clinicians about a qualitative anticoagulant effect of DOAC. 
Indeed, an optimised TT and a sensitive reagent of aPTT can inform about 
residual dabigatran presence and a prolonged PT with a sensitive reagent can 
inform about clinically relevant presence of rivaroxaban and edoxaban.  
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However, routine tests can be prolonged due to induced coagulopathies 
caused by e.g. polytrauma or life threatening bleeding with aggressive fluid 
therapy.  
Therefore, as already discussed, non-specific anti-Xa chromogenic assays 
are accurate enough to detect low and high plasma levels of direct anti-Xa 
agents.
70
  
When severe bleeding patients are treated with antidotes and aggressive 
conventional therapy, aPTT, TT and PT cannot be used to monitor the 
reversal of DOACs.   
Therefore, the residual anticoagulant effect can be accurately estimated with 
specific laboratory tests. Even if the antidote is administered before the 
availability of DOAC plasma estimation, having later on the initial 
concentrations may help to assess the efficient dosage of the antidote.  
When laboratory tests can be realized on time, for patients with serious 
bleeding, a DOAC concentrations > 50 ng/ml is sufficiently high to warrant 
antidote administration, whereas in those requiring an urgent intervention 
associated with a high risk of bleeding, antidote administration should be 
considered if the drug concentration > 30 ng/ml.
130
 However, for the last 
point, the administration of an antidote could be delayed into the operating 
room, if haemostatic conditions are unsatisfying during the procedure. 
Levy et al. estimate that an antidote is unlikely to be necessary if the last 
dose of DOAC was taken 24 hours before, in patients with normal renal 
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function.
130
 Blood samples of patients treated with rivaroxaban in our 
institution and collected at CTROUGH (24 hours after last rivaroxaban 
administration) had commonly plasma concentrations > 50 ng/ml (confirmed 
with LCMS-MS). Therefore laboratory tests have a key role in the way we 
should administer the antidotes and some experts have expressed recently 
the urgent need to have DOAC monitoring widely available to manage 
emergencies and antidote administration.
135
 
2) Follow-up after DOAC administration 
In any case, laboratory tests will assess the effect of the antidote after its 
administration, and in this setting, the specific coagulation assays dedicated 
to low concentrations will have more accurate estimation of residual DOACs 
activity. This might be helpful to guarantee reasonable haemostatic 
conditions during a high risk bleeding surgery or to assess if a bleeding is 
still caused by significant DOAC concentrations to guide further bleeding 
management. 
Furthermore, DOACs distribute within the intra- and extra-vascular 
compartment, and when DOACs has been removed or antagonised in the 
intravascular space, the extravascular compartment will redistribute the 
remaining DOACs concentration into the intravascular space. This concerns 
also the removing of dabigatran with haemodialysis.
220
 In patients with 
impaired renal function, monitoring the reversal of Idarucizumab should be 
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realized after 24 hours to exclude dabigatran reapparance, especially if 
bleeding reoccurs lately. 
Greinacher et al.
220
 described well the potential issues with the development 
of immunogenicity due to antidote’s use with DOACs and argue the need to 
monitor it. 
For Idarucizumab, about 15% of normal individuals have natural antibodies 
binding the cleavage site of Fab fragments. Important is that there do not 
block the drug effect or cause cell alterations. A potential problem with pre-
existing anti-Fab antibodies might be that the complexes of dabigatran-
Idarucizumab and anti-Fab antibodies are too large to be filtered by the 
kidney and therefore may prolong the resistance to new doses of dabigatran. 
A further theoretical risk is the formation of anti-idiotype antibodies that 
bind to the variable region of an antibody and could thereby inactivate the 
dabigatran antidote in a further attempt to reverse dabigatran. Other 
problematic is that anti-idiotype antibodies can sterically mimick the original 
antigen of the idiotype antibody, thus in this case an anti-idiotype antibody 
against Idarucizumab may mimick sterically dabigatran and could become 
an endogenous thrombin inhibitor.  
Concerning Andexanet alfa, a modified human protein presents always the 
risk to induce antibodies.
220
 
These potential risks with the use of antidotes should be kept in mind in the 
follow-up of patients on DOACs. 
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V. Overall conclusions 
 
Since the DOACs have been licensed, a lot of progress has been realized in 
the field of their perioperative management. Despite they were licensed 
without the need of routine monitoring, tricky clinical settings has lead to the 
development of accurate DOAC monitoring.  
Our involvement in the improvement of the perioperative management of 
DOACs was to evaluate the potential of an optimised TT in the estimation of 
dabigatran plasma concentrations, and to assess the accuracy of specific 
laboratory assays developed for the estimation of low plasma concentrations 
of dabigratran and rivaroxaban. The results of these research studies have led 
to the development of an institutional strategy that enables the monitoring of 
DOACs in different clinical settings with the most accurate tests. Futur 
perioperative research projects need to confirm our results in larger cohorts 
and validate an institutional perioperative management. Further optimization 
of the performance and specificity of laboratory assays are needed for the 
monitoring of low plasma concentrations of direct anti-Xa agents. The role 
of DOACs monitoring is nowadays better understood and some experts raise 
concerns about the urgent need to have this monitoring widely available to 
manage life-threatening emergencies in patients treated with DOACs.
135
 
There are still improvements that can be realized to have a reduced TAT of 
DOACs monitoring in this setting. Therefore, the perioperative management 
of DOACs offers still challenges to work on. 
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